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Zusammenfassung
Damit eine Zelle den Zellyklus durchlaufen kann, müssen bestimmte regulatorische Proteine, 
zu denen Securin und mitotische Cykline gehören, abgebaut werden. Diese Abbaureaktionen 
werden vom Anaphase-promoting Complex/Cyclosome (APC) initiiert, einem 1.5 MDa 
grossen Ubiquitinligase-Komplex, der aus mindestens einem Dutzend Untereinheiten 
besteht. Die Substrat-Ubiquitinketten werden vom APC auf eine prozessive Art und Weise
generiert. Für diese Prozessivität wird die APC-Untereinheit Doc1 benötigt. Wie allerdings 
Doc1 diese Prozessivität vermittelt ist nicht bekannt.
Um Proteine zu identifizieren, die mit Doc1 interagieren, habe ich eine Photocrosslinking-
Methode etabliert. Dazu habe ich APC aus der Bäckerhefe sowie rekombinantes Doc1, 
welches einen spezifischen Photocrosslinker enthält, verwendet. Diesen Crosslinker habe ich 
an verschiedenen Stellen innerhalb von Doc1 eingebaut, von denen gezeigt wurde, dass sie 
entweder für Doc1s Funktion als Prozessivitätsfaktor oder für die Bindung von Doc1 an den 
APC wichtig sind. Außerdem habe ich den Crosslinker an verschiedenen Stellen auf der 
Oberfläche des Doc1 Moleküls eingebaut und damit die Interaktionen von 10 % der 
Aminosäurereste von Doc1 untersucht. Ich habe herausgefunden, dass Doc1 innerhalb des 
APC an die „tetratrico peptide repeat” (TPR) Proteine Cdc16 and Cdc27 bindet. Dazu 
verwendet Doc1 seine C-terminale Region beziehungsweise seinen C-terminalen „IR tail“.  
Desweiteren konnte ich Aminosäurereste in Doc1 identifizieren, die direkt die größte 
Untereinheit des APC, Apc1, kontaktieren. Ich habe diese Technik auch verwendet, um nach 
Bindungspartnern der N-terminalen Loop-Region von Doc1 zu suchen. Der Grund dafür 
war, dass postuliert wurde, dass Doc1 über diese Region die Prozessivität in 
Ubiquitinierungsreaktionen vermittelt. Allerdings haben diese Experimente nicht zu der 
Identifikation eines möglichen Liganden geführt.
Um die Rolle von Doc1 innerhalb des APC zu verstehen und um einen Einblick in die 
dreidimensionale (3D) Organisation der 13 APC Untereinheiten zu bekommen, haben wir 
damit begonnen, den APC aus der Bäckerhefe mittels Elektronenmikroskopie zu analysieren. 
Wir haben ein 3D Modell für den Wildtyp-APC erstellt, der eine asymmetrische und 
insgesamt trianguläre Form aufweist. Um Doc1 innerhalb des APC zu lokalisieren, haben wir
ein Modell für eine APC-Mutante, der Doc1 fehlt, erstellt. Indem wir diese Struktur mit der 
des Wildtyp-APC verglichen haben, konnten wir eine zusätzliche Masse im Wildtyp-APC 
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ausfindig machen, bei der es sich wahrscheinlich um Doc1 handelt. Um weitere APC 
Untereinheiten zu lokalisieren, haben wir einen Satz von Hefestämmen hergestellt, in denen 
ein 50 kDa großer Tag mit dem C-terminus von jeweils einer der APC Untereinheiten 
fusioniert wurde. Diese Tags sind groß genug, um sie mittels Negativfärbung und 
Elektonenmikroskopie sichtbar zu machen. Wir haben APC aus diesen Hefestämmen 
gereinigt und dabei herausgefunden, dass für neun der getaggten APC Untereinheiten die 
Komposition des APC nicht beeinflusst wurde. Bisher wurden Strukuren für zwei der neu 
generierten APC Versionen ermittelt; in einem der Komplexe war Cdc27 getaggt und in dem 
anderen Apc5. Der Vergleich dieser Strukturen mit der des Wildtyp-APC hat uns ermöglicht, 
die C-termini von Cdc27 und Apc5 präzise zu lokalisieren. Während Apc5 ein Teil der 
“Plattform” des APC zu sein scheint, befindet sich der C-terminus von Cdc27 in 
unmittelbarer Nähe der Masse, bei der es sich wahrscheinlich um Doc1 handelt. Die 
Interaktion zwischen Doc1 und Cdc27, die ich mittels Photocrosslinking ermittelt habe, ist 
damit konsistent mit unserem 3D Modell des APC. Doc1 könnte die katalytische Aktivität 
des APC beeinflussen, indem es mit einem TPR Protein Subkomplex assoziiert, welcher 
Cdc27 und Cdc16 beinhaltet. Durch gleichzeitige Bindung an eine zweite Region innerhalb 
des APC, welche möglicherweise Apc1 enthält, könnte Doc1 strukturelle Veränderungen 
innerhalb des APC verursachen, welche die prozessive Substratubiquitinierung ermöglichen. 
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Abstract
Progression through mitosis depends on the degradation of certain regulatory proteins, such 
as securin and mitotic cyclins. These degradation reactions are initiated by the anaphase-
promoting complex/cyclosome (APC), a 1.5 MDa ubiquitin ligase complex that is composed 
of at least a dozen subunits. APC assembles ubiquitin chains on substrates in a processive 
manner. This processivity depends on the APC subunit Doc1, but how Doc1 confers 
processivity to the APC is unknown.
To identify the binding partners of Doc1, I have established a photocrosslinking approach 
using budding yeast APC and recombinant Doc1 mutants containing a site-specific 
crosslinker. I have inserted this photocrosslinker at different sites which were shown to be 
important for Doc1’s function as a processivity factor and for its binding to the APC. In 
addition, I have inserted the crosslinker at various sites on the surface of the Doc1 structure 
and thereby mapped interactions of about 10 % of Doc1’s amino acid residues. I have found 
that within the APC, Doc1 binds to the tetratrico peptide repeat (TPR) proteins Cdc16 and 
Cdc27 via Doc1’s C-terminal region and the C-terminal IR tail, respectively. In addition, I 
could identify sites which directly contact APC’s largest subunit, Apc1. I also used this 
technique to search for interaction partners which might bind to an N-terminal loop region 
in Doc1, because this region has been proposed to mediate processivity in ubiquitination 
reactions. However, these experiments did not result in the identification of a potential 
ligand. 
To understand Doc1’s role within APC and to get insight into the three-dimensional (3D) 
organisation of all 13 APC subunits, we have started to analyze budding yeast APC by 
electron microscopy (EM). We have generated a 3D model for wild type APC which displays 
an asymmetric and overall triangular shape. To localize Doc1 within APC, we have obtained 
a 3D model of APC lacking Doc1. Comparing this structure with that of wild type APC has 
revealed one additional density in the wild type structure; this mass is likely to represent Doc1. 
In order to analyze the localization of further APC subunits we have created a set of yeast 
strains which each carry a 50 kDa-tag fused to the C-terminus of one of the APC subunits. 
These tags are large enough to be visualized by negative staining EM. We have purified APC 
from these strains and have found that for nine tagged APC subunits, APC composition 
remained unaffected. Structures have so far been generated for two APC versions; in one 
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complex Cdc27 was tagged and in the other one Apc5. Comparison of those structures with 
that of wild type APC has allowed the precise localization of the C-termini of Cdc27 and 
Apc5. Whereas Apc5 appears to be part of the “platform” of APC, the C-terminus of Cdc27 
localizes close to the mass which likely represents Doc1. The Doc1-Cdc27 interaction 
detected by photocrosslinking is therefore in good agreement with our 3D model of APC. 
Doc1 might affect the catalytic activity of APC by associating with a TPR protein-containing 
subcomplex including Cdc27 and Cdc16; through simultaneous binding of a second region 
within APC, which might include Apc1, Doc1 might cause structural rearrangements within 
APC which allow processive substrate ubiquitination. 
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1 Introduction
1.1 The cell cycle
The cell cycle is an ordered series of events which lead to cell division and the production of 
two daughter cells, each containing exact copies of the parental cells’ chromosomes. In the 
case of a unicellular organism, cell division leads to proliferation, whereas in a multicellular 
organism, cell division results in growth. Duplication of the parental chromosomes occurs 
during the S phase of the cycle, and one of the resulting daughter chromosomes is 
distributed to each daughter cell during mitosis. These two cell cycle phases are separated by 
two gap phases, G1 and G2 phases, which allow cells to prepare for the subsequent 
duplication and division stages by synthesizing RNA and protein, and by growing in size. 
During mitosis, the cell undergoes major morphological changes. In most eukaryotic cells 
except for fungi, the nucleus disassembles in prophase and chromosomes start to condense. 
Sister chromatids are held together by a mechanism called cohesion. The formation of a 
bipolar mitotic spindle begins, onto which chromosomes start to align in prometaphase. In
metaphase all chromosomes are aligned to form a so-called metaphase plate. Cohesion is lost 
at the onset of anaphase and sister chromatids move to opposite spindle poles. During 
telophase, the chromosomes decondense and the nucleus reforms. Finally, the two daughter 
cells become separated by cell membrane ingression in a process called cytokinesis (Morgan, 
2007). Precise temporal control of the cell cycle events ensures that both chromosome 
replication and chromosome segregation to daughter cells occur in the proper order and 
with high fidelity. Regulation of the cell cycle is critical for the normal development of all 
organisms, and loss of controlled division can ultimately lead to cell death or 
hyperproliferation as it is found in cancer.
1.2 Cell cycle control
The cell cycle is driven onwards by a system of highly regulated oscillating waves of cyclin-
dependent kinase (Cdk) activity. Cdk activity is high during DNA synthesis and early mitosis
and low during cytokinesis and G1. High Cdk activity results from association of the 
catalytic subunit Cdk with its regulatory cyclin subunit (Murray, 2004). Budding and fission 
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yeasts only use a single Cdk, whereas higher organisms have several Cdks. Budding yeast 
Cdk1 (initially termed Cdc28), can associate with nine different cyclins to induce major cell 
cycle events including the commitment to cell division (with G1 phase cyclins Cln1 to 3, 
(Nasmyth, 1993)), DNA replication (with S phase cyclins Clb5 and 6, (Murray, 2004)) and 
entry into mitosis (with M phase cyclins Clb1 to 4, (Andrews and Measday, 1998)). In animal 
cells, Cdk4 and Cdk6, paired with D-type cyclins, are active in G1; Cdk2 associated with A-
type and E-type cyclins initiates DNA replication, and Cdk1 together with B-type cyclins
promotes mitotic entry (Pagano and Jackson, 2004).
Whereas Cdks are constantly present during the cell cycle, levels of their activating cyclins 
are periodically fluctuating (Murray, 2004). Moreover, Cdk activities are controlled by Cdk 
inhibitors, whose levels also fluctuate. Oscillations of both cyclins and Cdk inhibitors are 
partially controlled on the transcriptional level, but are largely accomplished by the action of 
the ubiquitin proteasome system (Morgan, 2007). Proteolysis therefore ensures irreversible 
cell cycle transitions and moves the cell cycle forward in a unidirectional fashion. 
1.3 Ubiquitin dependent proteolysis
Cyclins and many other cell cycle regulators are targeted to the proteasome (Voges et al., 
1999) by the addition of ubiquitin chains. Ubiquitin is a highly conserved 76 amino acid 
protein found in all eukaryotes. The C-terminus of ubiquitin is conjugated to lysine residues 
of target proteins by the action of three enzymes: a ubiquitin activating enzyme (E1), a 
ubiquitin conjugating enzyme (E2) and a ubiquitin ligase (E3). In a first step, the E1 activates 
ubiquitin by first forming a ubiquitin-adenylate which requires ATP hydrolysis and then 
creating a thioester bond between its catalytic cysteine and the C-terminal glycine residue of 
ubiquitin. The activated ubiquitin molecule is then transferred to the catalytic cysteine of an 
E2 in a transesterification reaction. In the final and most tightly regulated step, an E3 
recognizes the target protein and catalyzes the formation of an isopeptide bond between the 
C-terminus of ubiquitin and a substrate’s lysine side chain. When ubiquitins are conjugated 
to lysine residues within ubiquitin itself in subsequent reactions, polyubiquitin chains are 
formed on the target protein ((Pickart, 2001); Figure 1–1).
By targeting proteins for degradation, ubiquitin converts many proteasomal substrates into 
very short-lived proteins. Ubiquitin itself, however, escapes degradation and is removed 
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from its conjugates by deubiquitinating enzymes (DUBs), allowing recycling of ubiquitin and 
maintenance of a pool of free ubiquitin in the cell (Amerik and Hochstrasser, 2004). 
Furthermore, DUBs are required for generating conjugation-competent ubiquitin from 
precursors (Amerik and Hochstrasser, 2004). It has been proposed that DUBs might serve a 
proofreading function in that poorly ubiquitinated or slowly degraded proteins are 
diconjugated from their ubiquitin chains and therefore rescued from degradation before 
proteasomal processing could take place (Lam et al., 1997). Apart from their general role in 
ubiquitin processing and recycling, DUBs have been implicated in specific biological 
processes (Amerik and Hochstrasser, 2004). Furthermore, it has been shown that some 
DUBs are target-specific (Cohen et al., 2003; Li et al., 2002). DUBs might therefore be 
involved in “fine-tuning” of ubiquitin dependent proteolysis by contributing to balancing the 
levels between ubiquitination and deubiquitination. 
E3
E1
ub
E2
E2
ub
ub
ub
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ub
ub
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Figure 1-1: The ubiquitin proteasome pathway. Three enzymes act in a cascade to attach 
ubiquitin moieties to target proteins. Note that steps including ubiquitin precursor 
processing and two ATP dependent processes, ubiquitin activation and translocation of 
substrates into the proteasome, were omitted for simplicity. Attachment of ubiquitin can 
result in monoubiquitination, multiubiquitination (i.e. several distinct substrate lysines are 
ubiquitinated) and polyubiquitination (as shown). Deubiquitinating enzymes (DUB) can also 
act at other steps in the pathway. See text for details.
The first implication that ubiquitin dependent proteolysis might underlie cell cycle regulation 
came from the observation that the temperature sensitive mouse cell line ts85, which carries 
a point mutation in the E1 enzyme, arrests the cell cycle in G2 (Finley et al., 1984). This 
hypothesis was proven to be correct when mitotic cyclins were shown to be ubiquitinated 
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and degraded by the proteasome (Glotzer et al., 1991; Hershko et al., 1991). The two key 
enzymes which are involved in major cell cycle transitions by mediating the conjugation of 
ubiquitin to cell cycle regulators were identified as the anaphase promoting 
complex/cyclosome (APC) (Irniger et al., 1995; King et al., 1995; Sudakin et al., 1995; 
Tugendreich et al., 1995) and the Skp1/Cullin/F box complex (SCF) (Feldman et al., 1997; 
Skowyra et al., 1997). 
1.4 Roles of the APC
The cell cycle is driven by periodic fluctuations in the activity of Cdk1. Whereas activation of 
Cdk1 is a prerequisite for the initiation of many mitotic events including entry into mitosis, 
nuclear envelope breakdown, spindle assembly and chromosome condensation, inactivation 
of Cdk1 must occur before a cell can exit mitosis. Inactivation of Cdk1 is accomplished by 
degradation of its activating subunits cyclin A and cyclin B. Before the ubiquitin ligase 
responsible had been discovered, it became evident that the same activity is also responsible 
for degrading an inhibitor of anaphase onset (Holloway et al., 1993). Yeast genetic studies as 
well as biochemical fractionation experiments then identified APC as the ubiquitin ligase 
responsible for both anaphase onset and mitotic exit in yeast, clam and frog egg extracts 
(Hershko et al., 1991; Irniger et al., 1995; King et al., 1995). At the metaphase to anaphase 
transition, when all chromosomes have been attached to both poles of the mitotic spindle, 
APC mediates the ubiquitination of securin, which is an inhibitor of separase. Once separase 
is active, it cleaves the cohesin complex, allowing anaphase onset (Nasmyth, 2002). Cohesin 
is a ring-shaped complex which embraces sister chromatids and thereby holds them together 
until cleavage of cohesin’s Scc1 releases cohesin from chromatids (Nasmyth, 2002). APC 
ubiquitination of cyclin B establishes and maintains a state of low Cdk activity that is 
necessary for mitotic exit (Amon et al., 1994; Morgan, 1999; Sullivan and Morgan, 2007). 
Dephosphorylation of Cdk1 substrates is essential for disassemby of the mitotic spindle, 
reformation of the nuclear envelope, decondensation of chromosomes and cytokinesis. In 
vertebrates, APC might not only activate separase by mediating securin desctruction, but also 
by ubiquitinating cyclin B. Phosphorylation of separase and association with Cdk1-cyclin B 
inactivates the protease; the low Cdk state created by APC might therefore fully activate 
separase (Gorr et al., 2005; Stemmann et al., 2001). Persisting APC activity during G1 and 
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therefore low Cdk1 activity allows formation of prereplicative complexes on origins of 
replication. Initiation of DNA synthesis by DNA polymerases is dependent on high Cdk 
activity. APC activity therefore prevents premature S phase entry (Diffley, 2004; Zachariae 
and Nasmyth, 1999).
Apart from cyclins and securin, a growing number of additional cell cycle substrates have 
been identified as APC targets including proteins involved in DNA replication (geminin and 
Cdc6 in mammals, Dbf4 in yeast), mitotic kinases (yeast and human polo kinases), the APC 
cofactor Cdc20 and proteins involved in spindle function in yeast (Ase1, Kip1, Cin8) or 
frogs (Xkid). For some of those, additional forms of regulation apart from proteolysis exist. 
One example is Plk1, which can be inactivated at the end of mitosis by either degradation or 
dephosphorylation (Lindon and Pines, 2004). Moreover, studies in budding yeast have 
shown that the only essential APC targets, at least in this organism, are securin and mitotic 
cyclins (Thornton et al., 2006). 
1.5 APC and SCF
The main two ubiquitin ligases catalyzing cell cycle transitions are APC and SCF. Whereas
APC is mainly active during mitosis and G1 phase (see above), various SCF complexes are 
acting at many cell cycle stages as well as beyond the cell cycle (Petroski and Deshaies, 2005; 
Vodermaier, 2004). APC and SCF are distantly related multi-subunit complexes which 
belong to the family of really interesting new gene (RING) ubiquitin ligases (Passmore and 
Barford, 2004). These ligases use a small zinc-binding RING finger protein (Apc11 in APC 
and Roc1/Rbx1/Hrt1 in SCF) to recruit E2 enzymes. There is no evidence that RING 
proteins directly take part in transfer of ubiquitin from E2 to a substrate. This is in contrast 
to a second family of ubiquitin ligases which uses homology to E6-AP C-terminus (HECT) 
domain proteins to form a thioester linkage with ubiquitin (Passmore and Barford, 2004). In 
both APC and SCF the RING subunits are associated with C-termini of proteins containing 
cullin domains (Apc2 in APC, Cdc53 in SCF). Substrate binding in SCF complexes is 
accomplished by substrate adaptors. These typically contain an N-terminal domain which 
contacts the cullin subunit and a C-terminal domain which binds to substrates (Petroski and 
Deshaies, 2005). One of the two cullin binding domains known so far comprises an 
approximately 40 amino acid F box motif. F box proteins contain substrate-binding domains 
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such as WD40 and leucine-rich repeats to bind to their numerous substrates (Petroski and 
Deshaies, 2005). WD40 repeats are also found in APC coactivator proteins which play an 
important role in APC substrate recognition and binding (see below). Structural information 
available for SCF (Schulman et al., 2000; Zheng et al., 2002) allows insight into the function 
of the SCF ubiquitin ligase. The structures suggest that the main function of SCF is to form 
a scaffold (built by the rigid cullin subunit) which correctly positions ubiquitin-charged E2 
(bound via cullin and the RING finger) and substrate (bound by the F box protein) to 
facilitate ubiquitination. Despite the fact that SCF contains three to five, and APC at least 
twelve subunits, it was proposed that both complexes might share a similar structural 
backbone and therefore similar modes of mediating substrate ubiquitination (Ohi et al., 
2007). 
Although SCF and APC display basic similarities in their core domains, there is a 
fundamental difference in their regulation during the cell cycle. SCF is a constitutively active 
complex and the regulation takes place at the substrate level. In most cases, phosphorylation 
targets SCF substrates to the ligase, but other signals including oligosaccharides have also 
been observed (Petroski and Deshaies, 2005; Yoshida, 2007). APC in contrast becomes 
phosphorylated itself, which allows activator proteins to bind and activate the complex 
(Vodermaier, 2004). Thus, whereas for SCF substrate availability is restrained, it is the 
enzyme itself which is regulated in case of APC (see below). However, it has become evident 
that substrate modification provides an additional layer of regulation to control APC activity. 
Substrates including yeast Pds1 (Wang et al., 2001), aurora A (Littlepage and Ruderman, 
2002), Cdc6 (Mailand and Diffley, 2005) and Skp2 (Rodier et al., 2008) are protected from 
APC-mediated destruction by phosphorylation. 
1.6 APC regulation in mitosis
Since inappropriate APC-mediated protein degradation could have fatal consequences for a 
cell or an organism, APC activity is restrained at multiple levels by several cellular 
mechanisms (Peters, 2006). To become active, APC has to associate with one of its 
coactivator proteins, which in mitosis are Cdc20 and Cdh1. APC-Cdc20 is activated early in 
mitosis, whereas APC-Cdh1 takes over in late mitosis and remains active until late G1 phase
(Peters, 2006). An important basis for the strictly regulated time frames in which these two 
INTRODUCTION
11
forms of APC are active is the opposing effect that phosphorylation has on APC-Cdc20 and 
APC-Cdh1: Whereas Cdc20 can only bind to and activate phosphorylated APC, Cdh1 is kept 
in an inactive state by phosphorylation (Peters, 2006). Levels of Cdc20 oscillate in a cell cycle 
dependent manner with transcription and protein expression profiles being similar to those 
of cyclins promoting mitosis (Shirayama et al., 1998). Cdc20 accumulates during late S phase 
and is present until late mitosis. Phosphorylation of APC by Plk1 and Cdk paired with 
mitotic cyclins allows activation of APC-Cdc20 (Kraft et al., 2003; Kramer et al., 1998; 
Rudner and Murray, 2000; Shteinberg et al., 1999), which then mediates the destruction of 
mitotic B-type cyclins, thereby creating a “low Cdk activity state”. Phosphatases such as 
Cdc14 in yeast are activated which remove inhibitory phosphates on Cdh1. APC-Cdh1 
becomes active (Shou et al., 1999; Visintin et al., 1998; Zachariae et al., 1998a) and promotes 
Cdc20 destruction. Thus, Cdc20 not only mediates the degradation of mitotic cyclins, but 
indirectly also its own (Prinz et al., 1998; Shirayama et al., 1998). In contrast to Cdc20, Cdh1 
is present throughout the cell cycle. APC-Cdh1 remains active during G1, and this prevents 
reaccumulation of mitotic cyclins. At the G1/S phase transition, however, APC has to be 
inactivated to allow reaccumulation of APC substrates required for DNA replication and 
mitotic entry. This is, in part, accomplished by Cdk1-mediated phosphorylation which 
promotes Cdh1 dissociation from APC (Jaspersen et al., 1999; Kramer et al., 1998; Zachariae 
et al., 1998a). Phosphorylation of Cdh1 might also target it for degradation by SCF in S phase 
(Benmaamar and Pagano, 2005; Kramer et al., 1998; Yamaguchi et al., 2000).
A model for autonomous APC regulation has been proposed based on the observation that 
APC-Cdh1 promotes its own inactivation by mediating destruction of UbcH10 (Rape and 
Kirschner, 2004), an E2 enzyme that appears to collaborate exclusively with APC (Yu et al., 
1996). Cyclin A degradation is critically dependent on levels of UbcH10 (Rape and 
Kirschner, 2004). During mitosis, APC-Cdh1 together with UbcH10 is “busy” degrading 
APC substrates. At the end of mitosis, however, when most of APC substrates have been 
degraded, APC-Cdh1 promotes UbcH10 autoubiquitination and degradation. Rising levels of 
cyclin A result in inactivation of APC-Cdh1 by cyclin A-Cdk2-mediated phosphorylation 
(Rape and Kirschner, 2004). In addition, APC-Cdh1 is directly inhibited by a protein called 
early mitotic inhibitor-1 (Emi1) in vertebrate cells and regulator of cyclin A (Rca1) in
Drosophila during S and G2 phases (Dong et al., 1997; Grosskortenhaus and Sprenger, 2002; 
Hsu et al., 2002), allowing accumulation of cyclin A and other APC substrates. Emi1 was 
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reported to also prevent APC-Cdc20 activation prior to and in early mitosis, when Cdk1 
activity might already activate APC and promote Cdc20 binding (Guardavaccaro et al., 2003; 
Margottin-Goguet et al., 2003). Emi1 can directly bind to APC coactivators (Hsu et al., 2002; 
Reimann et al., 2001; Reimann and Jackson, 2002) and core APC (Miller et al., 2006) and 
might thereby inhibit substrate recruitment to the APC. A more recent study has shown that 
Emi1 destruction is not required for mitotic entry, which implies that Emi1 might not 
regulate APC-Cdc20; however, it is important for inhibiting APC-Cdh1 during interphase to 
prevent rereplication (Di Fiore and Pines, 2007). Emi1 degradation is initiated by Plk1-
mediated phosphorylation which targets Emi1 for SCF-mediated degradation at 
prometaphase onset (Hansen et al., 2004; Moshe et al., 2004).
1.7 APC regulation by the spindle assembly checkpoint
A surveillance mechanism known as the spindle assembly checkpoint (SAC) ensures proper 
chromosome segregation in mitosis (Musacchio and Hardwick, 2002). Checkpoints are 
regulated transition points at which progression to the next cell cycle state can be arrested if 
certain conditions arise. In case of the SAC, a single unattached kinetochore can lead to a 
prolonged prometaphase. The SAC targets APC-Cdc20 and delays its ubiquitination activity 
towards securin and cyclin B, whose degradation is required for anaphase onset and mitotic 
exit, respectively. Remarkably, the SAC inhibits APC in a substrate-specific manner: While 
degradation of securin and cyclin B is prevented, cyclin A and Nek2A degradation remains 
unaffected (den Elzen and Pines, 2001; Geley et al., 2001; Hames et al., 2001; Hayes et al., 
2006). SAC activation is thought to generate a diffusible signal, which delays mitotic 
progression until all chromosomes have become attached to both poles of the mitotic 
spindle. 
Several proteins have been implicated in the function of the spindle assembly checkpoint, 
including Mad1, Mad2, BubR1, Bub1 and Bub3 (Musacchio and Hardwick, 2002; Musacchio 
and Salmon, 2007). Direct binding of Mad2 to Cdc20 is essential for SAC function (Hwang 
et al., 1998; Kim et al., 1998). Mad2 and BubR1 have been shown to directly bind to APC in 
vivo and to impair its ubiquitination activity in vitro (Fang et al., 1998; Sudakin et al., 2001; 
Tang et al., 2001a). An elegant so-called “template model” has been proposed to explain how 
a weak signal caused by only one unattached kinetochore could be rapidly amplified to affect 
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the entire cell: Upon SAC activation, Mad2 is recruited to unattached kinetochores by Mad1 
(Sironi et al., 2002). Mad2 of Mad1-Mad2 complexes forms an asymmetric dimer with 
diffusible Mad2 (Mapelli et al., 2007) and as part of this complex, Mad2 may function as a 
template for the assembly of Mad2-Cdc20 complexes (De Antoni et al., 2005; Luo et al., 
2002). Newly assembled Mad2-Cdc20 complexes may themselves function as templates for 
additional Mad2-Cdc20 complexes, thereby rapidly multiplying their amounts. A mitotic 
checkpoint complex consisting of Mad2, BubR1/Mad3, Bub3 and Cdc20 (Fraschini et al., 
2001) might be an effector of the SAC; MCC efficiently inhibits APC upon SAC activation 
(Morrow et al., 2005; Sudakin et al., 2001). The mechanism of APC inhibition remains to be 
understood. Recent data suggest that SAC activation and MCC association prevent substrate 
binding to APC-Cdc20 and effect APC’s catalytic activity (Herzog et al., manuscript in 
preparation). Once all requirements of the checkpoint are satisfied, Cdc20 has to be rapidly 
liberated from its inhibition. It has been proposed that APC itself might relieve Cdc20 by 
ubiquitination, leading to dissociation of BubR1 and Mad2 from Cdc20 (Reddy et al., 2007). 
In this setting, the deubiquitinating enzyme Usp44 antagonizes APC activity towards Cdc20
by disassembling ubiquitin chains, thereby stabilizing BubR1-Mad2-Cdc20 complexes 
required for SAC function (Stegmeier et al., 2007). 
1.8 What is known about APC subunits
APC is an unusually complex ubiquitin ligase (Table 1-1). So far, 13 subunits have been 
detected in budding and fission yeasts and twelve in humans (Peters, 2002; Peters, 2006). 
The complexity of the APC is somewhat surprising because many other RING ubiquitin 
ligases consist of a single or few subunits, indicating that the ubiquitin ligase reaction per se 
does not require complex multi-subunit enzymes (Passmore and Barford, 2004). The reason 
for the complexity of the APC is still a mystery and the molecular function of many APC 
subunits unknown. The cullin-containing subunit Apc2 and the RING finger Apc11 are 
required for APC ubiquitination activity (Section 1.5). Apc11 and the E2 enzyme UbcH5 
alone were reported to assemble ubiquitin chains on substrates in vitro (Gmachl et al., 2000; 
Leverson et al., 2000; Tang et al., 2001b) whereas the cullin domain of Apc2 is required in 
addition when UbcH10 is used instead of UbcH5 (Tang et al., 2001b). These reactions 
display low substrate specificity (Gmachl et al., 2000; Leverson et al., 2000; Tang et al., 2001b). 
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One might therefore speculate that Apc11 alone or together with Apc2 is responsible for 
APC’s ubiquitin ligase activity and the remaining subunits are required to regulate APC 
activity and to confer substrate specificity. 
Table 1-1: APC subunits and coactivators identified to date in human cells, 
Saccharomyces cerevisiae (S.c.) and Schizosaccharomyces pombe (S.p.). Modified 
from (Peters, 2006; Thornton and Toczyski, 2006). anaphase promoting complex/cyclosome
(APC); regulatory particle non-ATPase (Rpn); ubiquitin conjugating enzyme (E2); tetratrico 
peptide repeats (TPR); really interesting new gene (RING); tryptophane aspartate (WD40); 
degradation of cyclin B protein-1 (Doc1); temperature sensitive (ts); spore wall maturation 
protein-1 (Swm1); meiotic nuclear division protein-2 (Mnd2).
human S. c. S. p. essential? known motifs or functions
core APC subunits
Apc1 Apc1 Cut4 yes homology to Rpn1, Rpn2 (proteasomal subunits)
Apc2 Apc2 Apc2 yes cullin domain; catalytic activity, E2 binding
Apc3 Cdc27 Nuc2 yes TPRs; coactivator binding
Apc4 Apc4 Lid1 yes WD40 repeats; bridges Apc1 and TPR subunits
Apc5 Apc5 Apc5 yes bridges Apc1 and TPR subunits
Apc6 Cdc16 Cut9 yes TPRs; required for Cdc27 association with APC
Apc7 - - ? TPRs
Apc8 Cdc23 Cut23 yes TPRs; required for Cdc16 and Cdc27 association
- Apc9 - no promotes association of Cdc27
Apc10 Doc1 Apc10 essential in S.p.
deletion ts in S.c.
DOC domain, IR tail; processivity, substrate binding
Apc11 Apc11 Apc11 yes RING finger;  catalytic activity, E2 binding
Cdc26 Cdc26 Hcn1 deletion ts in S.c. upregulated at higher temperature
Apc13 Swm1 Apc13
essential in S.p.
deletion ts in S.c.
promotes association of Cdc16,Cdc27,Cdc26, Apc9,
required for sporulation
Apc14 no
Mnd2 Apc15 no Inhibition of Ama1 in meiosis
APC coactivators
Cdc20 Cdc20 Slp1 yes WD40 repeats, C box, IR tail; substrate recruitment
Cdh1 Cdh1 Ste9 no WD40 repeats, C box, IR tail; substrate recruitment
Ama1 - - no WD40 repeats, C box, IR tail; substrate recruitment
APC activity depends on the association of one of several coactivator proteins, the best 
studied of which are the mitotic APC coactivators Cdc20 and Cdh1. Additional meiosis-
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specific coactivators have so far only been identified in budding yeast and Drosophila (Table
1-1, (Peters, 2006)). APC coactivators have several sequence motifs in common: They 
contain a WD40 domain which is predicted to fold into a seven-bladed propeller (Orlicky et 
al., 2003; Wu et al., 2003). This domain is required for the direct interaction of Cdh1 with a 
prominent substrate recognition element, the D box (Kraft et al., 2005). Two sequence 
elements mediate coactivator binding to APC. The C-terminal IR tail associates with the 
TPR subunit Cdc27 (see below), whereas the internal C box (Schwab et al., 2001) mediates
binding to APC’s catalytic subunits (Thornton et al., 2006). 
The small protein Doc1 most likely represents the best-studied APC subunit. DOC1
mutation or deletion results in temperature sensitive budding yeast strains (Hwang and 
Murray, 1997). In fission yeast and Drosophila, Doc1 is essential (Kominami et al., 1998; Pal et 
al., 2007b). Moreover, disruption of Apc10/Doc1 alleles was found to be responsible for a 
radiation-induced phenotype in mice that is associated with oligosyndactylism (Pravtcheva 
and Wise, 2001; Wise and Pravtcheva, 2004). Doc1 almost entirely consists of the conserved 
so-called DOC domain (Grossberger et al., 1999) which is also found in Doc1 orthologs and 
in several predicted multidomain proteins (Grossberger et al., 1999; Kominami et al., 1998). 
All these proteins have in common that they possess additional domains, such as cullin 
homology regions, RING fingers or HECT domains, which imply a role for them in 
ubiquitination reactions. It was therefore speculated, that DOC domain-containing proteins 
might play a general role in ubiquitination reactions (Grossberger et al., 1999; Kominami et 
al., 1998). In the meantime, some of these proteins have indeed been found to be ubiquitin 
ligases or to function in ubiquitin-dependent processes (DiAntonio et al., 2001; Dias et al., 
2002; Nikolaev et al., 2003). Furthermore, based on structural, biochemical and yeast genetic 
data, Doc1 has been proposed to be involved in APC substrate recognition and 
ubiquitination, possibly by directly binding to APC substrates (Section 1.12). 
The non-essential APC subunits Apc13/Swm1, Cdc26 and Apc9 play a role in the structural 
integrity of yeast APC. Mutations or loss of any one of these proteins leads to the 
dissociation of other APC subunits or the destabilization of subcomplexes (Passmore et al., 
2003; Schwickart et al., 2004; Zachariae et al., 1998b). In absence of Apc9, levels of Cdc27 are 
significantly reduced (Passmore et al., 2003; Zachariae et al., 1998b). Furthermore, Swm1 is 
required for the association of Cdc16, Cdc27, Apc9 and Cdc26 with APC (Schwickart et al., 
2004). Cdc26 fulfills a similar function as Swm1 with the exception that Swm1 incorporation 
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into APC does not require Cdc26. Both Cdc26 and Swm1 are only required at temperatures 
above 37°C, whereas at 25°C either subunit is sufficient to promote the formation of active 
APC (Schwickart et al., 2004). In addition, Swm1 is required for sporulation during meiosis 
(Schwickart et al., 2004; Ufano et al., 1999). Another APC subunit with meiosis-specific 
function is Mnd2 (Rabitsch et al., 2001; Yoon et al., 2002). Mnd2 APC bound to the 
coactivator Ama1 during meiotic S phase and prophase I. This ensures the timely destruction 
of Pds1 and prevents premature sister chromatid separation (Oelschlaegel et al., 2005; 
Penkner et al., 2005). 
1.9 Analysis of APC subcomplexes
Insight into APC subunit organization has been gained by dissociating the complex into 
smaller subcomplexes, either biochemically (Vodermaier et al., 2003) or after mutation or 
deletion of individual subunits (Schwickart et al., 2004; Thornton et al., 2006). Apc2 and 
Apc11 form a stable subcomplex with Apc1, Apc4 and Apc5 (Vodermaier et al., 2003). 
When dissociating Apc2 and Apc11 from APC by high-salt washes, levels of Doc1 are also 
reduced, indicating that Doc1 interacts with Apc2 or Apc11, but also with (an)other APC 
subunit(s) (Vodermaier et al., 2003). Vertebrate APC contains four tetratrico peptide repeat 
(TPR) proteins, whereas yeast APC has only three of them; Apc7 is exclusively found in 
higher eukaryotes (Pal et al., 2007a; Yu et al., 1998). TPR domains were discovered in the first 
identified APC subunits (Irniger et al., 1995; Lamb et al., 1994) and represent the largest 
group of structurally related proteins within APC. TPR domains were proposed to serve as 
receptors for C-terminal peptide motifs (Gatto et al., 2000). Consistent with this, TPR 
subunits can bind to peptides corresponding to the C-termini of Cdh1, Cdc20 (Vodermaier 
et al., 2003), and Doc1 (Wendt et al., 2001). Several TPR subunits which are each present 
more than once per complex (Dube et al., 2005; Huang and Raff, 2002; Ohi et al., 2007; 
Passmore et al., 2005b) might therefore function as versatile acceptor sites for interactions 
with a variety of regulatory proteins (Vodermaier et al., 2003) and possibly substrates ((Hayes 
et al., 2006), Section 1.11). 
Thornton and Toczisky have identified conditions under which APC becomes nonessential 
in yeast, allowing the deletion of otherwise essential APC subunits (Thornton et al., 2006). By 
systematic deletion of subunits, followed by purification and subunit analysis of the 
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remainder of APC, the authors have been able to draw a detailed subunit assembly map 
((Thornton et al., 2006), Figure 1-2). According to their map, the largest subunit Apc1 builds 
a structural scaffold together with Apc4 and Apc5 and associates independently with two 
separable subcomplexes. The functions of these three subunits are not understood. Based on 
sequence homologies to the Rpn1 and Rpn2 subunits of the proteasome (Lupas et al., 1997)
it has been proposed that Apc1 might have a proteasome-related function such as delivery of 
polyubiquitinated substrates to the proteasome or unfolding of substrates (Kajava, 2002; 
Lupas et al., 1997), but there are no experimental data supporting this hypothesis. 
Furthermore, Apc4 was predicted to fold into a WD40 propeller (Peters, 2006).
Doc1
Cdc27
Apc1
Apc2
Apc11
Apc4Apc5
Cdc23
Swm1
Cdc26
Apc9
Cdc16
E2
ub
Apc9
ub
D box
Cdh1
ub
ub
Figure 1-2: Model depicting APC subunit interactions and substrate ubiquitination. 
Modified after (Peters, 2006; Thornton et al., 2006). Interactions are described in the text in 
detail. Subunits belonging to the “catalytic subcomplex” are light green and those of the 
“TPR subcomplex” are turquoise. The ubiquitin-loaded E2 enzyme is recruited by the RING 
finger Apc11. The cullin Apc2 might, in analogy to SCF complexes, serve as a scaffold that 
positions substrate receptor and the E2 with the help of Apc11. The substrate is recruited via 
its recognition element (here: a D box) by the coactivator and probably by a core APC 
subunit, which might be Doc1. APC then assembles ubiquitin chains onto substrate proteins. 
Doc1 functions as a processivity factor for APC ubiquitination and aids in substrate binding. 
Vertical stripes indicate TPR subunits. Metazoan APC contains an additional TPR subunit, 
Apc7, which is not depicted here. Apc9, which has so far only been found in yeast, is 
hatched. Of the core subunits, Apc1, Apc2, Cdc27, Cdc16, Apc4, Apc5, Cdc16, Cdc23, and 
Apc11 are essential in yeast, whereas Apc9, Doc1, Cdc26 and Swm1 are not (see Table 1-1). 
One of the subcomplexes identified by Thornton et al. is composed of Apc2, Apc11 and 
Doc1, therefore referred to as the “catalytic subcomplex” (Thornton et al., 2006). The “TPR 
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subcomplex” contains the TPR subunits and, according to earlier findings most likely Apc9, 
Swm1 and Cdc26 (Passmore et al., 2003; Schwickart et al., 2004; Zachariae et al., 1996). 
Among the TPR subunits, Cdc27 is the most peripheral and Cdc23 the most internal 
component (Figure 1-2). Apc1, Apc4, Apc5 and Cdc23 associate interdependently, such that 
loss of any of them greatly reduces binding of the remaining three proteins (Thornton et al., 
2006). Upon deletion of Apc2, Apc11 and Doc1 are lost (Thornton et al., 2006). The 
situation appears to be different in human APC, where only partial loss of Doc1 is observed 
in an APC version lacking Apc2 and Apc11 (Vodermaier et al., 2003).
1.10 Electron microscopic analysis of APC structures
An idea how APC’s many subunits might assemble into a three-dimensional (3D) structure 
comes from recent cryo-electron microscopy (EM) data. Structures obtained for APC 
purified from frog egg extracts and human cells (Dube et al., 2005; Gieffers et al., 2001), as 
well from budding (Passmore et al., 2005b) and fission yeasts (Ohi et al., 2007) have revealed 
that the APC is an asymmetric triangular complex with an internal cavity. The structures 
differ from each other significantly with respect to the size of the cavity, which might be too 
small to accommodate all factors required for substrate ubiquitination (substrate, E2, 
ubiquitin) in the mammalian, frog and budding yeast APCs; the recent structure of fission 
yeast APC in contrast includes a prominent cavity in which the ubiquitination reaction was 
proposed to take place (Ohi et al., 2007). Labeling experiments performed with human APC 
contradict the existence of an inner reaction chamber since Cdh1 and the cullin domain of 
Apc2 are located on the outside of the complex (Dube et al., 2005). Since most of the 
subunits and many functions are conserved among APC molecules from different species, it 
is plausible that the overall structural organization and the reaction mechanism should be 
similar as well. Further experimental and structure determination approaches will have to 
clarify this issue. Vertebrate APC contains two domains referred to as “platform” and "arc 
lamp" which exhibit a large degree of flexibility relative to each other. A movement of the 
domains resulting in a diminished angle between “platform” and “arc lamp” can be observed 
upon Cdh1 binding to APC which implies that coactivator binding might induce 
conformational changes within APC (Dube et al., 2005). Two comprehensive antibody 
labeling data sets are largely consistent with the outlined APC subunit map (Schwickart et al., 
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2004; Thornton et al., 2006; Vodermaier et al., 2003); Figure 1-2). Ohi et al. have presented an 
almost-complete set of localized fission yeast APC subunits, the interpretation of which is 
however somewhat limited due to the fact that subunit positions are only available in two 
dimensions (2D) (Ohi et al., 2007). Subunit localization of eight human APC subunits,
performed similar as described in an earlier study (Dube et al., 2005), has yielded an 
impressive and largely “annotated” structure of human APC (Herzog et al., manuscript in 
preparation).
1.11 APC substrate recognition
Most APC substrates contain either one or both of two cis elements called the destruction 
box (D box, consensus sequence R-X-X-L-X-X-X-X-N, (Glotzer et al., 1991)) or the KEN 
box (K-E-N-X-X-X-E/D/N, (Pfleger and Kirschner, 2000)) that target them for 
ubiquitination by APC. Other less well characterized degrons include the A box (Littlepage
and Ruderman, 2002), the GxEN motif (Castro et al., 2003) and the O box (Araki et al., 
2005). Several studies have shown a direct association between coactivators and various APC 
substrates in vitro (Vodermaier, 2001), indicating that the coactivators might function 
similarly to the WD40 repeat-containing F box proteins in SCF complexes. Not all reports, 
however, were consistent with respect to the questions which regions within the coactivators 
are responsible for substrate binding and whether or not the coactivator-substrate interaction 
is D/KEN box dependent (Peters, 2006; Vodermaier, 2001). A direct interaction between 
the WD40 domain of Cdh1 and a D box-containing substrate peptide has recently been 
reported (Kraft et al., 2005). Importantly, residues within the WD40 domain required for the 
D box interaction were identified; mutations in these residues result in a Cdh1 version which 
is not able to efficiently ubiquitinate substrates anymore. This implies that the WD40 
domain is a functionally important D box receptor (Kraft et al., 2005). The first evidence that 
core APC might directly interact with substrates can be found in a study by Yamano et al.
who used a tandem D box affinity matrix to isolate APC from frog egg extracts (Yamano et 
al., 2004). Cdc20 was depleted and since Cdh1 is believed to be absent from these extracts, 
they did not contain any coactivators; yet APC was able to bind (Yamano et al., 2004). Some 
support for Yamano’s finding comes from a study on Emi1, which proposed that Emi1 
inhibit APC by acting as a pseudosubstrate inhibitor (Miller et al., 2006). The Emi1-APC 
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binding depends on Emi1’s D box and was also observed in frog egg extracts from which 
Cdc20 was depleted; lending support to Yamano’s findings that holo-APC contains a D box 
receptor (Miller et al., 2006). Substrates have recently been shown to be targeted to APC via a 
C-terminal MR motif (Hayes et al., 2006). This interaction occurs independently of Cdc20 
and is reminiscent of the IR tail-dependent binding of coactivators and Doc1 to APC core 
subunits (Vodermaier et al., 2003; Wendt et al., 2001).
Elegant experiments have put forward the idea of a stoichiometric APC-coactivator-
substrate complex. Passmore and Barford have reported that APC, coactivator and substrate 
form a ternary complex, and that the amount of APC-substrate binding directly correlates 
with the amount of APC-coactivator association (Passmore and Barford, 2005). “Isotope 
trapping” experiments have shown that a complex between APC and Cdc20 binds substrate 
with higher affinity than APC or Cdc20 alone (Eytan et al., 2006). Importantly, substrate 
binding to APC in the absence of coactivators occurs with highly reduced selectivity and 
affinity (Eytan et al., 2006), which again underlines the important role of coactivators in this 
process. Some studies have implicated specific APC subunits as APC substrate receptors. 
Whereas a yeast two-hybrid screen identified an interaction between the D box of the B-type 
cyclin Clb2 and Cdc23 (Meyn et al., 2002), several studies proposed Doc1 as an APC 
substrate receptor (Carroll et al., 2005; Nourry et al., 2004; Passmore et al., 2003).
1.12 …and the proposed role of Doc1 
Substrates have been reported to bind to APC in the absence of coactivators (Eytan et al., 
2006; Hayes et al., 2006; Yamano et al., 2004) and core APC has been shown to contribute to 
efficient substrate recognition together with coactivators (Burton et al., 2005; Eytan et al., 
2006; Kraft et al., 2005; Passmore and Barford, 2005) – yet the identity of the putative APC 
substrate receptor is still unknown. The best candidate so far is Doc1. APC lacking Doc1
can no longer bind substrates but is still able to associate with Cdc20 and Cdh1 (Passmore et 
al., 2003). This indicates that Doc1 contributes to substrate binding either directly or 
together with other APC subunits, but not via Cdc20 or Cdh1 (Passmore et al., 2003). 
Kinetic analysis has revealed a defect of APCdoc1 in processivity (Carroll and Morgan, 2002).
In a processive ubiquitination reaction, the substrate remains bound to APC while repeated 
cycles of ubiquitination occur; in absence of Doc1 only short substrate-ubiquitin conjugates 
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are formed (Carroll and Morgan, 2002). Residual APCdoc1 activity is not further reduced if 
the D box in substrates is mutated, indicating that Doc1 might contribute to D box 
recognition (Carroll et al., 2005).
ligand binding
surface
propeller
substrate
active site
Figure 1-3: Crystal structures of yeast Doc1 and a bacterial sialidase; structure 
overlay. A) Crystal structure of yeast Doc1. The Doc domain is shown in yellow and the 
putative ligand binding region is depicted. B) Three-domain structure of bacterial sialidase. 
The galactose binding domain which folds into a jelly-roll is overlaid with the similar Doc1 
structure. Sialidase consists of a 41 kDa propeller domain which was both crystallized 
separately bound to an inhibitor (shown in turquoise) and together with the IgG linker 
domain and the galactose binding domain bound to galactose (shown in purple). C) The 
sialidase structure is rotated by 90° to show the propeller fold of the 41 kDa domain. 
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The crystal structures of both human and budding yeast Apc10/Doc1 have been solved (Au 
et al., 2002; Wendt et al., 2001). Apc10/Doc1 exhibits a jelly-roll fold (Figure 1-3A) which is 
also found in other proteins; all these proteins have in common that they use the same 
surface to bind to their diverse ligands (Au et al., 2002; Wendt et al., 2001). Interestingly, 
residues conserved among Doc1 orthologs are found in a region of Doc1 that corresponds 
to this ligand-binding surface (Figure 1-3A). Mutational analysis has shown that Doc1 can no 
longer function as a processivity factor if four residues within this ligand binding surface are 
changed to alanines (Carroll et al., 2005). Doc1 might therefore use this surface to bind to a 
putative ligand, which could be an APC substrate or any other factor important in the 
ubiquitination reaction. A ternary APC-coactivator-substrate complex might therefore be 
formed when a substrate (via its D box) interacts with the WD40 propeller domain of a 
coactivator and with an APC subunit such as Doc1, either in a simultaneous or a sequential 
fashion (Figure 1-3B). Such a Doc1-coactivator arrangement would be strikingly similar to 
the domain structure of sialidase. The crystal structure of this sugar-hydrolyzing enzyme has 
revealed a propeller domain (Figure 1-3C) and a jelly-roll fold domain, connected by a linker 
domain, which collaborate in substrate binding and catalysis (Figure 1-3B; (Gaskell et al., 
1995; Peters, 2006)).
1.13 Aim of this study
The mechanisms of substrate recognition and ubiquitination by APC are only poorly 
understood. The APC subunit Doc1 has been shown to be a processivity factor for APC 
ubiquitination. The molecular basis for this function is not known. Doc1 might mediate 
processive ubiquitination reactions by directly binding to an APC substrate or any other 
factor important in the ubiquitination reaction. Alternatively Doc1 could have an indirect 
effect on APC activity by causing structural rearrangements within APC once a substrate is 
bound to the complex. I therefore set out to study the role of Doc1 in APC-mediated 
substrate ubiquitination by identifying the interaction partners of this subunit, both within 
APC and among factors involved in APC-catalyzed ubiquitination reactions. Because 
interactions involved in APC substrate recognition are thought to be very transient, I have 
chosen a site-specific photo crosslinking approach which allows “freezing” of transient 
interactions between Doc1 and its possible binding partners.
INTRODUCTION
23
Understanding how APC subunits, including Doc1, cooperate to recognize and ubiquitinate 
substrates will ultimately require information about their 3D organization within APC. We 
have decided to extend our EM studies to budding yeast APC, to be able to generate and 
analyze mutant and engineered APC versions. The first aim was to generate a 3D model of 
yeast APC. We then wanted to analyze mutant complexes such as APC lacking Doc1. 
Comparing 3D models of wild type APC and APC lacking Doc1 should reveal the localization 
of Doc1. Furthermore, we set out to analyze the localizations of additional APC subunits by 
fusing big globular tags to these proteins, which would not interfere with APC subunit 
assembly and function. Comparing an APC structure which contains a tagged protein with 
the wild type structure should reveal an additional mass which indicates the localization of the
epitope tag. By using this strategy for many APC subunits we aimed at generating an APC 
subunit topology map which is more precise than those presented before.
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2 Results
2.1 Site-specific photocrosslinking to identify interaction 
partners of Doc1
2.1.1 Yeast Doc1 comprises 250 and not 283 amino acids 
DOC1 was first identified as a gene involved in cyclin proteolysis in a genetic screen for 
mitotic arrest mutants (Hwang and Murray, 1997). Hwang and Murray had isolated a Doc1 
mutant, doc1-1, whose phenotype was rescued with a minimal sequence containing an open 
reading frame (ORF) which encoded a protein of 283 amino acids (Hwang and Murray, 
1997). The Saccharomyces genome database (SGD, http://www.yeastgenome.org/) entry for 
Doc1, however, comprises only 250 amino acids. Most Doc1 publications, including the 
work by Carroll et al. that I will be referring to often, used the 283 amino acid version
(Carroll et al., 2005).
In order to find out which version of Doc1 exists in the cell, I generated Doc1 from DNA 
templates encoding the “long” (Dl) and the “short” (Ds) version by in vitro translation (IVT). 
These DNA templates were generated by polymerase chain reaction (PCR)-amplification 
from genomic yeast DNA. For this I used two different forward primers which annealed 
upstream of either of the two proposed start codons and contained a T7 promotor and a 
Kozak sequence; the reverse primer used for both reactions annealed downstream of the 
stop codon. The “long” DNA template therefore contained two translation initiation sites. I 
separated the proteins obtained from the in vitro translation reactions by SDS-PAGE along 
with yeast cell extracts and purified APC. Doc1 was visualized by immunobloting using a 
Doc1 antibody and by phosphorimaging (Figure 2–1). The phosphorimage shows that when 
using DNA encoding the “long” Doc1 for the translation reaction, two versions of Doc1 
were generated, presumably because the template contained both translation start sites
(Figure 2–1, lane 3). In contrast, only one Doc1 version was obtained in the reactions using 
the “short” Doc1 template had the same size as the faster migrating band in the “long” 
Doc1 sample (Figure 2–1, lane 2). The endogenous Doc1 protein that was present in the cell 
extract (Figure 2–1, lane 5) and in the purified APC sample (Figure 2–1, lane 4) clearly 
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comigrated with the short version of Doc1 (Figure 2–1, lane 2). I therefore decided to use 
the 250 amino acid long version of Doc1 in my in vitro assays.
Figure 2-1: Doc1 contained in yeast cell extracts comigrates with the 250, and not the 
283 amino acid long version. The product of an in vitro translation (IVT) using the short 
DOC1 ORF version as a template (lane 2) was loaded next to an IVT that had been 
generated from a template that also comprised the earlier translation start site. Lanes 1 and 4 
contain TAP-purified APC from doc1 (d) and wild type (wt) strains and lane 5 the extract 
(xt) of a wild type strain for size comparison. Samples were analyzed by immunobloting using 
Cdc16 and Doc1 antibodies and by phosphorimaging of the same membrane. The asterix 
marks an unspecific signal recognized by the Cdc16 antibody on cell extracts. On the 
phorphorimage, in vitro translated proteins labeled with [S35]methionine are visualized.
2.1.2 APC can be reconstituted from APCdoc1 and recombinant Doc1
To identify interaction partners of Doc1 I wanted to replace endogenous Doc1 with a form 
of Doc1 that carries a photocrosslinker at a defined amino acid site. It has been shown 
before that adding back recombinant Doc1 to mutant APCdoc1 fully restores APC’s ubiquitin 
ligase activity (Passmore et al., 2003). APC was purified to high homogeneity from a yeast 
strain carrying a TAP-tag on Apc4 via the TAP-method ((Figure 2–2A), Passmore et al., 
2005a; Puig et al., 2001). DOC1 was deleted from this strain (which renders it temperature 
sensitive) to allow complete replacement with a recombinant crosslinker-containing version,
and the deletion was analyzed by silver staining (Figure 2–2A) and by immunobloting (Figure 
2–2B). APC lacking Doc1 is stable and was reported to contain all other core subunits at 
levels similar to wild type APC (Carroll and Morgan, 2002; Passmore et al., 2003; Schwickart 
et al., 2004). In my preparations, all subunits seemed to be unaffected with the exception of 
Apc11, whose levels were slightly reduced (Figure 2–2A, auto contrasted panel).
RESULTS
26
Figure 2-2: Addition of in vitro translated Doc1 to APC lacking Doc1 restores wild 
type activity. A) APC from a wild type strain (wt) and a strain lacking Doc1 (doc1) was 
purified by the TAP-method and analyzed by SDS-PAGE and silver staining. APC subunits
were identified by their electrophoretic mobility and by mass spectrometry. The asterix 
marks a contaminating band which does not contain APC subunits. Preparations were from 
strains J319 (wt) and J323 (doc1). B) The Doc1 protein is absent from yeast strains after 
DOC1 deletion. APC purified from wild type (wt) and doc1yeast strains was analyzed by 
immunobloting using myc and Doc1 antibodies. Both yeast strains (J42, J187) carried a myc-
tag on Apc5. C) APC lacking Doc1 shows impaired ubiquitination activity, and activity of the 
wild type can be restored by adding recombinant Doc1. In vitro ubiquitination assay using an
[S35]methionine-labeled Hsl1-fragment (amino acids 667 to 872) as model substrate. 
Substrate and ubiquitin conjugates are visualized on a phosphorimage.
I carried out in vitro ubiquitination assays in which recombinant in vitro translated Cdh1 was 
used to activate APC, to measure APC activity. Wild type APC assembled polyubiquitin 
chains on the yeast Hsl1(667-872)model substrate (Figure 2–2C, lanes 1 to 9). In contrast, 
substrates processed by APCdoc1 were modified with short conjugates only (Figure 2–2C, 
lanes 10 to 15). These results are consistent with previous data (Carroll et al., 2005; Passmore 
et al., 2003) and are in line with the notion that Doc1 acts as a processivity factor for APC 
ubiquitination (Carroll et al., 2005). The activity of the wild type enzyme can be largely restored 
by adding back Doc1 to APCdoc1 ((Carroll et al., 2005; Passmore et al., 2003), Figure 2–2B, 
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lanes 16 and 17). Despite the complication that the reticulocyte lysate contributes to 
enzymatic activity (Figure 2–2C, lanes 18 and 19), I used Doc1 generated by IVT for 
restoring APC activity, because I was using this system also for incorporation of the 
photocrosslinker (see below). 
2.1.3 Identification of Doc 1 interaction partners within the APC
Photocrosslinking techniques have recently been adopted to study APC-substrate 
interactions (Kraft et al., 2005). We decided to use the crosslinker compound L-4’-(3-
[trifluoromethyl]-3H-diazirine-3yl) phenylalanine ((tmd)phe, Figure 2–3A), which can be 
introduced into a protein in an in vitro transcription/translation system using a suppressor 
tRNA approach (Brunner, 1993). (Tmd)phe is a structural analogue of phenylalanine which 
upon photolysis generates a very reactive carbene that is capable of forming covalent 
interactions with a broad range of organic bonds ((Brunner, 1993), Figure 2–3A). Because of 
its reasonably small size, (tmd)phe may be incorporated into proteins without seriously 
affecting protein structure or the protein’s interactions with adjacent components (High et 
al., 1993). The incorporation of the modified amino acid is directed by the presence of an 
“amber” stop codon (TAG) which is introduced into the coding sequence of the cDNA to be 
expressed. In an in vitro transcription/translation reaction, the use of an amber suppresser 
tRNA coupled to (tmd)phe ((tmd)phe-tRNA) allows translation beyond the stop codon, 
resulting in a protein carrying a photoactivatable amino acid at one specific site. 
Figure 2–3B shows an example of an in vitro translation product of a Doc1 amber mutant in 
the presence or absence of (tmd)phe-tRNA; the position of the amber mutations is described 
below. As predicted, a truncated version of the protein was generated in the absence of 
(tmd)phe-tRNA (Figure 2–3C, lane 1). After addition of the compound, most of the
translation product represents full-length protein with incorporated crosslinker (Figure 2–
3C, lane 2) which had the same size as a translation product obtained from wild type cDNA 
(Figure 2–3C, lane 3). The incorporation efficiency was about 75 % on average for all Doc1 
mutants generated (not shown). An efficient suppression required the presence of 
magnesium acetate in the reaction, which in turn decreased the total translation efficiency 
about three to four-fold (compare Figure 2–3C, lanes 2 and 3; quantification not shown).
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(tmd)phe:
L-4‘-(3-[trifluoromethyl]-
3H-diazirin-3-yl)phenylalanine
UAG
AUC
Phe
Phe Phe Glu AlaSer Arg
IVT
DOC1 amber mRNA Doc1*
Figure 2-3: Introduction of (tmd)phe into Doc1 by in vitro translation. A) Structure of 
L-4’-(3-[trifluoromethyl]-3H-diazirine-3yl) phenylalanine ((tmd)phe)). B) An amber stop 
codon is introduced into the cDNA encoding the protein of interest. The protein is in vitro
translated in the presence of a non-natural suppressor tRNA coupled to a (tmd)phe and 
[S35]methionine. C) Every full-length protein contains the photoreactive amino acid. 
Phosphorimage showing the in vitro translation of Doc1 wild type (wt) and mutant#2 in 
absence and presence of (tmd)phe-tRNA. 
To set up the conditions for photocrosslinking experiments with Doc1, I first introduced the 
modified amino acid within a region which was known to be important for Doc1 interaction 
with the APC. A mutational analysis had shown that two amino acids close to the C-
terminus of Doc1 (depicted in Figure 2–4A), which are highly conserved among Doc1 
orthologs, are important for Doc1 binding to the APC (Carroll et al., 2005). Carroll et al. had 
found that mutation of these two sites, K129 and R130, to alanine and simultaneous deletion 
of the C-terminus, greatly reduced the binding of Doc1 to APC (Carroll et al., 2005). I 
therefore decided to introduce the photocrosslinker at three different sites within this “C-
terminal region” (at K129, R130 and an adjacent site, S128, Figure 2–4A). These three 
mutants were used in photocrosslinking experiments. The experimental setup is outlined in 
Figure 2–4B. I incubated APCdoc1 that was immobilized on IgG sepharose beads via a TAP-
tag on Apc4 with the Doc1 crosslinker versions, washed off the reticulocyte lysate 
translation mixture and activated the photocrosslinker with UV-light. SDS-PAGE and 
phosphorimage analysis revealed two major crosslink products for mutants S128amber and 
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K129amber at sizes of ~120 kDa and ~200 kDa (Figure 2–4C, lanes 2 and 3). No crosslink 
products were obtained for mutant R130 (not shown). These results indicate that Doc1’s 
interaction partners can be identified with this approach.
purify APC + Doc1*
([S35]-labeled)
UV
?
UV              - +  
Doc1 
xlink
APC4-TAP
doc1
Figure 2-4: Insertion of a photocrosslinker at single sites within several regions of 
Doc1 results, upon photolysis, in specific crosslink products with different 
electrophoretic mobilities. A) Structure of S. cerevisiae Doc1 generated with pymol 
(DeLano, W.L. The PyMOL Molecular Graphics System (2002), http://www.pymol.org). 
Two regions which were proven to be important for Doc1 function (Carroll et al., 2005) are 
depicted. When a photoreactive amino acid was inserted at the sites shown in the structure, 
specific crosslink (xlink) products were obtained. B) Experimental outline. APC from strains 
lacking Doc1 was bound to beads via a TAP-tag on Apc4. Radiolabeled Doc1 containing a 
photocrosslinker is bound to APC and the photocrosslinker is activated by UV-light. 
Samples were analyzed by SDS-PAGE and phosphorimaging for mobility shifts occurring 
upon UV-irradiation. C) Overview of crosslink products obtained with Doc1amber mutants 
carrying the photocrosslinker at the positions indicated in A). APC was bound to beads and 
incubated with Doc1 versions carrying photocrosslinker at the given positions. After UV-
irradiation, bead-bound proteins were eluted by SDS sample buffer and samples were 
analyzed by phosphorimaging. The contrast settings of the phosphorimage were changed to 
visualize the crosslink products, which ran at three different sizes. 
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I then went on to test further 21 Doc1 amber mutants under the above conditions. Subsets of 
these mutants contained the photocrosslinker within regions or at sites that were described 
as being important for Doc1 function before (Carroll et al., 2005), such as the putative ligand 
Table 2-1: List of all sites in Doc1 which were exchanged for the photoreactive amino 
acid. For easier comparison with studies such as the one from (Carroll et al., 2005), the 
corresponding positions in the “long” Doc1 versions are also given. Regions within Doc1 
were roughly classified based on the view shown in Figure 2-4A. Abbreviations are: back side
(BS), N-terminal helix (NH), front side (FS), C-terminal region (CR), processivity loop (PL),
IR tail (IR).
site of incorporation site in “long” Doc1 location of site in structure
R37 R70 BS
H67 H100 NH
Q71 Q104 NH
K91 K124 FS
K96 K129 FS
L97 L130 FS
F103 F136 FS
D110 D143 FS
D116 D149 FS
S128 S161 CR
K129 K162 CR
R130 R163 CR
E146 E179 BS
K154 K187 FS
R182 R215 BS
R199 R232 FS
N205 N238 PL
H206 H239 PL
E207 E240 PL
N208 N241 PL
K210 K243 PL
D211 D244 PL
E239 E272 IR
F244 F277 IR
binding region (Figure 2–4A, Section 2.1.4). In addition, I selected sites for crosslinker 
incorporation in all areas of the surface of Doc1. In total I exchanged 24 residues for 
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(tmd)phe, corresponding to 10 % of all Doc1 amino acid residues. Table 2–1 lists all mutants 
that I generated and tested.
I obtained crosslink products with six mutants, as shown in Figure 2–4C. Mutants 
K154amber and N205amber gave a similar 200 kDa crosslink product as mutant S128amber (in 
Figure 2–4C, lanes 2, 4, 5). Using R182amber resulted in a crosslink product similar in size to 
the one observed with K129amber (in Figure 2–4C, lanes 2 and 6). Finally, I obtained a 
product which ran at a size of about 120 kDa with mutant F244amber (in Figure 2–4C, lane 
7) and with mutant E239amber (not shown).
Figure 2-5: Myc-tagging of APC subunits results in significant mobility shifts. APC 
was purified from tagged and untagged strains by myc-immunoprecipitation (IP) in (A) or by 
myc-IP and IgG pull-down (IgG p.d., B to D). APC subunits were visualized by 
immunobloting using antibodies against Apc1 (A), Apc2 (B), Cdc16 (C) and Cdc27 (D) and 
the myc-epitope (B to D). All strains used also carried a myc-tag on Apc5. Visualizing the 
shift of Apc5 upon tagging with the myc9-epitope could not be demonstrated in a similar 
way since an antibody against yeast Apc5 was not available. The following strains were used:
strains J61 and J134 for (A); J189 and J187 for (B); J235 and J187 for (C); J266 and J187 for 
(D); as a control strain (ctrl), J202 was used; the TAP-purified (TAP-purif.) samples were
from J180.
To test if the observed crosslink products represent Doc1 bound to APC subunits, and to 
determine the identity of these subunits, we generated a new set of yeast strains. These 
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strains, in addition to the doc1 deletion and the TAP-tag on APC4, each carried a myc-tag on 
one of the candidate subunits. Since the observed crosslink products were in the range of 
100 to 200 kDa, the molecular weight of Doc1’s possible interaction partners was predicted 
to be 80 kDa or more. We therefore created yeast strains a tag on Apc1, Apc2, Cdc27, 
Cdc16 or Apc5; we used myc6-, myc9- or myc18-tags. Figure 2–5 shows that these tags were 
big enough to clearly alter the electrophoretic mobility of the tagged APC subunits. 
Figure 2-6: Identification of Doc1’s interaction partners within APC. Doc1 directly 
interacts with Cdc16 (A and B), Cdc27 (B) and Apc1 (C). Crosslinker-containing Doc1 
versions were incubated with APC immobilized on beads. Photolysis was induced by UV-
irradiation and samples were analyzed by SDS-PAGE and phosphorimaging. A) Doc1 binds 
to Cdc16 via K129. To identify the subunit, strains carrying tags on Cdc16, Apc2, Apc5 and 
Cdc27 (J235, J189, J187, J266) were used. B) Doc1 interacts with Cdc16 via K182 and with 
Cdc27 via F244. The experiment was carried out using strains with myc-tagged Apc2, Ccd16 
and Cdc27 (J189, J235, J266). C) Doc1 contacts Apc1 via S128, K154 and N205. Strains 
carrying myc-tags on Apc1 and Apc2 were used (J182, J189).
Using these strains in crosslinking experiments should therefore result in an additional 
mobility shift compared to the initial crosslink once the “right” strain was used for APC 
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isolation and Doc1 was crosslinked to a myc-tagged subunit. Following this strategy led to 
the identification of Cdc16 as a binding partner of Doc1’s residue K129 in the C-terminal 
region (Figure 2–6A, compare lane 2 with lanes 5 to 7). The same interaction was also found 
with the mutant R182amber (Figure 2–6B, compare lane 3 with lanes 1 and 2). R182 is in 
proximity to K129 and emanates from the lower back of the molecule (Figure 2–4A). 
Residues in Doc1’s C-terminal protrusion, the IR tail, directly interacted with Cdc27 (Figure 
2–6B, compare lane 7 with lanes 5 and 6, and data not shown). Two mutants crosslinked
strongly to Apc1; one of them carries the crosslinker in the C-terminal region (S128, Figure 
2–6C, compare lanes 3 and 4) and in the other one it extends the lower right from a -sheet 
(K154, Figure 2–6C, compare lanes 6 and 7). In addition, N205amber, in which the 
crosslinker is located in the putative ligand binding region, crosslinked weakly to Apc1
(Figure 2–6C, compare lanes 9 and 10). With mutant K129amber, which strongly crosslinked
to Cdc16, I also obtained a weak crosslink to Apc1 (not shown). Table 2–2 lists successful 
crosslinker mutants and the identified interaction partners.
Table 2-2: List of all Doc1 interactions identified by photocrosslinking. +++ marks a 
strong and + a crosslink.
site of incorporation site in “long” Doc1 interaction partner
S128 S161 Apc1 (+++)
Cdc16 (+)
K129 K162 Cdc16 (+++)
Apc1 (+)
K154 K187 Apc1 (+++)
R182 R215 Cdc16 (+++)
N205 N238 Apc1 (+)
F244 F277 Cdc27 (+++)
In the budding yeast APC subunit map by Thornton et al., Cdc16 is required for the 
association of Cdc27 with APC (Thornton et al., 2006). The same authors have reported that 
APC isolated from a cdc27 strain retains residual ubiquitination activity, whereas cdc16
APC is inactive (Thornton et al., 2006). This suggests that Cdc16 might have an additional 
function beyond mediating Cdc27 binding to APC. We hypothesized that the interaction of
Doc1 with Cdc16 might be important for the residual ubiquitination activity of cdc27
RESULTS
34
APC. One prerequisite for this would be that the Doc1-Cdc16 interaction can take place also 
in the absence of Cdc27. I therefore decided to analyze the effect of Doc1’s IR tail, which 
directly binds to Cdc27, on the interaction with Cdc16. For this, I first had to find 
conditions, under which wild type Doc1 and a version lacking the C-terminal 16 amino acids 
(Doc1IR) were binding to APCdoc1 at similar levels. TAP-tagged APCdoc1 bound to IgG 
sepharose was incubated with the two in vitro translated Doc1 versions and subsequently 
eluted by TEV protease cleavage at different time points. At early time points, more wild type
Doc1 was bound to APC than Doc1IR, but the effect of the IR tail deletion decreased over 
time with no difference left after 60 min (Figure 2–7A, lanes 15 and 16). Comparable levels 
Figure 2-7: Doc1’s C-terminal IR tail enhances binding of Doc1 to APC. A) The effect 
of a C-terminal deletion of Doc1 decreases over time. TAP-tagged APC was bound to IgG 
sepharose, incubated with in vitro translated [S35]-labeled Doc1 wild type (wt) and a truncated
version (IR). Bound material was eluted by TEV cleavage and analyzed by SDS-PAGE and 
immunobloting as well as phosphorimaging. 10 % of the input was also analyzed. Yeast 
strains used in this experiment contained myc-tagged Apc5, which was stained with 9E10 
antibody. B) Quantification of the experiment shown in (A) and three independent similar 
experiments using ImageQuant. C) The crosslink of Doc1 to Cdc16 via Doc1’s K129 is 
four-fold reduced after IR tail deletion. Doc1 and Doc1IR both carrying a crosslinker at 
K129 were bound to APC-beads for the times indicated with arrows in (B) to achieve equal 
amounts being bound of both versions. After photolysis, samples were analyzed by SDS-
PAGE and phosphorimaging. Samples were produced in duplicates.
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of both Doc1 versions were bound when allowing wild type Doc1 to bind for 10 and 
Doc1IR for 30 min. (Figure 2–7B, arrows). 
I then used this information for a crosslinking experiment, assuming that the presence of the 
photocrosslinker would have no or the same effect on the binding of both Doc1 versions. 
The photocrosslinkers were inserted into wild type Doc1 and Doc1IR at K129, proteins 
were bound to APCdoc1-beads, and after UV-irradiation and SDS-PAGE analysis I 
compared the crosslink intensities by quantifying the phosphorimage (Figure 2-7). The 
crosslink obtained with wild type Doc1 is about four times stronger than the one with 
Doc1IR (Figure 2-7, compare lanes 2 and 3 with lanes 4 and 5). The binding of Cdc27 to 
Doc1’s IR tail therefore significantly enhances the Doc1-Cdc16 interaction.
2.1.4 Searching for a putative ligand of Doc1’s “processivity loop”
The results above demonstrated that the photocrosslinking approach allows the 
identification of Doc1 interacting proteins. We therefore wanted to use this technique to 
exploit the mechanism underlying the role of Doc1 in processive APC-mediated 
ubiquitination reactions (Carroll and Morgan, 2002; Passmore et al., 2003). Doc1’s 
“processivity loop” (Figure 2-4A) has been proposed to bind to a putative ligand (Au et al., 
2002; Wendt et al., 2001), and biochemical and yeast genetic studies implied that this ligand 
might be an APC substrate (Carroll et al., 2005; Passmore et al., 2003). Importantly, a
mutational analysis has revealed four amino acids located in the putative ligand binding 
region, which are essential for Doc1’s function in processivity (Carroll et al., 2005).
We therefore speculated that Doc1 might use this “processivity loop” to bind to a putative 
ligand, which could be the substrate or any other component present in the ubiquitination 
reaction. Since in an in vitro ubiquitination assay a severe difference in the presence and 
absence of Doc1 can be observed ((Carroll and Morgan, 2002; Passmore et al., 2003), Figure 
2-2), I performed crosslinking in this experimental set up (Figure 2-8A). Figure 2-8B shows 
that purified APC was able to ubiquitinate the substrate used in this set of experiments,
GST-Hsl1(667-872). I had decided to use GST-Hsl1(667-872) in this set of experiments, because the 
Hsl1 fragment was shown to be a an APC substrate (Burton and Solomon, 2000; Burton and 
Solomon, 2001) which is processively ubiquitinated by APC (Carroll et al., 2005). 
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Furthermore, the fusion with GST rendered it a 55 kDa protein. Possible crosslinks with 
Doc1 (33 kDa) would therefore be bigger than 70 kDa; at 70 kDa I often observed 
unspecific crosslinks, possibly due to Doc1 molecules reaction with each other (see below). 
APC lacking Doc1 was immobilized on beads and incubated with Doc1 crosslinker versions 
in which one of the “processivity loop” residues had been exchanged for the 
photoactivatable amino acid. Before UV-irradiation I added the components of an in vitro
ubiquitination assay mix (termed ubiquitination mix), namely E1 and E2 enzymes, Cdh1, 
substrate, ubiquitin, ATP and 0.12 µM substrate (lanes 1, 4 and 7 in Figure 2-8B, C and D). 
In an additional sample set, I added 100-fold more substrate (12 µM) to facilitate the 
formation of a possible crosslink to a substrate (lanes 3, 6 and 9 in Figure 2-8B, C and D). A 
control set was incubated with ubiquitination buffer instead of the ubiquitination mix (lanes 
2, 5 and 8 in Figure 2-8B, C and D). Phosphorimages after SDS-PAGE were then
specifically analyzed for crosslink products which were dependent on the presence of the 
ubiquitination mix in the crosslinking experiment. Because the substrate is the most 
prominent candidate for a Doc1 interactor (Carroll et al., 2005; Passmore et al., 2003), I also 
tested another model substrate, human cyclin B (amino acids 1 to 87) which is also well 
ubiquitinated by yeast APC in similar assays (not shown). All conditions were tested at least 
twice and radioactive gels were exposed to screens for up to eight weeks in order to enhance
possible weak bands. Nevertheless, no specific bands could be detected when comparing 
samples that were UV-irradiated in absence and presence of the ubiquitination mix. 
Furthermore, I tried leaving out individual components of the ubiquitination mix when 
performing the crosslinking, but this also did not lead to the loss of any of the obtained 
bands (not shown). The mobility shift pattern obtained due to the interactions of Doc1 with 
Cdc16, Cdc27 and Apc1 was not affected by the addition of ubiquitination mix during the 
UV-exposure (lanes 1 to 3 in Figure 2-8B, C and D). The intensity of the crosslinks, 
however, was decreased in some cases (Figure 2-8B, compare lanes 1 and 3 with lane 2, and 
data not shown) when the samples were incubated with the ubiquitination mix before UV-
irradiation.
As Figure 2-8B to C shows, the phosphorimages obtained from experiments employing the 
Doc1 loop amber mutants were not empty, but indeed contained several bands, the most 
prominent of which were running at 45 kDa, 70 kDa, and between 120 to 140 kDa. Two 
reasons, however, made us think that these bands do not represent crosslinks of Doc1 to its 
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putative ligand. First of all, these bands, and in particular those at 45 kDa and 70 kDa size
were observed frequently and with several mutants which carried the crosslinker at different 
positions on Doc1. According to the manufacturer’s manual provided with our reticulocyte 
lysate translation system (Promega), labeling of a 42 kDa protein is frequently obtained when 
using rabbit reticulocyte lysate with [S35]methionine of a quality below “cell labeling grade” 
Figure 2-8: Crosslinking experiments employing Doc1 mutants containing a 
photocrosslinker in the putative ligand binding region. A) The GST-Hsl1 fragment 
(amino acids 667 to 872, GST-Hsl1(667-872)) is ubiquitinated by purified APC. TAP-purified 
APC was incubated with E1, E2, Cdh1, ubiquitin, ATP and GST-Hsl1(667-872) for the times 
indicated and samples were analyzed by SDS-PAGE and immunobloting using a Hsl1 
antibody (1740). B) Crosslinking experiment testing Doc1 mutants K129, E207 and N208. 
Each mutant was tested in presence of ubiquitination mix containing 0.12 µM GST-Hsl1(667-
872) (+), 12 µM GST-Hsl1(667-872) (++) and in absence of the ubiquitination mix (-). K129 
served as a positive control, it crosslinks to Cdc16 independent of the ubiquitination mix. 
After 10 min of UV-exposure, samples were analyzed by SDS-PAGE and phosphorimaging. 
C) Same experimental set-up as in (B) but this time using mutants F244 (positive control, 
crosslinks to Cdc27), K210 and D211. D) Same as in (B) but testing mutants N205 and 
H206 with K154 (crosslinks to Apc1) as a positive control. For the gel region above the 
Doc1 input contrast settings were changed to facilitate visualization of weak bands. The 
black asterices mark unspecific crosslink products and the colored asterices crosslinks to 
APC subunits (see text).
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(Jackson and Hunt, 1983). I could, despite the use of different labels including the 
recommended company and grade, often observe a band in the 45 kDa region in translation 
reactions generating Doc1 versions or other proteins (not shown). One explanation for the 
existence of the putatively unspecific 42 kDa bands could therefore be that the labeled rabbit 
reticulocyte lysate 42 kDa protein was not washed off before the UV-exposure. This is
supported by the observation that the 42 kDa band was also present in control reactions that 
had not been exposed to UV-light (not shown). The band at 70 kDa might contain Doc1 
dimers resulting from two Doc1 molecules bound to each other. Formation of this band is 
not dependent on APC, because this band was also observed in control reactions for which 
IgG beads were incubated with extracts of yeast strains that did not contain a TAP-tag (not 
shown). Crosslinker containing Doc1 versions might therefore bind non-specifically to IgG 
beads and crosslink to each other in an unspecific manner. Accordingly, weaker unspecific 
bands observed at a size of 120 to 140 kDa could be due to formation of Doc1 trimers and 
tetramers. It is important to note, however, that the crosslinks to Cdc16 can clearly be 
distinguished from the unspecific bands. The specific crosslinks not only ran at a slightly 
lower size when proteins on the gel were well-separated (Figure 2-6A lanes 2 and 5), but 
importantly the mobility of the unspecific bands was not changed upon use of myc-tagged 
APC strains (Figure 2-6A).
2.1.5 Functionality of photocrosslinker containing Doc1 versions
For those mutants with which I could identify specific crosslink products (Table 2-2), I also 
tested if these mutants can restore APC activity in ubiquitination assays. I made use of the 
fact that APC lacking Doc1 (APCdoc1) shows impaired ubiquitination activity (Carroll and 
Morgan, 2002; Passmore et al., 2003) and that wild type ubiquitination activity can be restored 
by adding back recombinant Doc1 (Figure 2-2; (Carroll et al., 2005; Passmore et al., 2003)). 
To assess whether the crosslinker-containing Doc1 versions were also able to restore wild type
ubiquitination activity to APCdoc1, I carried out in vitro ubiquitination assays (Figure 2-9A).
Mutant APC was pre-incubated with Doc1 mutants and then assayed for its ability to 
assemble ubiquitin chains onto the Hsl1 fragment after addition of E1 and E2 enzymes, 
Cdh1, ubiquitin and ATP. Since Doc1, Cdh1 and Hsl1(667-872) were produced by in vitro
translation in reticulocyte lysate, strong background activity in the absence of Doc1 was 
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observed (Figure 2-9A, lanes 2 and 3). Mutants that carry the crosslinker in the C-terminus 
showed more activity in this assay than those with the mutated amino acid inserted within
the processivity loop Figure 2-9A, lanes 10 and 11, data not shown). In particular, Doc1 
versions with crosslinkers inserted at K129, R182, and F244 largely restored wild type
ubiquitination activity (Figure Figure 2-9A, lanes 8, 9, 14 to 19), indicating that the crosslinks 
to Cdc16 and Cdc27 were obtained with functional mutants. Mutants carrying the 
photocrosslinker at K154 and N205, which crosslinked to Apc1, clearly retained only little
(Figure 2-9A, lanes 10 to 13), but notably more than background activity. S128, which also 
crosslinked predominantly to Apc1, showed intermediate activity (Figure 2-9A, lanes 6 and 
7). 
Next, we performed growth test experiments to examine whether the temperature sensitivity 
of a DOC1 deleted strain could be rescued by Doc1 mutants which carry single 
phenylalanine mutations under the endogenous DOC1 promoter. Strains lacking Doc1 are 
temperature sensitive and can not grow at 37°C (Figure 2-9C). This phenotype can be 
partially rescued by introducing wild type DOC1 on an integrative plasmid under the 
endogenous DOC1 promoter (Figure 2-9C). We then mutated all sites which by 
photocrosslinking had been shown to interact with an APC subunit (Table 2-2) to 
phenylalanine. Since the photoactivatable amino acid (tmd)phe is a phenylalanine analog
(Figure 2-3A), we reasoned that with this amino acid exchange we would mimick the “real”
situation best and might be able to estimate the effect of (tmd)phe on Doc1 function “in 
vivo”. Importantly, no difference could be observed with our phenylalanine mutants in this 
assay (Figure 2-9C), indicating that the overall function of these Doc1 versions might not be 
impaired by insertion of a bulky amino acid. In particular, if sites that interacted with Cdc16, 
Cdc27 or Apc1 were exchanged for a phenylalanine, Doc1 was still able to exert its overall 
cellular function. These observations further support the notion that the crosslinks were 
obtained with at least partially functional Doc1 versions.
Doc1 versions carrying a photocrosslinker in the processivity loop were greatly impaired in 
their ability to restore activity to mutant APC, as measured in in vitro ubiquitination assays 
using TAP-purified APC (Figure 2-9A and data not shown). Nevertheless, the measured 
activities were above background levels (Figure 2-9A and data not shown). In order to 
explore directly whether ubiquitination could be stimulated by Doc1 under conditions of a 
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Figure 2-9: Analyzing functionality of Doc1 versions containing a photocrosslinker.
A) In vitro ubiquitination assay of APC reconstituted from mutant APC lacking Doc1 and 
from crosslinker-containing Doc1 versions. TAP-purified mutant APC was pre-incubated 
with the indicated Doc1 versions that had been generated by in vitro translation. As a control, 
reticulocyte lysate was used. E1, E2, Cdh1, ubiquitin, ATP and a [S35]-labeled Hsl1-fragment 
(Hsl1(667-872)) were added and reactions were stopped after 45 and 90 minutes. Samples were 
analyzed by SDS-PAGE and phosphorimaging. B) Quantification of the experiment shown 
in (A) using ImageQuant. Intensity of ubiquitin conjugates above the yellow mark was
divided by the intensity below the mark to obtain an arbitrary activity value. The axis 
intersection was set to the value obtained with the reticulocyte lysate control after 90 min 
incubation (lane 3 in (A). Crosslinks obtained initially with mutant R199 were not 
reproducible and are not shown in this study. Therefore, R199 was not included in the 
quantification. C) Doc1 growth assay. The temperature sensitivity of doc1 strains 
transformed with Doc1 wild type, Doc1 Phe-mutants (see text) or empty plasmid as a control 
was analyzed by spotting assays and incubation at 37°C. In the mutant which crosslinked to 
Cdc27 (F244), a phenylalanine had been exchanged for (tmd)phe. D) Test of ubiquitination 
activity of Doc1 mutants carrying the crosslinker in the processivity loop during the 
crosslinking experiment. Supernatants from the experiment shown in Figure 2-8D were
analyzed by immunobloting using an antibody against ubiquitin. Lanes 13 and 14 contain 
equally treated samples to control ubiquitination activity. No Doc1 was added to mutant 
APC in lane 14 and wild type APC was analyzed in lane 13 (ubiquitination mix (ubi mix), see 
text).
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crosslinking experiment, I analyzed the formation of substrate-ubiquitin conjugates during 
the actual crosslinking experiment. I took advantage of the fact that substrates can be largely 
separated from bead-bound APC by centrifugation. APCdoc1on beads, bound Doc1 and 
potentially crosslinked ubiquitination mix components were analyzed by phosphorimaging 
(Section 2.1.4). At the same time the supernatants could be separated by SDS-PAGE and 
analyzed by immunobloting with antibodies specific for the substrate or ubiquitin. Figure
2-9A shows such an analysis with supernatant samples taken from the experiment in Figure
2-8D. All samples were therefore generated by incubating APC lacking Doc1 bound to 
beads with Doc1 crosslinker mutants, before adding an ubiquitination mix containing GST-
Hsl1(667-872) as a substrate for 15 min. After UV-exposure bead-bound material was removed. 
A sample to which no Doc1 had been added (Figure 2-9D, lane 14) and a sample in which 
wild type APC was used (Figure 2-9D, lane 13) were analyzed in parallel. The experiment 
showed that Doc1 loop mutants were indeed able to stimulate APC activity (Figure 2-9D, 
compare lanes 1, 4 and 7 with lanes 10 and 13 for wild type activity and with lane 14 for “no 
Doc1” activity). Although this was not a quantitative immunoblot and the assay did not 
seem to be very sensitive (since only little difference between wild type Doc1 and mutant 
Doc1 could be observed, compare lanes 1, 4 and 7 with lane 10 in Figure 2-9D), the result 
clearly showed that Doc1-mediated ubiquitination was occuring during the actual 
crosslinking experiments. I therefore carried out my search for a putative Doc1 ligand under 
conditions which allowed at least partially functional Doc1 versions to stimulate substrate 
ubiquitination.  
2.2 Role of Doc1 in potential APC dimerization
In order to determine the size of yeast APC, yeast extracts have been sedimented through 
glycerol gradients. Yeast APC sediments as a 36S particle (Zachariae et al., 1996), whereas 
Xenopus and HeLa APC have been reported to sediment as 20S and 22S particles, 
respectively (Gieffers et al., 2001; King et al., 1995). When running purified APC on non-
denaturing gels, a doublet can be observed with the slower migrating form being about twice 
as large as the faster migrating one, which in turn matches estimates of the size of yeast APC 
(Passmore and Barford, 2005). Monomeric and dimeric form can be separated from each 
other. When used in activity assays, the dimeric form seems to process its substrate with an 
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increased processivity compared to the monomeric version (Passmore et al., 2005b). This 
raises the interesting question whether Doc1 contributes to the processivity of APC-
catalyzed ubiquitination reactions by mediating APC dimerization. 
Because Apc1 is the only APC subunit that has never been proposed to be present more 
than once per complex, I used the ability of Apc1 to self-associate (Zachariae et al., 1996) as 
a second readout for APC dimerization. Similar to Zachariae et al. (Zachariae et al., 1996), I 
used a yeast strain which contained two different epitope-tagged versions of Apc1. I 
performed co-immunoprecipitation experiments to determine whether one epitope-tagged 
component could co-immunoprecipitate the other epitope-tagged version of itself, and vice 
versa. In a diploid strain expressing Apc1-myc6 and Apc1-HA3, the myc antibody 
immunoprecipitated both Apc1-myc6 and Apc1-HA3 (Figure 2-10, lanes 8 and 9). Apc1-
HA3 was not pulled down from a strain producing only Apc1-myc6 (Figure 2-10, lane 8), 
indicating the specificity of the antibody. In the reciprocal experiment, anti-HA 
immunoprecipitates obtained from the diploid APC1-myc6 APC1-HA3 strain, but not the 
single myc-tagged, strain contained Apc1-myc6 in addition to Apc1-HA3. (Figure 2-10, lane 
3). We then constructed a similar set of epitope-tagged strains containing homozygous 
deletions of DOC1 and carried out the same experiments again (Figure 2-10, lanes 4 to 6 and 
10 to 12). The absence of Doc1 did not lead to a significant decrease in Apc1-self-
association. Doc1 therefore, at least in this assay, does not contribute to APC dimerization. 
Figure 2-10: Self association of Apc1 is not impaired in the absence of Doc1. Apc1 was 
immunoprecipitated from extracts of yeast strains expressing the indicated epitope-tagged 
Apc1 versions in a wild type (wt) or doc1 background. Antibodies to myc and HA epitopes 
were used for immunprecipitation. Bound proteins were eluted with glycine and analyzed by 
immunobloting with myc and HA antibodies. Strains J109, J110, J325, J326, J327, J328 were 
used in this experiment.
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2.3 Electron microscopic analysis of yeast APC
2.3.1 Obtaining a 3D model of budding yeast APC
Substrate ubiquitination mediated by APC requires the concerted action of more than a 
dozen subunits (Passmore and Barford, 2004; Peters, 2006). A mechanistic understanding of 
how APC catalyzes these reactions and how this is regulated during the cell cycle requires 
information about the overall APC structure and the 3D organization of its many subunits.
We have decided to extend our structural studies from human and frog APC (Dube et al., 
2005; Gieffers et al., 2001) to the budding yeast complex. The reasons for this are manifold. 
Comparing complexes from different organisms and thereby discovering similarities and 
differences might provide valuable hints for preserved mechanisms, distinct regulations, etc.
In addition, the EM structure published of budding yeast APC (Passmore et al., 2005b)
surprisingly different from the structures of vertebrate APC. We therefore decided to 
compare the structures of yeast and human APC under identical imaging conditions. 
Furthermore, establishing a novel strategy for localizing individual subunits within the 3D
APC model, we will in the future create a more detailed 3D map of APC subunit
localizations.
To this end, I purified budding yeast APC by the TAP-method from strains that were 
deleted of the protease Pep4 and contained a TAP-tag on either Cdc16 or Apc4. The 
purified complex was then enriched and fixed by dual glycerol-glutaraldehyde density 
gradient centrifugation (Kastner et al., 2008) and fractions containing APC were analyzed by 
EM of double carbon foil negative stain preparations (Figure 2-11B). Most of the APC 
particles on the grids were monomeric, but we could also observe dimeric particles among 
them, in agreement with the study by Passmore et al. ((Passmore et al., 2005b), Figure 2-11B). 
In some cases it was difficult to judge whether a particle was dimeric or whether two 
monomers were just very close to each other. The purity of the preparation was analyzed by 
SDS-PAGE and silver staining (Figure 2-11A).
The 3D model was determined by angular reconstitution from cryo-negative stain images. 
Figure 2-11C shows our 3D model in comparison with that published by the Barfod lab 
(Passmore et al., 2005b). Our structure appears slimmer and strikingly more asymmetric. 
When looking at both models in several views, similarities become apparent, such as the 
overall triangular shape with one vertex being more pronounced and the other two being 
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Figure 2-11: Purification and 3D reconstruction of budding yeast APC after negative 
staining EM. A) APC was purified from strain J315 (CDC16-TAP pep4) via the TAP-
method and analyzed by SDS-PAGE and silver staining. The sample was taken before the 
preparation was further purified and fixed by glycerol-glutaraldehyde centrifugation. Subunits 
were identified by their electrophoretic mobility and by mass spectrometry. B) Typical EM 
raw image of yeast APC prepared by the double carbon foil sandwich technique. C) Our 
yeast APC structure (purple) in comparison with a previously published budding yeast 
structure shown in red (Passmore 2005), which was obtained by cryo-EM and angular 
reconstitution. Both structures are shown in several comparable orientations. Arrows and 
angles are in reference to the top structures. D) Surface views of yeast APC (purple) and 
human APC (yellow) structures obtained by angular reconstitution. Both structures are 
shown in several orientations. Arrows and angles are in reference to the top structures. 
more “rounded” (“main” view in Figure 2-11C). The yeast APC model resembles that of 
human APC (which was obtained in a similar way, Herzog et al., manuscript in preparation) 
in many details but also displays some striking differences. Similar to human APC, yeast 
APC has an asymmetric shape with a convexly curved “back” side and a concavely curved 
“front” side (Figure 2-11D). Both complexes contain a central cavity and prominent ridges at 
the back side. Human APC has a pronounced head-like structure at one end ((Dube et al., 
2005), Figure 2-11D) which is significantly smaller in yeast APC. The overall structure of 
yeast APC appears somehow compressed in comparison to human APC. Moreover, yeast 
APC contains a prominent extra mass at the right side of the complex (Figure 2-11D, 
“front” view).  The “rear” side views of both APC models implicate that yeast APC lacks 
one of the ridges (Figure 2-11D) which, together with the smaller head region, might create 
the more compressed appearance.  
2.3.2 Localization of Doc1 within APC
Using site-specific photocrosslinking, I have identified the interaction partners of Doc1 
within APC (see 2.1). Localization of Doc1 within the 3D structure of APC could, combined 
with the possible localization of further subunits (see below) or with available subunit maps 
and interaction data ((Dube et al., 2005; Kraft et al., 2005; Ohi et al., 2007; Passmore et al., 
2005b; Thornton et al., 2006; Vodermaier et al., 2003), Herzog et al., manuscript in 
preparation) help to verify the observed interactions and might lead to a better 
understanding of Doc1’s role within APC. Deletion of Doc1 does not affect the overall 
subunit composition of APC (Carroll and Morgan, 2002; Passmore et al., 2003). Determining 
a 3D map of APC purified from a strain lacking Doc1 and comparison with that of wild type 
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APC cells should therefore allow the localization of Doc1. APC was purified as before from 
yeast cells lacking Doc1 and the purified sample was processed and analyzed as before 
(Section 2.3.1, Figure 2-12).
The 3D models of APC and APCdoc1 are indeed similar in their overall shapes (Figure
2-12B). APC is slightly more flexible in the absence of Doc1 and the 3D model for APCdoc1
is therefore not as well defined as the wild type structure. APCdoc1 reveals small differences in 
few areas compared to wild type APC. There is, however, only one single location where
APCdoc1 lacks a prominent density compared to APC (Figure 2-12B). This extra density in 
wild type APC is located in the center of the complex (front view) beneath the head region
and to the right-hand side of the central cavity (Figure 2-12B). The volume and the round 
shape of this “mass” are consistent with a globular protein of 35 kDa size. To confirm the 
localization of Doc1, we are planning to reconstitute APC from purified APCdoc1 and from
recombinant Doc1 purified from E. coli, and to analyze this complex by negative staining 
EM. I obtained very pure His-Doc1 from E. coli by Ni-NTA batch purification followed by 
gel filtration (Figure 2-12C). Doc1 from this preparation can restore wild type ubiquitination 
activity when added to APCdoc1 ((Passmore et al., 2003) and data not shown) indicating that 
Doc1 binds to its physiological site on APC. EM analysis of a reconstituted APCdoc1-Doc1 
sample might therefore be suitable to confirm the Doc1 localization.
2.3.3 Localization of further APC subunits within the 3D model
To gain inside into the organization of APC subunits within the complex, antibody labeling 
experiments have been carried out This approach has led to the localization of several
subunits of yeast and human APC within the corresponding 3D models ((Dube et al., 2005; 
Ohi et al., 2007; Passmore et al., 2005b), Herzog et al., manuscript in preparation). Combining 
these data with those obtained from interaction studies of vertebrate and yeast APC subunits 
(Kraft et al., 2005; Thornton et al., 2006; Vodermaier et al., 2003) has already contributed to a 
better understanding of the 3D organization of APC (Peters, 2006). Precise subunit 
localizations have not been feasible so far due to technical limitations. For human APC, for 
example, it has not been possible to generate a 3D structure of APC in complex with an 
antibody because of the inherent flexibility of the antibody (Franz Herzog and Holger Stark, 
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personal communication). Subunits have therefore been localized by computational analysis 
of 2D images and projection onto a 3D structure ((Dube et al., 2005) Herzog et al., 
manuscript in preparation). Alternatively, subunits have been localized in 2D only (Ohi et al., 
2007). 
Figure 2-12: Localization of Doc1 on APC. A) Purification of APCdoc1 from yeast strain 
J320 (CDC16-TAP doc1pep). The sample was taken before fixation by glycerol-
glutaraldehyde centrifugation and analysis by negative staining EM. B) The 3D model 
obtained for APC purified from a wild type strain is shown in purple (left), and that for APC 
purified from a doc1 strain in blue (middle). In the model to the right, the differences in 
density found between the two structures are shown in red. C) Purified Doc1 which will be 
used to confirm the Doc1 localization. His-tagged Doc1 was purified from E. coli by Ni-
NTA chromatography (batch mode) and gel filtration. Samples of Doc1 containing fractions 
obtained after gel filtration were separated by SDS-PAGE and stained with Coomassie. 
To be able to localize subunits in 3D, we decided to fuse relatively large globular tags to the 
C-termini of individual APC subunits. We wanted the tags to be large enough to be visible 
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on electron micrographs but ideally they should not interfere with APC assembly and 
function. Purification of APC carrying such a tag and generating a 3D model by negative 
staining EM should, when this 3D model is compared to that of untagged APC, lead to the 
identification of an additional mass. This mass should then indicate the localization of the C-
terminus of the tagged subunit. Tdimer2 (td2) is a tandem dimer of a dimeric DsRed variant 
and has a size of about 50 kDa (Campbell et al., 2002). This protein has been successfully 
used for the localization of three subunits of a yeast splicosomal subcomplex by a “tagging 
approach” similar to the one outlined before (personal communication from Irina Haecker 
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Figure 2-13: Subunit composition of APC purified from various yeast strains each 
carrying a td2-tag on a different APC subunit. A) Preparations from strains carrying a 
td2-tag on Apc4 (J347), Cdc27 (J376), Cdc16 (J378) or Apc5 (J380), and from a strain 
carrying a tmono-tag (see text) on Apc1 (J329). APC was purified using the TAP-method via 
a TAP-tag on Apc4 or Cdc16 and analyzed by SDS-PAGE and silver staining. Preparations 
from strains without td2- or tmono-tags (CDC16-TAP, J315 and APC4-TAP, J319) are 
shown for reference. All strains in addition were pep4. Subunits were identified by analysis 
of the electrophoretic mobility pattern. The contrast settings were changed within the left 
half of the gel to visualize weak bands. B) Preparations from strains carrying a td2-tag on 
Apc2 (J408), Mnd2 (J407), Apc11 (J422), Cdc26 (J406) or Swm1 (J428), and from a strain 
carrying no td2-tag (J315). All strains carried TAP-tags on APC 4 and were deleted of Pep4. 
APC was purified using the TAP-method and analyzed by SDS-PAGE and silver staining. 
Subunits were identified by their electrophoretic mobility. C) Immunoblot analysis 
demonstrating the successful tagging of Apc11 (left) and Cdc26 (right panel) and the 
resulting mobility shifts. Different amounts of samples from the APC11-td2 CDC16-TAP
and CDC26-td2 CDC16-TAP preparations shown in (B) were loaded together with control 
samples (CDC16-TAP) and analyzed by immunobloting using antibodies against Apc1, 
Apc11 and Cdc26.
and Reinhard Lührmann). We therefore set out to generate a set of yeast strains which each 
carried a C-terminal td2-tag on one of the APC subunits. We succeeded in tagging the C-
termini of APC2, CDC27, CDC16, APC4, APC5, APC11, CDC26, SWM1 and MND2 with 
td2 (Table 2-3) using available one-step tagging cassettes (Sheff and Thorn, 2004). Tagging 
of APC1 was only possible with a modified version of the tag which consisted of a DsRed 
monomer (tmono). We did not obtain any viable spores when we tried to tag CDC23 or 
APC9 with td2 or tmono (not shown). Strains were then crossed into APC4-TAP pep4 and 
CDC16-TAP pep4backgrounds and APC was purified from these strains using the TAP-
method. The subunit composition was analyzed by SDS-PAGE and silver staining. APC 
purified from all but one strain carrying a td2-tag appeared to have a normal APC subunit 
composition (Figure 2-13A and B). APC purified from APC4-td2 cells was the only complex 
which seemed to have lost some subunits, such as Apc1, or contain them at 
substoichiometric levels (Figure 2-13A). Mass spectrometry analysis after in solution digest, 
however, revealed the presence of all 13 APC subunits in this preparation (not shown). We 
therefore decided to subject APC purified from all of these newly generated td2- or tmono-
tagged strains for negative staining EM analysis. So far, electron micrographs have been 
prepared for APC purified from strains carrying tags on Apc1, Cdc27, Apc4, Apc5 and
Cdc16 (Table 2-3). To this end, APC was purified by the TAP-method as before, followed 
by glycerol glutaraldehyde centrifugation. For APC carrying td2-tags on Apc1, Cdc27, Apc5 
and Cdc16, negatively stained electron micrographs revealed asymmetric particles which 
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looked similar to those of wild type APC (not shown). No intact particles could be found for 
the Apc4-td2sample, the silver gel analysis of which had already indicated unusual subunit 
stoichiometry (Figure 2-13A). Tagging of Apc4 might have therefore led to the structural 
destabilization of APC. APC purified from the remaining five yeast strains will be purified 
and analyzed by EM after submission of this thesis (see Table 2-3).
Table 2-3: Generated yeast strains containing td2-tagged APC subunits and current 
status of their EM analysis. Doc1 was not tagged since C-terminal tagging avoids 
association of Doc1 with APC (Carroll et al., 2005). 
APC subunit strain subunit 
composition?
EM 
analysis?
3D model 
obtained?
tag visible?
Apc1 J329 ok in process no
Apc2 J408 ok to be done
Cdc27 J376 ok in process yes yes
Apc4 J347 not ok impossible
Apc5 J380 ok in process yes yes
Cdc16 J378 ok in process yes yes
Cdc23 not viable
Apc9 not viable
Apc11 J422 ok to be done
Cdc26 J406 ok to be done
Swm1 J428 ok to be done
Mnd2 J407 ok to be done
Figure 2-14 shows the 3D model obtained for Cdc27-td2-tagged APC after EM negative 
staining and angular reconstitution. After building class averages from EM raw images, the 
tag is clearly visible as a “horn-like” protrusion which is not present in corresponding views 
of untagged APC (Figure 2-14). According to this, the 3D model contains one additional 
blob which is missing in the wild type structure, indicating the localization of Cdc27’s C-
terminus (Figure 2-14). It is located directly next to the mass that might represent Doc1 
(Figure 2-12B), close to the head region and at the edge of the prominent back-side ridges.
Passmore et al. have analyzed the stoichiometry of budding yeast APC by iodine-labeling and 
found two to three copies of Cdc27 per complex (Passmore et al., 2005b). We only found 
one major additional mass. This does not, however, exclude the possibility that further 
additional masses are buried within the complex. 
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Figure 2-14: EM of APC carrying a td2-tag on Cdc27 and of untagged APC. Two class 
averages are shown each for td2-tagged and untagged APC in corresponding projection 
directions. Contour lines of the class averages are below the particles to outline the similar 
projection directions. The pink shape outlines the additional mass which is only present in 
the upper row images. Front views of the resulting 3D models of tagged (pink) and untagged 
(grey) APC are shown.  
We also obtained a precise localization of Apc5 after analysis of APC purified from the 
APC5-td2 cells. Figure 2-15 shows the resulting 3D model in comparison with that of wild 
type APC, yielding the localization Apc5 within the “platform” of the complex. By analyzing 
the remaining complexes in a similar fashion we will create a detailed APC subunit map 
which is more precise than the ones which have been obtained previously. 
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Figure 2-15: A 3D model of APC carrying a td2-tag on Apc5 in comparison to that of
untagged APC. The model obtained for APC purified from a yeast strain carrying a td2-tag 
on Apc5 is shown to the left and that for APC purified from a wild type strain in the middle. 
To the right the main density difference which can be found between the two structures is 
shown is in yellow. The bottom panel shows the structures in the “top” view. Class averages 
of EM raw images are not shown because the additional mass was not clearly visible on 
them.
2.4 Conditions for photocrosslinking with the artificial 
substrate N702x-GST
The mechanism of substrate recognition by APC and the role of APC core subunits largely
remain a mystery. Our Doc1 photocrosslinking approach has not enabled us to identify the 
interaction partner of Doc1’s putative ligand binding loop (Section 2.1.4). Several pieces of 
evidence have implied that Doc1 might use this loop to bind to APC substrates and that way 
function as a processivity factor for APC ubiquitination (Carroll et al., 2005; Passmore et al., 
2003; Wendt et al., 2001); likewise Doc1 might, via this loop, interact with other factors 
important in the ubiquitination reaction. We have decided to undertake a more unbiased 
approach to continue our search for the APC substrate receptor. In this section, I am 
describing the conditions which I established for a photocrosslinking approach employing
substrate constructs which contain a photoactivatable amino acid at various sites. This 
approach might allow us to identify the APC substrate receptor, which would be an 
important step towards a better understanding of APC substrate recognition.
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APC coactivators clearly play an important role in this process, as they were shown to 
directly interact with the substrates’ D and KEN boxes and are believed to thereby recruit 
substrates to the APC (Burton et al., 2005; Kraft et al., 2005). There is evidence that also core 
APC subunits contribute to APC substrate recognition (Carroll et al., 2005; Eytan et al., 2006; 
Passmore et al., 2003; Yamano et al., 2004) and strikingly, Xenopus and human APC was 
found to bind to D box sequences even in the absence of coactivators (Eytan et al., 2006; 
Yamano et al., 2004). The latter two studies both used the same artificial substrate construct 
(first introduced by Yamano et al., (Yamano et al., 1996; Yamano et al., 1998)), expressed in 
and purified from E. coli, which consists of a double fragment of the N-terminal 70 amino 
acids of fission yeast cyclin B fused to a C-terminal GST-tag (termed N702x-GST).
Importantly, Ivana Primorac in our lab could show that binding of this construct to APC is 
not only dependent on its D boxes, but is also largely diminished if APC is inhibited by 
MCC (Herzog et al., manuscript in preparation). This indicated that binding of N702x-GST to
APC might be highly specific and that the construct might indeed resemble a physiological 
APC substrate. 
However, the identity of the APC subunits which mediate substrate interactions remains
unknown. We therefore decided to use N702x-GST in site-specific photocrosslinking 
experiments. Similar as described in section 2.1, I decided to use an in vitro translation system 
and non-natural amber suppressor tRNA coupled to a photocrosslinkable amino acid for the 
crosslinker incorporation. Setting up the experimental conditions therefore required the
specific binding of N702x-GST generated by in vitro translation to APC. To test if in vitro
translated N702x-GST binds to APC specifically the following experiment was performed: 
APC isolated from HeLa cells which had been arrested in mitosis with an inactive spindle 
assembly checkpoint (SAC) was incubated with in vitro translated N702x-GST versions. 
Bound proteins were eluted by addition of SDS sample buffer and analyzed by 
immunobloting and phosphorimaging. As shown in Figure 2-16B, the wild type construct 
strongly bound to APC (lanes 9 and 11) whereas a version in which both D boxes were 
mutated bound only very poorly (lanes 10 and 12). The same result was obtained when using 
purified proteins (Figure 2-16B, lanes 5 and 6). When analyzing phosphorimages (Figure
2-16B, lower panel) and long exposures of immunoblots (not shown), I observed strong 
ubiquitination of in vitro translated N702x-GST, which was dependent on the reticulocyte 
lysate translation mix and largely on addition of purified APC (Figure 2-16B, compare lane 3, 
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input substrate incubated at room temperature with lanes 9 and 11, substrate after 
incubation with APC; data not shown). 
              
N70 GSTN70
D boxD box
              
Figure 2-16: N702x-GST produced by in vitro translation binds to mitotic APC. A)
Schematic drawing depicting the substrate construct used for these experiments. A tandem 
fragment comprising the N-terminal 70 amino acids of fission yeast cyclin B (Cdc13) is fused 
to GST. In a D box mutant, the R-x-x-L sequence is changed to A-x-x-A. B) APC was 
immunoprecipitated from HeLa arrested in mitosis with a Cdc27 antibody and subsequently 
incubated with N702x-GST protein purified from E. coli (rec, lanes 5 and 6) or generated by 
in vitro translation (IVT, lanes 7 to 12). Wild type (wt) and a version with a mutated D box 
(DM) were analyzed in parallel. In lanes 11 and 12, a 1.5-fold amount of protein was added. 
Bound protein was eluted with glycine and analyzed by SDS-PAGE and immunobloting with 
Apc2 and GST antibodies. A phosphorimage of the same membrane that was used for 
immunobloting shows the radiolabeled in vitro translated proteins.
These circumstances were problematic for my photocrosslinking experiments for two 
reasons. First, low levels of unmodified substrate would decrease the chances of detecting a 
crosslink signal, since usually only a small fraction of the input shifts to a higher molecular 
weight upon photolysis ((Kraft et al., 2005) and Figure 2-4C). Second, the presence of 
ubiquitin chains covalently attached to radiolabeled substrate in the samples might cover a 
weak crosslink product on phosphorimages after SDS-PAGE and would therefore hinder 
the analysis. I therefore set out to avoid ubiquitination or revert it by four different means.
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N-ethylmaleimide (NEM) is commonly used for blocking sulfhydryl groups and should not 
chemically attack the photocrosslinker’s diazirin group (personal communication from Josef 
Brunner). UbcH10C114S (Townsley et al., 1997) is a dominant negative version of the E2 
enzyme which is predominantly used by APC and should, when added at an excess, 
“counteract” the activity of E2 enzymes present in the lysate (similarly to its effect after 
addition to HeLa lysates, (Rape et al., 2006; Reddy et al., 2007)). N702x-GST generated by in 
vitro translation was therefore treated with NEM before incubation with APC (Figure
2-17A). Alternatively, UbcH10C114S was added to the APC-substrate binding reaction (Figure
2-17B). In both cases, the ubiquitination of N702x-GST was reduced with increasing 
concentrations of the chemical or biological inhibitor. Ubiquitination can be reverted by 
deubiquitinating enzymes (Amerik and Hochstrasser, 2004). When seeking for a 
deubiquitination enzyme that would also cleave APC generated ubiquitin chains in vitro, I 
chose Usp2-cc (Ryu et al., 2006), the catalytic core of the deubiquitinating enzyme Usp2. This 
enzyme does not contain a domain conferring substrate specificity and was reported to 
cleave all ubiquitin fusions, including linear or branched mono- or multiubiquitin chains after 
the ubiquitin’s C-terminal glycine (Baker et al., 2005; Catanzariti et al., 2004; Ryu et al., 2006).
Addition of Usp2-cc during the APC-substrate binding reaction similar as in Figure 2-17B 
completely prevented the formation of N702x-GST-ubiquitin conjugates at a concentration 
of 4 µM (not shown). Furthermore, Usp2-cc added to substrate-APC beads after the APC-
substrate binding step and removal of the reticulocyte lysate by several washes also 
completely removed ubiquitin chains (Figure 2-17C, lanes 2 to 6). Prior UV-treatment of 
samples slightly reduced the deubiquitinating effect of Usp2-cc and lead to a weak “smear”
being left after Usp2-cc treatment (Figure 2-17C lanes 7 to 11). Ubiquitination was still 
greatly reverted, but two bands at about 120 kDa and 200 kDa size could not be removed
(Figure 2-17C lanes 7 to 11). These bands could represent unspecific crosslink products 
which were sometimes generated even when using proteins that carried no crosslinker (e.g. 
inFigure 2-8D, lane 12 and not shown). Alternatively, UV-exposure might have denatured
long polyubiquitin chains resulting in ubiquitin moieties that could not be recognized and 
cleaved by Usp2-cc anymore. In a fourth attempt to interfere with N702x-GST ubiquitination 
by APC and cofactors present in the reticulocyte lysate, I sought after a translation system 
which would allow efficient production of N702x-GST. Bacterial S30 extracts (Promega) do 
not contain an ubiquitin proteasome system. Translating the N702x-GST wild type construct 
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resulted in protein levels 5 to 10 times higher than those obtained with the reticulocyte lysate 
system (Figure 2-17D, lane 1; data not shown). I have, however, not tested yet whether the 
S30-translated N702x-GST binds to APC with similar specificity as the reticulocyte lysate 
system-produced protein
Figure 2-17: Four different ways of avoiding or reverting ubiquitination of N702x-GST
when it is bound to mitotic APC. A) Reticulocyte lysate extracts containing translated N702x-
GST were treated with the indicated amounts of N-ethylmaleimide (NEM) and then 
incubated with bead-bound APC. Bound proteins were washed and eluted from beads by 
SDS sample buffer. Samples were analyzed by SDS-PAGE and phosphorimaging. B) N702x-
GST produced by in vitro translation in reticulocyte lysate was bound to bead-bound APC. 
During this binding reaction, the indicated amounts of a dominant negative version of 
UbcH10 (UbcH10C114S) were added. Samples were analyzed as in (A). C) N702x-GST 
produced by in vitro translation in reticulocyte lysate was bound to bead-bound APC and 
reticulocyte lysate was washed off. Samples were then incubated for 10 min at 8°C while they 
were exposed to UV-light (lanes 7 to 11). Control reactions were not exposed (lanes 2 to 6). 
Samples were then incubated with the indicated amounts of purified Usp2-cc. Samples were 
analyzed as in (A). D) In vitro translation of N702x-GST in bacterial S30 extracts. Wild type
N702x-GST and different constructs were translated in the presence or absence of 
(tmd)phe-tRNA. Full-length protein is only obtained in reactions which contained (tmd)phe-
tRNA. The translation efficiency in this extract system is only about 35 %; therefore, a high 
portion of truncated versions (trunc.@1st/2nd amber) was generated. The asterices mark 
unpecific translation products.
RESULTS
57
Having found conditions under which wild type N702x-GST (translated in reticulocyte lysate) 
binds specifically to APC and which allow detecting possible crosslinks, I generated 
crosslinker containing mutants similarly as described for Doc1 (see Section 2.1). To this end 
I chose six sites within a single “N70” fragment which I decided to exchange for the 
photocrosslinker. I generated constructs which carried the modified amino acid in the first, 
the second, in both or in a single N70 fragment of the construct (Figure 2-18). Incorporation 
of (tmd)phe worked with 40 to 70 % efficiency when reticulocyte lysate was used as a 
translation system. Crosslinker containing versions of N702x-GST were still able to bind to 
APC beads (not shown), but binding was reduced though in constructs carrying the 
photocrosslinker within the D box (observed e.g. for mutant “#4 1stamber”, not shown). 
Tmd(phe) incorporation was also possible when translating the substrate construct in S30 
extracts. The incorporation efficiency, however, did not exceed 35 % in this system (Figure
2-17D, lanes 2 to 8; quantification not shown). Because the translation efficiency is a lot 
higher in S30 extracts, the amount of full length crosslinker containing proteins generated in 
this system was still up to 25 times higher compared to those translated in the reticulocyte 
lysate system (not shown). As for the wild type construct, I have not tested whether S30-
produced crosslinker containing versions of N702x-GST can bind to APC beads. Likewise we 
MGTTRRLTRQHLLANTLGNNDENHPSNHIARAKSSLHSSENSLVNGKKATVSSTNVPKKRHALDDVSNFHNVMG
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Figure 2-18: Schematic drawing of N702x-GST constructs which were generated for 
substrate photocrosslinking experiments. Colors and symbols are similar as in Figure
2-16. The sequence of N702x-GST is shown. The D box sequence is highlighted in orange and 
sites of photocrosslinker incorporation are indicated with a yellow mark. For each indicated residue
four different constructs were generated. In “1st amber” the crosslinker was inserted within the first 
N70 fragment; “2nd amber” carried the crosslinker in the second fragment, “double amber” in both 
fragments. “Single amber” only consists of one “N70” fused to GST.
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do not know if the higher amount of incomplete translation products might interfere with 
binding. These and the actual crosslinking experiments will be carried out after submission 
of this thesis.In the future I might use both, N702x-GST generated in the reticulocyte lysate 
system and bacterial S30 lysate-produced N702x-GST in photocrosslinking experiments with 
mitotic human APC. Crosslinking experiments performed with reticulocyte lysate system-
generated N702x-GST will be followed by incubation with Usp2-cc for removal of ubiquitin 
chains. In case I will obtain specific crosslink products, I will analyze their identity by 
denaturation and re-immunoprecipitation using APC subunit specific antibodies, similar as in 
Kraft et al. (Kraft et al., 2005).
2.5 The protein encoded by c10ORF104 is a novel subunit of 
vertebrate APC
As described in Section 2.4, we are carrying out substrate photocrosslinking experiments to 
identify the D box receptor on APC. We are hoping to detect specific crosslink products in 
these experiments which might result from interactions between the substrate and APC. In 
order to then be able to identify the substrate-interacting APC subunit we need to know all 
subunits of human APC. APC composition has been analyzed intensively in the last decade 
and twelve human subunits have been identified so far (Table 1-1). We were therefore 
surprised that Martina Sykora and Jim Hutchins as part of their MitoCheck work 
(www.mitocheck.org) were able to detect a protein whose association with APC had not 
been described before. They had analyzed APC purified by the localization and affinity 
purification (LAP) method from HeLa cells expressing LAP-tagged Apc1, Apc5, 
Apc6/Cdc16, Apc8/Cdc23, Cdc26, Apc13 or Cdc20. In all these preparations, the gene 
product of c10orf104 was found by mass spectrometry after in solution digest. Importantly, it 
was never found in purifications of non-APC subunits or interactors (Martina Sykora and 
Jim Hutchins, personal communication). Furthermore, the c10orf104 gene product was 
associated with APC in immunoprecipitations using the Cdc27 antibody followed by peptide 
elution (Franz Herzog, personal communication). 
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Figure 2-19: Antibodies raised against three regions of the C10orf104 protein 
specifically recognize the protein on Western blots. C10orf104 can be depleted by two 
different siRNAs. A) Protein sequence of C10orf104 depicting the peptides used for 
antibody generation. B) Antibodies recognize a band at 15 kDa size on protein extracts (xt) 
and on Cdc27-immunoprecipitates (IP). HeLa extracts prepared from logarithmically grown 
cells (log) and from cells that had been arrested in mitosis with nocodazole (noc) were loaded 
next to a glycine-eluate of a Cdc27-immunoprecipitation from log-cells. Immunblots were 
analyzed with the glycine elutions of purified 2184, 2185 and 2186 antibodies at 2 µg/ml. C) 
The band specifically recognized by 2186 and 2184 is reduced after siRNA treatment. Cells 
were treated with siRNAs 117 or 118 or with water as a control for the indicated times. 
Protein extracts were prepared and the soluble fraction was analyzed by SDS-PAGE and 
immunobloting using glycine elutions of purified antibodies as in (B).
We decided to analyze this protein and its putative interaction with APC further. C10orf104 
encodes a hypothetical protein comprising 110 amino acids that is remarkably conserved 
among higher eukaryotes but could not be found in yeasts, worms or flies (Maria 
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Novatchkova, personal communication, Section 5.3). We generated antibodies against the 
c10orf104 gene product by immunization of rabbits with peptides which were derived from 
three regions of the c10orf104 protein sequence (Figure 2-19A). In immunoblot 
experiments, a 15 kDa band was recognized by these antibodies in APC purifications, which 
was also detected in crude extracts from interphase or mitotic HeLa cells (Figure 2-19B). 
These antibodies also stained a band at about 200 kDa size in APC immunoprecipitates 
(Figure 2-19B, lanes 3, 6, 9 and not shown), the identity of which is presently unknown. We 
then performed RNAi experiments using two siRNAs directed against the c10orf104
sequence. After transfecting cells with siRNA specific for c10orf104 the 15 kDa band was 
strongly reduced (Figure 2-19C). These observations indicate that the 15 kDa band 
represents C10orf104. 
In immunoprecipitates obtained with one of the C10orf104 antibodies (2186) from extracts 
of logarithmically growing HeLa cells, the C10orf104 protein and Apc2 were detected by 
immunobloting at similar levels as in Cdc27 immunoprecipitates (Figure 2-19, lanes 7, 9 and 
15). This supports the hypothesis that the C10orf104 protein is an APC interactor.
Figure 2-20: Antibodies raised against C10orf104 immunoprecipitate APC. Glycin (G) 
and magnesium (M) elutions of purified antibodies (ab) raised against C10orf104, bound to 
protein A beads and crosslinked if indicated, were incubated with cleared extracts of 
logarithmically grown HeLa cells. Crosslinked Cdc27 antibodies were used as a control 
Bound protein was eluted with glycine and analyzed by SDS-PAGE and immunobloting with 
Cdc27 and C10orf104 (2184) antibodies.
To address which fraction of the C10orf104 protein is associated with APC in cell extracts, 
sucrose density centrifugation experiments were performed. Cdc16, Apc10/Doc1 and the 
C10orf104 protein sedimented in the same fractions (Figure 2-21). However, not all of 
C10orf104 is stably associated with APC since a subpopulation could also be detected in 
fractions 7 to 9 (Figure 2-21). This also explains why the C10orf104 band recognized in the 
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input lanes was stronger than the Cdc16 input band, but in the APC peak fractions, the 
Cdc16 staining was more intense than the C10orf104 staining (Figure 2-21).
Figure 2-21: C10orf104 co-sediments with APC. Sucrose density gradient centrifugation of 
extracts prepared from logarithmically grown HeLa cells. Extracts were sedimented  through 
a 10 to 30 % sucrose gradient for 18 h and fractionated into 28 fractions per gradient. APC 
sedimentation was analyzed by immunobloting with Cdc16, Doc1 and C10orf104 (2186) 
antibodies. The asterix marks an unspecific band recognized by the Apc10/Doc1 antibody.
Immunobloting on samples taken every 90 minutes within 18 hours after release from a 
double thymidine arrest showed that – although immunoblot signals were slightly decreased 
at time points 13.5, 15 and 16.5 – the C10orf104 protein is expressed continuously 
throughout the cell cycle (Figure 2-22). Further analysis will be required to test whether 
levels are constant or whether the apparent decrease of C10orf104 protein levels (Figure
2-22, lanes 10 to 12) is a reproducible and meaningful phenomenon. 
Figure 2-22: C10orf104 is expressed throughout the cell cycle. Samples were taken after 
cells had been synchronized by a double thymidine arrest release protocol. At the time of the 
second release, the first time point was taken (lane 1); cells therefore were in early S phase. 
Cells then accumulate cyclin B while proceeding through G1 (lanes 4 to 7). Cyclin B (lane 8) 
degradation marks mitosis. Time points were taken until cells again were in early S phase.
Equal numbers of cells were lysed by adding SDS sample buffer and by sonication. 
Immunobloting was performed using antibodies against cyclin B, C10orf104 (2184) and 
tubulin. 
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APC is bound to and its activity inhibited by the MCC during early mitosis until all 
chromosomes are properly attached to the mitotic spindle (Musacchio and Salmon, 2007). 
The association of the C10orf104 protein with APC could therefore either be direct or could 
be mediated by the MCC. The observation that the C10orf104 antibody immunoprecipitated 
Apc2 from interphase cells, where APC is not associated with the MCC (Sudakin et al., 
2001), already indicated that C10orf104 is part of APC and not MCC. To confirm this 
notion, we performed immunoprecipitation experiments with C10orf104 (2186) and Cdc27 
antibodies from extracts of interphase, mitotic and S phase HeLa cells. All samples showed
the typical “APC pattern” when analyzed by SDS-PAGE and silver staining (Figure 2-23A).
This indicates that C10orf104 is bound to APC throughout the cell cycle, in contrast to 
MCC. To test whether the C10orf104 antibody precipitates active APC, we carried out 
ubiquitination assays. APC purified from interphase extracts using the C10orf104 antibody 
was similarly active in ubiquitination assays as Cdc27 immunoprecipitates (Figure 2-23B).
We then wanted to get insight into the function of C10orf104 as an APC subunit. To this 
end, we depleted C10orf104 by siRNA transfection for 48 hours and tested whether cells 
accumulated in mitosis – as one might predict given APC’s essential function at the 
metaphase to anaphase transition (Peters, 2006) by counting the mitotic index of fixed cells 
and by analyzing cyclin B1 levels. Accumulation of cells in mitosis leads to an increased
mitotic index and to higher levels of cyclin B1. However, we found the contrary. Whereas in 
the control sample we determined a mitotic index of 3.2, we found only 1.6 % of the cells to 
be mitotic in the siRNA treated samples (Figure 2-24A). Immunoblot analysis of cyclin B 
levels in these cells demonstrated that the amount of cyclin B1 was reduced upon C10orf104 
depletion (Figure 2-24A). To further investigate whether this observation was due to a 
reduced number of mitotic cells we depleted C10orf104 by RNAi and arrested cells with
thymidine to block them in early S phase. Six hours after release from thymidine we added
taxol for three hours to activate the spindle checkpoint and let cells accumulate in mitosis. 
Analysis of the cells before and after taxol treatment by immunofluorescence microscopy 
using cyclin B1 and BubR1 antibodies showed than under control conditions about 90 % of 
cells were in S or G2 phase six hours after thymidine release. These cells were positive for
BubR1 and cyclin B1 in the cytosol; the DAPI staining showed that the chromatin was in a 
decondensed state. After three hours of taxol treatment 50 % of control cells were in a 
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Figure 2-23: C10orf104 is a subunit of human APC. A) APC was purified by 
immunoprecipitation (IP) using C10orf104 (2186) and Cdc27 antibodies. Cell extracts used 
for this experiment were prepared from logarithmically grown HeLa cells (log), from HeLa 
cells that had been arrested in S phase by addition of hydroxyurea (HU) or in mitosis by 
nocodazole treatment (noc). Bound proteins were eluted with glycine and analyzed by SDS-
PAGE and silver staining. APC subunits were identified by their electrophoretic mobility. 
C10orf104 could not be detected by silver staining. The candidate bands at around 15 kDa 
were excised and analyzed by mass spectrometry. C10orf104 was not detected. B) C10orf104 
antibody pulls down active APC. In vitro ubiquitination assay using a [I125]-labeled human 
cyclin B fragment (amino acids 1 to 84, cycB (1-84)) as a model substrate. 
Immunoprecipitates obtained with Cdc27 and C10orf104 antibodies were incubated with E1 
and E2 enzymes, recombinant Cdh1, substrate, ubiquitin and ATP for the times indicated 
and analyzed by SDS-PAGE and phorphorimaging. As controls, antibodies specific for the 
condensin complex (lane 12) and empty protein A beads (lane 11) were used. The asterix 
marks a contaminating band present in the substrate preparation.
prometaphase state with BubR1 staining the kinetochores, condensed chromatin and 
cytoplasmic staining of cyclin B1 (Figure 2-24B). In contrast, cells depleted of C10orf104 did
not accumulate in mitosis. They retained cytosolic BubR1 and cyclin B1 staining, which is
indicative of a G2 or S phase state (Figure 2-24B). There were no cells that had passed 
metaphase which would have been cyclin B1 negative. This indicates that cells lacking 
C10orf104 might be delayed in their progression through S and G2 or in mitotic entry. 
Although its function is not clear yet, the above findings strongly indicate that the c10orf104
gene product is a novel subunit of human APC and we therefore propose to rename it to 
“Apc16”.
RESULTS
64
Figure 2-24: Depletion of C10orf104 leads to a reduction of cyclin B1 levels in 
asynchronously growing HeLa cells and decreases the number of mitotically arrested 
cells after taxol treatment. A) Cells were transfected with c10orf104 siRNA for 4 h and 
afterwards split onto coverslips and tissue culture plates. Cells on coverslips were PFA-fixed 
and stained with DAPI and antibodies against H3S10ph to count the mitotic index 48 h after 
transfection. Remaining cells were harvested, extracted and analyzed by SDS-PAGE and 
immunobloting. Membranes were probed with cyclin B1, C10orf104 (2184G) and WAPL 
antibodies. B) Cells were transfected with c10orf104 siRNA for 12 h and then split onto 
coverslips and tissue culture plates. Afterwards, cells were treated with 2 mM thymidine for 
24 h, then released into fresh medium and fixed 6 (time point 1, TP1) or 9 (TP2) h later after
a 3 h-treatment with 10 µM taxol. Cells were fixed with PFA and stained with BubR1 and 
cyclin B1 antibodies as well as DAPI. More than 200 cells were counted at each time point 
and scored as interphase (BubR1/cyclin B1 negative nuclei), prophase (cyclin B1-positive 
nuclei before nuclear envelope breakdown) or prometa- and metaphase cells (BubR1-positive 
kinetochores and condensed chromosome morphology). For the immunoblot control cells 
were harvested at time point 2 and processed as in (A). An antibody against Rad21 was used 
as a loading control. In both experiments, control cells (ctrl) were tansfected with water.
2.6 Contributions
Marta Galova created most of the yeast strains which contain myc- or td2-tagged APC 
subunits and carried out TAP-purifications of some of the created td2-tagged APC strains to 
analyze APC composition. She also created the pRS316-Doc1 plasmid and all mutations in 
this plasmid. The yeast growth test (Figure 2-9C) was performed by Claudine Kraft (ETH 
Zurich, Switzerland). Electron microscopy experiments were carried out in collaboration 
with Prakash Dube and Holger Stark at the Max Planck Institute for Biophysical Chemistry 
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in Göttingen, Germany. The C10orf104 experiments were performed together with Björn 
Hegemann. Maria Novatchkova performed bioinformatical analyses on C10orf104
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3 Discussion
3.1 Site-specific crosslinking identifies three Doc1 binding 
partners within APC
The APC subunit Doc1 has been shown to be required for processive APC-mediated 
ubiquitination reactions (Carroll and Morgan, 2002; Passmore et al., 2003; Carroll and Morgan, 
2002) and is a prominent candidate for being involved in substrate recognition (Carroll et al., 
2005; Passmore et al., 2003; Wendt et al., 2001). The molecular basis of this processivity 
function of Doc1 is unknown. Doc1 might directly bind to the substrate or any other factor 
being important in the ubiquitination reaction. For example, Doc1 might bind a substrate 
and thereby keep it in place while ubiquitin moieties are being attached to it. Doc1’s “DOC 
domain” also exists in a few unrelated proteins, some of which have been predicted or 
demonstrated to function as ubiquitin ligases (DiAntonio et al., 2001; Dias et al., 2002; 
Nikolaev et al., 2003). Therefore, one could also imagine Doc1 assisting in efficient 
ubiquitination by binding a general component of ubiquitination reaction, such as ubiquitin
or an E2 enzyme. Alternatively, Doc1 might exert its processivity function indirectly by 
causing structural rearrangements within APC once a substrate is bound to the complex. 
Understanding Doc1’s role in APC processivity therefore requires information about Doc1’s 
direct interaction partners. To identify these, I have set up a photocrosslinking approach 
using budding yeast APC and recombinant Doc1 mutants containing a site specific 
photocrosslinker. I have inserted this photocrosslinker within different regions of Doc1,
some of which have been shown to be important for Doc1’s function as a processivity factor 
or for its binding to the APC (Carroll et al., 2005); other sites have been chosen randomly. I 
have found that within the APC, Doc1 binds to the TPR proteins Cdc16 and Cdc27 via its 
C-terminal region and the IR tail, respectively. In addition, I could identify sites which 
directly contact APC’s biggest subunit, Apc1. However, this technique did not identify a 
possible interaction partner of the Doc1 loop region, which has been shown to be important 
for APC processivity (Carroll et al., 2005).
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3.1.1 Doc1 interacts with the TPR subunits Cdc16 and Cdc27
It has been suggested that within APC, TPR proteins might serve as versatile adaptors for IR
tail containing proteins (Hayes et al., 2006; Vodermaier et al., 2003; Wendt et al., 2001). More 
than half of the total mass of APC consists of tandem arrays of TPR motifs which in 
budding yeast APC are present in the three subunits, Cdc16, Cdc23 and Cdc27 (Lamb et al., 
1994; Zachariae and Nasmyth, 1996). Each subunit contains eight to ten copies of the TPR 
motif in tandem arrays. A TPR motif contains 34 amino acids; the structural consensus 
sequence is composed of eight residues which are conserved in terms of size, hydrophobicity 
and spacing rather than in sequence (Blatch and Lassle, 1999; Lamb et al., 1995). Structural 
analysis of other TPR proteins has shown that this motif forms into a pair of antiparallel -
helices, and clusters of tandem TPR motifs fold into a right-handed superhelical structure 
(Passmore, 2004). Within APC, the TPR subunits form a stable subcomplex together with 
Cdc26, Apc9 and Swm1 (Schwickart et al., 2004; Thornton et al., 2006; Vodermaier et al., 
2003; Zachariae et al., 1996). TPR subunits might form a scaffold-like structure onto which 
other APC subunits, regulators and substrates might assemble (Vodermaier et al., 2003). 
Recruitment of the coactivators Cdc20 and Cdh1 to APC requires IR tails at the C-termini of 
coactivators and TPR proteins within APC (Passmore et al., 2003; Vodermaier et al., 2003). 
Both Apc3/Cdc27 and Apc7 can bind IR-containing peptides (Vodermaier et al., 2003). 
Crosslinking studies have identified Apc3/Cdc27 as the APC subunit to which Cdh1 binds
(Kraft et al., 2005). Binding of Cdc20 and Cdh1 is reduced in mutants lacking their IR tails
(Kraft et al., 2005; Thornton et al., 2006). Doc1 is the only core APC subunit which contains 
an IR tail – in fact, it is an “ILR tail” in budding yeast – and its interaction with the TPR 
subcomplex has been proposed based on in vitro binding assays (Wendt et al., 2001). In these 
experiments, full-length Doc1, C-terminally truncated versions or peptides corresponding to 
the C-terminus of human Apc10/Doc1 have been coupled to a matrix and incubated with 
lysate of insect cells which expressed different human APC subunits (Wendt et al., 2001). 
Cdc27 was found to interact with the peptide corresponding to Doc1’s C-terminus as well as 
with the full-length Apc10/Doc1; the binding was abolished when the last 14 or 23 amino 
acids of Doc1 were missing (Wendt et al., 2001). In our crosslinking experiments we have 
identified one crosslinker mutant, which carries the photoreactive amino acid close to the C-
terminus (three residues distance to the IR tail) and interacts with Cdc27 (Section 2.1.3). 
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Figure 3-1: Sites on Doc1 which have been exchanged for the photocrosslinker. A 
total of 24 Doc1 versions have been created, each carrying the photoreactive amino acid at 
one site. Sites have been picked based on earlier data (indicated in pink or turquoise) or 
arbitrarily (yellow).  Sites within an N-terminal loop region have been shown to be important 
for Doc1’s ability to stimulate the processivity of APC-mediated ubiquitination reactions 
(Carroll et al., 2005). Therefore, all six sites within this loop – one at a time – were exchanged 
for the photocrosslinker. These sites are indicated in turquoise. A Doc1 mutant that has two 
residues in the C-terminal region exchanged for alanines and in addition lacks 23 residues at 
the C-terminus including the so-called IR tail is impaired in binding to APC (Carroll et al., 
2005). The photocrosslinker was therefore inserted at three sites within the C-terminal region 
and at two sites within the IR tail, indicated in pink.. In addition, 13 residues at various sites 
spread allover Doc1 were exchanged for the photocrosslinker. These sites are shown in 
yellow.  The C-termini of both human and yeast Apc10/Doc1 have not been included in the 
crystal structures. This region is therefore represented as a grey dotted line.
Using a second Doc1 version with the crosslinker in the C-terminus (eight residues distance 
to theIR tail) resulted in a crosslinking product of the same size. Since the size of this 
product is clearly different from the size of the Doc1-Cdc16 crosslink products, we assume 
that it is result of a Doc1-Cdc27 interaction (not shown). Our data therefore fully support 
the previously reported interaction between Doc1’s C-terminal region and Cdc27. Moreover, 
they provide the first evidence of a direct interaction between an IR tail and a TPR subunit,
observed with full-length proteins and in the context of the intact APC.
We have found a second TPR subunit which directly interacts with Doc1. Doc1 crosslinks to 
Cdc16 via two residues which are both located in its “C-terminal region”. One site has been 
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found in the study of Carroll et al. to be important for Doc1 binding to APC (Carroll et al., 
2005) and was therefore replaced with a crosslinker amino acid residue; the other site, 
emanating from the lower back side of the molecule, has successfully been exchanged as one 
of the “randomly” picked residues. After deletion of the C-terminal IR tail the interaction 
between Doc1 and Cdc16 was four-fold reduced (Section 2.1.3). The IR tail-dependent 
interaction of Doc1 with Cdc27 therefore stimulates the interaction of Doc1 with Cdc16. In 
the study mentioned above, Wendt et al. have also tested binding of insect cell-expressed 
Cdc16 to the Doc1 matrices. Cdc16 bound to full length Apc10/Doc1, but this association 
was weaker compared to that of Cdc27. Importantly, Cdc16 and not Cdc27 was able to 
weakly associate with the Doc1 version lacking the C-terminal 23 amino acids (Wendt et al., 
2001). This is consistent with a Doc1-Cdc16 interaction being promoted by, but not 
dependent on the Doc1 IR tail. Peculiarly, in these experiments both Cdc16 and Cdc27 did 
not bind to the Doc1 version lacking the C-terminal 14 amino acids (Doc1C14). It has to 
be noted though, that this Doc1 version was not, as the other Doc1 versions used in this 
experiment, a GST-fusion protein bound to a glutathione matrix; instead, the untagged 
Doc1C14 was coupled to a matrix via cyanogen bromide activation (Wendt et al., 2001)
which might have caused damage to the protein. 
3.1.2 Does Doc1 interact with Apc1 or Apc2?
Budding yeast APC lacking Cdc27 (Kraft et al., 2005; Thornton et al., 2006) or Cdc16 
(Thornton et al., 2006) contains normal levels of Doc1, indicating that Doc1 might be able to 
interact with the APC also via different subunits. A C-terminally truncated Doc1 mutant 
which in addition has two conserved residues within the C-terminal region changed to 
alanines is impaired in binding to APC in vitro; this defect can, however, be overcome by 
adding higher levels of Doc1 (Carroll et al., 2005). This indicates that Doc1 must bind to 
additional APC subunits via sites distinct from the C-terminal region and the IR tail.
Which subunit apart from Cdc16 and Cdc27 does Doc1 bind to? A subcomplex of human 
APC which is lacking Apc2 and Apc11 shows reduced levels of Doc1 (Vodermaier et al., 
2003). This suggests Apc2 or Apc11 as candidate binding partners for Doc1 but clearly 
indicates that binding of Doc1 to APC also occurs via subunits except Apc2 and Apc11. In 
contrast, Thornton et al. observed complete loss of Doc1 from the APC in strains lacking 
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Apc2 (Thornton et al., 2006). Likewise, Apc11 was absent from these preparations. 
Moreover, APC purified from an apc11 strain contains reduced levels of Doc1 and Apc2, 
whereas Doc1 deletion does not affect any other known subunits (Thornton et al., 2006). 
This study therefore implicates Apc2 as a direct interaction partner of Doc1. In our 
crosslinking experiments, we have not detected an interaction between Doc1 and Apc2 or 
Apc11, although I have “scanned” 10 % of Doc1’s amino acids and thereby tried to cover all 
surfaces (Section 2.1; Figure 3-1). This does, however, not rule out the possibility that Doc1
directly binds to Apc2. I could have missed the Apc2-interacting surface when choosing the 
sites of crosslinker-incorporation. Alternatively, the structures of some of the mutants could 
have been distorted due to crosslinker insertion; these mutants, possibly including those 
carrying the crosslinker at putative Apc2-interacting sites, might have therefore not been 
functional in crosslinking experiments.
Instead, however, I have obtained crosslinks to Apc1 with four different Doc1 crosslinker 
mutants (Section 2.1.3). Two mutants crosslink strongly to Apc1; in one of these mutants the 
crosslinker is located in the C-terminal region, right next to the site which strongly interacts 
with Cdc16; in the other mutant the crosslinker is emerging from a -sheet to the lower right 
side. Weak crosslinks have been obtained with a mutant, in which the crosslinker is located 
in the putative ligand binding region and with a mutant which strongly crosslinked to Cdc16. 
Conversely, the Doc1 version which has a crosslinker in the C-terminus and interacts 
strongly with Apc1 also interacts weekly with Cdc16 (for overview see Table 2-2). These 
observations raise several questions. Is it conceivable that a single crosslinker mutant can 
interact with two different proteins? We believe that if two sites located directly next to each 
other can strongly interact with two different proteins, then it might be plausible that they 
can also weakly contact the respective neighbor protein, since there should be some 
flexibility in the crosslinker itself. Another puzzling question becomes evident when looking 
at Figure 3-2B. The sites on Doc1 which crosslink to Apc1 cover an extensive surface area; 
Apc1 would have to be “wrapped” around Doc1 if the two proteins were simultaneously 
making contacts via these residues. Although unusual, there is some precedence for 
interactions in which one protein embraces its binding partner. One example is the ubiquitin 
ligase SCFSkp2 which requires the accessory protein Cks1 to recognize and ubiquitinate the 
substrate p27Kip1 (Ganoth et al., 2001; Spruck et al., 2001). Structural data available for this 
complex reveal that Skp2 “embraces” Cks1 by making contacts with residues which are 
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(within structure and sequence) distant from each other (Hao et al., 2005). Remarkably, 
within the above complex, the 9 kDa protein Cks1 directly interacts with three different 
proteins and Cks1 residues which make contacts to different proteins lie directly next to each 
other (Hao et al., 2005). It is therefore conceivable that Doc1 would be embraced be Apc1 in 
a similar fashion.
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Figure 3-2: Sites within Doc1 which interact with Cdc16, Cdc27 and Apc1; schematic 
drawing of Doc1 interactions within APC. A) The position of sites which interacted with 
Cdc16 (blue) or Cdc27 (green) are shown on the crystal structure of budding yeast Doc1. 
Because the C-terminus was not included in the structure, it is shown as a schematic drawing. 
B) Same as (A), but here sites which crosslinked to Apc1 are shown in orange. C) Model 
depicting Doc1 interactions within APC. Modified from (Thornton et al., 2006). Two 
scribbles on Doc1 indicate Doc1’s C-terminus, which directly contacts Cdc27, and the 
“processivity loop”, the putative interaction partner of which has not been identified. Pink 
dotted lines denote further observed interactions. 
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The most important questions which emerge from our interaction data are: Is the identified 
interaction between Apc1 and Doc1 physiological? And, could Doc1 then bind to Apc1 
“instead” of Apc2? Similar to the crosslinks to Cdc16 and Cdc27, we have only observed a 
crosslink to Apc1 with few (that is four) out of 24 crosslinker mutants; this indicates that the 
observed interactions might be specific. In contrast to the Doc1 versions which crosslinked 
to the TPR subcomplex, however, some of the crosslinker mutants which bind to Apc1 are 
greatly impaired in their ability to stimulate processive ubiquitination. Insertion of the 
crosslinker might therefore render some Doc1 versions inactive; hence they might bind 
“inappropriately”. Alternatively, insertion of the crosslinker at sites which are important for a 
protein’s function (such as those within the “processivity loop”) might inactivate the protein 
but yet allow it to bind to its native binding partner. We are not able to distinguish between 
these two options at the moment and therefore have to await results from EM analyses (see 
below). 
How could removal of Apc2 lead to loss of Doc1 from APC (Thornton et al., 2006), 
although Cdc16, Cdc27 and Apc1 are still present in the complex? Once Apc2 is removed 
from APC, either by high salt washes in case of human APC (Vodermaier et al., 2003) or 
upon Apc2 deletion in budding yeast APC (Thornton et al., 2006), Apc1 might adopt a 
confirmation which abolishes the interaction with Doc1. The interaction of Doc1 with
Apc1/Apc2 would have to be the predominant one such that Doc1 interactions with the 
TPR subcomplex only takes place upon binding of Doc1 to Apc1/Apc2. Alternatively, the 
interactions between Doc1 and Cdc16/Cdc27 may not be strong enough for stable binding 
of Doc1 to the APC. This might explain why in strains lacking Apc2, Doc1 is lost from 
APC. Alternatively and more likely, insertion of the crosslinker at certain sites within Doc1 
interferes with proper protein folding or function. Doc1 might preferably aggregate with the 
biggest APC subunit, Apc1. Within these Doc1-Apc1 aggregates, few sites might crosslink to 
Apc1. A preferable albeit possibly non-physiological association of Cdh1 with human APC 
was observed in EM experiments. Cdh1 appears to have an additional binding site to which 
the coactivator binds when added in superstoichiometric amounts (Herzog et al., manuscript 
in preparation). We will in the future try to explore the physiological relevance of the 
observed Apc1-Doc1 interaction by EM analysis. We are currently analyzing the localization 
of the C-termini of Apc1 and Apc2 within our 3D model (Table 2-3). In addition, we are 
planning to construct a yeast strain carrying an N-terminal td2-tag on Apc1. The localization 
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of Apc1 within the human complex has been determined by antibody labeling. According to 
this, the C-terminus of Apc1 is rather distant from Doc1 (Herzog et al., manuscript in 
preparation). Apc1 is, however, thought to form APC’s scaffold in a very “stretched-out” 
conformation. (Franz Herzog and Holger Stark, personal communication). We therefore 
consider it worthwhile to identify the position of Apc1’s N-terminus as well. 
3.2 Functions of the TPR subcomplex
Doc1 interacts with Cdc27 via residues in its C-terminus. We have not addressed whether 
this interaction is dependent on TPR motifs within Cdc27. Based on earlier findings (Gatto 
et al., 2000; Vodermaier et al., 2003), however, including those addressing the region 
responsible for the interaction between human Apc7 and Cdh1 (Vodermaier et al., 2003), we 
propose that this is likely to be the case. Apc7 is a homolog of Apc3 and is therefore also 
closely related to yeast Cdc27. In vitro interaction studies have shown that recombinant Apc3
and Apc7 can bind to peptides corresponding to the C-termini of Apc10/Doc1, Cdc20 and 
Cdh1 ((Vodermaier et al., 2003); Christian Gieffers and Hartmut Vodermaier, unpublished 
observation). The binding of Cdc20 and Cdh1 to yeast APC, which does not contain Apc7, 
is reduced in strains lacking Cdc27 (Kraft et al., 2005; Thornton et al., 2006). Several pieces of 
evidence therefore imply that TPR motifs within Cdc27 and possibly its homologue Apc7 
are docking sites for C-terminal IR tails present in APC coactivators and Apc10/Doc1. The 
evidence that one of the other TPR subunits, Apc6/Cdc16 or Apc8/Cdc23, interacts with
IR tails, is less convincing. Vodermaier et al. only observed weak binding of Cdc16 to 
peptides derived from the C-termini of Apc10/Doc1, Cdc20 or Cdh1 (Vodermaier et al., 
2003). Moreover, the binding of Cdc16 to Apc10/Doc1 appears to occur via a region 
outside of the IR tail (see 3.1.1). Cdc23 did not bind at all to C-terminal peptides 
corresponding to the C-termini of Cdc20 and Cdh1 (Vodermaier et al., 2003). 
Human APC appears to contain only one copy of Cdc27 and two copies of Apc7 per 
complex (Dube et al., 2005); the complex might therefore contain several docking sites for IR 
tails. Fission and budding yeasts do not have Apc7. Fission yeast might “compensate” for 
this by containing two copies of Cdc27 (Ohi et al., 2007). The Cdc27 copy number in 
budding yeast, however, is less clear. Whereas Passmore et al. have reported two to three
copies to be present per complex (Passmore et al., 2005b), we have found evidence that APC 
DISCUSSION
74
might contain only one Cdc27 molecule (Sections 2.3.3 and 3.5). In budding yeast the 
number of Cdc27 versions might therefore be smaller than the number of IR tail-containing 
binding candidates. This raises the question if Cdc27 can harbor more than one IR tail type 
at the same time or whether different IR tails bind in a mutually exclusive manner. Some 
studies implicate Doc1 as a non-constitutive APC subunit (Hwang and Murray, 1997; 
Kominami et al., 1998); nevertheless it seems unlikely that Cdh1 and Doc1 bind to APC in a 
mutually exclusive manner, given for example the effect of Doc1 on APC-Cdh1-mediated 
ubiquitination ((Carroll and Morgan, 2002; Carroll and Morgan, 2005; Passmore et al., 2003);
Section 2.1). Rather one could imagine that rearrangements within the TPR-IR interaction
module might somehow contribute to regulation of APC activity or substrate recognition, 
while the proteins remain associated with APC. 
Noticeably, Cdc20, Cdh1 and Doc1 bind to APC via additional sites; these interactions seem
to be independent of the IR and TPR modules and even functionally predominant (Peters, 
2006; Thornton and Toczyski, 2006). Cdh1 retains function independent of the interaction 
between Cdh1’s IR tail and Cdh1 (Thornton et al., 2006). This function is dependent on a
sequence called the “C box”, which might confer binding of Cdh1 to Apc2. This binding is 
either direct or indirect via Apc11 or Doc1. Moreover, the interaction between Cdc20’s IR 
tail and APC seems to be dispensable for viability (Thornton et al., 2006). Doc1’s binding to 
APC is dependent on a subunit outside of the TPR subcomplex, possibly Apc2 (Thornton et 
al., 2006; Vodermaier et al., 2003); Thornton et al. reported that in yeast Doc1 does not 
require TPR subunits for binding to APC (Thornton et al., 2006). 
What is the function of TPR subunits then? By providing additional binding sites for IR tail-
containing proteins they might be responsible for the correct positioning of proteins within 
APC. Simultaneous binding of IR tail-containing proteins to subunits of the catalytic and 
TPR subcomplexes might cause structural rearrangements (see below). Importantly, the IR 
tail-containing proteins Cdc20, Cdh1 and Doc1 are all required for efficient APC 
ubiquitination. Even small rearrangements within the IR-TPR binding interface could 
possibly affect APC activity. When performing crosslinking experiments with a Doc1 
version carrying the crosslinker in the IR tail I have observed the following: The Cdc27-
Doc1 crosslink was reduced in samples which had been incubated with a ubiquitination mix 
prior to UV-irradiation, compared to the samples which had been incubated with buffer 
instead. Importantly, all samples had similar amounts of Doc1 bound to APC (Section 2.1.4). 
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This ubiquitination mix contained E1 and E2 enzymes, ubiquitin, GST-Hsl1(667-872), ATP and 
recombinant purified Cdh1. This could observation could mean that, upon Cdh1 binding, 
the IR tail of Doc1 binds less stably to Cdc27 or is “rearranged” while Doc1 remains bound 
to APC. We have not followed up on this observation yet and it would be important to first 
test whether the reduced crosslink is caused by the presence of Cdh1 or any other particular 
component in the ubiquitination mix. 
The many TPR subunits in APC might allow the complex to interact with several proteins at 
the same time. While Cdc27 might be “specialized” for the interaction with Doc1, Cdh1 and 
possibly Cdc20 (Section 2.1.3; (Kraft et al., 2005; Vodermaier et al., 2003; Wendt et al., 2001)), 
functions of other TPR proteins remain to be identified. Likewise, other APC-related 
proteins contain IR tail-like C-termini, but the APC subunit to which they bind has not been 
identified yet: Recently it has been reported that the APC substrate Nek2A associates with 
APC dependent on Nek2A’s C-terminal MR tail (Hayes et al., 2006). This substrate is 
degraded in a Cdc20 dependent manner and therefore might require simultaneous binding of 
substrate and coactivator to (two different?) TPR subunits. Finally, apart from providing 
docking sites for IR tail-containing proteins, Cdc27 has been proposed to have an additional 
function (Thornton et al., 2006). This hypothesis is based on the observation that a cdh1
cdc20-IR yeast strain can grow whereas a cdc27 strain can not (Thornton et al., 2006). If 
Cdc27’s sole function was to be the IR tail receptor for Cdh1, one would expect the cdh1
cdc20-IR and cdc27 strains to show the same growth phenotypes. Cdc27 might therefore 
have an additional role; the authors suggested that this might be in APC catalysis, especially 
since CDC27 deletion does not affect APC subunit composition (Thornton et al., 2006). 
3.3 How does Doc1 confer processivity to APC ubiquitination? 
Our crosslinking approach has not led to the identification of a Doc1 interaction partner 
which could directly explain Doc1’s function as a processivity factor. Despite testing many 
Doc1 versions carrying the photocrosslinker under several conditions (Section 2.1.4), I could 
have yet “missed” the “right” site or conditions, or both. Alternatively, Doc1 might interact 
with a non-proteinaceous ligand, and with our experimental set up we would be unable to 
detect such type of ligand. I have assessed the functionality of my Doc1 versions carrying a 
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photocrosslinker in the “processivity loop” which is believed to interact with Doc1’s 
putative ligand (Au et al., 2002; Carroll et al., 2005; Wendt et al., 2001). The presence of the 
photocrosslinker has only mildly affected Doc1 function in my experimental set up (Section 
2.1.5); it should have therefore been possible to “catch” a ligand with this approach. 
Importantly, the fact that we have not been successful does not argue against the simplest 
explanation for Doc1’s effect on processive APC ubiquitination, namely that it directly 
interacts with the substrate (as suggested by (Carroll et al., 2005; Carroll and Morgan, 2002; 
Passmore et al., 2003)) or the growing ubiquitin chain on the substrate. To further test these 
possibilities, I have more recently established the conditions for a photocrosslinking 
approach employing a photocrosslinker-containing APC substrate which can stably bind to 
mitotic human APC (Section 2.4). Should this approach be successful we might get insight 
into the molecular basis of Doc1’s processivity function.
How, if not by directly contacting a substrate or any other component of the ubiquitination 
reaction, could Doc1 confer processivity to APC ubiquitination? Recently, budding yeast 
APC has been reported to ubiquitinate substrates in a more processive fashion when it is in a 
dimeric form, compared to APC monomers (Passmore et al., 2005b). Both monomeric and 
dimeric APC are able to bind and multiubiquitinate substrates (Passmore et al., 2005b). Since 
Doc1 has been shown to be a processivity factor for APC ubiquitination it is tempting to 
speculate that Doc1 might mediate this processivity by contributing to APC dimerization. 
Passmore and Barford have observed a doublet of bands when running purified APC on 
non-denaturing gels with the slower one having the estimated size of an APC dimer 
(Passmore and Barford, 2005). The authors also observed an enrichment of monomeric and 
dimeric APC versions when separating purified APC by sucrose and glycerol density 
centrifugations, respectively. When analyzing their APC preparations – which had been 
obtained by TAP-purification and contained 5 % glycerol – by electron microscopy, they 
observed monomeric and dimeric particles at a ratio of 3:1. In cryo-EM experiments, which 
do not allow glycerol to be present in samples, the same authors only observed monomeric 
APC (Passmore et al., 2005b), indicating that glycerol stabilizes APC dimers. Although a 
similar TAP-purification protocol including glycerol has been used by Hartmut Vodermaier 
in our lab, he found that the bulk of APC co-sediments with human APC in sucrose density 
gradient centrifugations (Kraft et al., 2005); human APC is believed to be monomeric and has 
an S value of 22 (Gieffers et al., 2001). 
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The S value of budding yeast APC has been determined to 36 (Zachariae et al., 1996) in 
glycerol gradient density centrifugation experiments in which total yeasts extracts were 
analyzed. Similar to Zachariae et al. (Zachariae et al., 1996) we have found APC to peak at an 
S value larger than that for the proteasome and smaller than that of yeast fatty acid synthase 
when we analyzed whole cell extracts by sucrose density gradient centrifugation (not shown), 
indicating that in the absence of glycerol APC dimers exist. Similar to Passmore et al., we 
have also observed APC dimers when analyzing TAP-purified samples by negative staining 
EM (Section 2.3.1 and not shown). Importantly, our samples are prepared by a fixation step 
on a gradient containing up to 40 % glycerol prior to grid preparation. Depending on the 
fraction of the gradient that is being used for grid preparation, we can see a lower or higher 
frequency of dimers. These dimers seem to have a specific orientation such that APC 
monomers are oriented to each other in a certain way within a dimer. (not shown). This 
indicates that APC dimerization might not simply be an artifact due to the presence of 
glycerol. We are currently analyzing these samples further and are hoping to identify the 
subunits involved in APC dimerization by combining these data with our subunit 
localizations obtained for yeast (Sections 2.3.2, 2.3.3) and human (Herzog et al., manuscript 
in preparation) APC. Furthermore, we will analyze our EM grids of APCdoc1 samples for the 
presence of APC dimers and compare wild type and doc1 yeast extracts in glycerol and 
sucrose density centrifugation experiments; the parallel analysis of TAP-purified APC 
samples might serve as monomeric control. This might provide insight into whether Doc1 
might be involved in the formation of APC dimers.
How could Doc1 mediate this process? Doc1 is a stoichiometric subunit of human and 
fission yeast APC (Dube et al., 2005; Ohi et al., 2007) and has been reported to be present 
twice in budding yeast APC (Passmore et al., 2005b). In order to link two complexes, Doc1 
would have to be bound stably to one or more subunits within one complex; in addition, it 
would have to make additional less stable contacts to (a) further subunit(s) within the second 
complex. For the latter contacts, Doc1 would have to dimerize itself, bind to the same set of 
subunits again or associate with different subunits. It has been speculated that Doc1 might 
be stably bound to Apc2 within one complex and by binding to Cdc27 from a second 
complex, might mediate APC dimerization (Thornton and Toczyski, 2006). This would 
imply that APC dimers are not “symmetric” in a way that different surfaces would be facing 
each other. 
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Our preliminary biochemical data speak against an involvement of Doc1 in formation of 
APC dimers (Section 2.2). In co-immunoprecipitation experiments, the ability of Apc1 to 
self-associate has not been significantly reduced in the absence of Doc1 (Section 2.2). We 
would like to repeat these experiments under different buffer- and salt-conditions. So far, 
however, Doc1 may be part of a dimeric interface and somehow act in that setting; but its 
contributions to the actual formation of an APC dimer seem to be minor. Since APC 
subunit composition and functions are largely conserved among different species, we would 
also expect its ubiquitination mechanism to be similar. Therefore it seems unlikely that 
dimerization is a key mechanism in budding yeast because no APC dimers have been 
observed in other organisms; the exception might be an observation by Gieffers et al. who 
reported a slower band in native gel electrophoreses (Gieffers et al., 2001). When analyzing 
human APC the same way as described for budding yeast APC (Kastner et al., 2008) we have 
so far not observed any dimers (Franz Herzog and Holger Stark, personal communication). 
Nevertheless, further side-by-side analysis of APC from different species in density gradient 
centrifugations, negative staining EM and native gels might be worthwhile. It would for 
example be interesting to see the sedimentation behavior of fission yeast APC when whole 
cell extracts are separated instead of purified samples. Notably, dimerization has been 
reported to play an important role for a yeast SCF complex (Tang et al., 2007). This 
dimerization is mediated by the WD40 domain containing F box proteins TrCP and Cdc4 
and it increases the catalytic efficiency of the ubiquitin ligase. Importantly, however, these 
adaptor proteins homo-dimerize via a so-called D domain which is missing from the WD40 
domain containing APC coactivators (Tang et al., 2007).
Instead of bringing two APCs together or act in such a setting, Doc1 might function by 
inducing conformational changes within a single complex. Similar to Cdh1, Doc1 seems to 
interact with both the TPR subcomplex (Vodermaier et al., 2003; Wendt et al., 2001) and with 
a member of the catalytic subcomplex, probably Apc2 (Thornton et al., 2006; Vodermaier et 
al., 2003). This might allow APC to close around a substrate and thereby prevent its 
dissociation during repeated cycles of ubiquitination. According to the budding yeast APC 
interaction map by Thornton et al., the TPR subunits form a subcomplex with Cdc23 being 
the innermost member which interacts with Apc4 and Apc5; Cdc27 is the middle and Cdc16 
the outermost subunit among the TPR subunits (Thornton et al., 2006). APC isolated from a 
cdc27 strain retains residual ubiquitination activity; cdc16APC in contrast is inactive 
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(Thornton et al., 2006). This suggests that Cdc16 might have an additional function beyond 
mediating Cdc27 binding to APC. Maybe, upon substrate binding to APC via a coactivator, 
APC needs the interaction between Cdc16/Cdc27 and Doc1 to fully enclose a substrate. The 
crosslinking data presented in this study would be consistent with this possibility. They 
suggest that both subunits, Cdc16 and Cdc27, are directly interacting with Doc1’s C-terminal 
region (Section 2.1.3). In a cdc16 strain, both Cdc16 and Cdc27 are lost from APC; hence,
the Doc1 interaction with the TPR subcomplex is abolished. 
Both the “dimerization” and the “conformational change” hypothesis do not provide an 
explanation for a possible involvement of Doc1’s putative ligand binding loop in processive 
APC ubiquitination. Although we have not been able to detect Doc1 binding to Apc2 in our 
crosslinking experiments and therefore do not know what region of Doc1 it binds to, it 
seems unlikely that the processivity loop mediates this interaction. Carroll et al. have purified 
APC from a yeast strain which carried four alanine mutations in the processivity loop. These 
mutations result in a processivity defect; yet is Doc1 associated with APC at normal levels 
(Carroll et al., 2005). Since in budding yeast Doc1 seems to associate with APC 
predominantly via Apc2, the processivity loop can not be required for this interaction. It 
therefore seems more plausible, that Doc1 – possibly upon APC dimerization or induction 
of conformational changes – employs its processivity loop to act as a processivity factor by 
binding to a still unidentified ligand. 
3.4 How does APC recognize substrates?
Several pieces of evidence suggest that both core APC and an APC coactivator contribute to 
substrate recognition (Burton et al., 2005; Carroll et al., 2005; Eytan et al., 2006; Hayes et al., 
2006; Kraft et al., 2005; Passmore and Barford, 2005; Passmore et al., 2003; Yamano et al., 
2004). The D box of an APC substrate has been shown to bind directly to Cdh1 (Kraft et al., 
2005). In contrast, the identity of the APC subunit(s) which is (are) binding to substrates is 
unknown. Our approach employing photocrosslinker-containing Doc1 versions has not 
revealed whether Doc1 is the APC subunit which interacts with APC substrates (Section 
2.1). I have therefore established the conditions for a crosslinking approach which uses the 
artificial substrate N702x-GST containing a photoactivatable amino acid. N702x-GST is a 
tandem fragment of fission yeast cyclin B/Cdc13 that is C-terminally fused to GST; 
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therefore it contains two D boxes as APC substrate degrons (Yamano et al., 1996; Yamano et 
al., 1998). Substrate photocrosslinking experiments have previously been carried out by 
Claudine Kraft in our lab. Whereas Claudine has demonstrated that substrate D boxes bind 
to the WD40 domain of Cdh1 (Kraft et al., 2005), she has not been able to identify a putative 
APC core substrate receptor ((Kraft et al., 2005); personal communication from Claudine 
Kraft). Claudine has used short peptides representing parts of the APC substrates cyclin B 
and securin, in which a photoactivatable amino acid was incorporated in proximity to the D 
box (Kraft et al., 2005). These peptides were specifically recognized and ubiquitinated by 
APC; binding to APC, however, could only be detected with the help of the 
photocrosslinking method (Kraft et al., 2005). We would now like to undertake a new 
attempt and thereby make use of the substrate construct N702x-GST, which has been shown 
to bind to mitotic APC very well in conventional binding assays. Importantly, this binding 
seems to be specific since it depends on the D boxes within this substrate (Eytan et al., 2006; 
Yamano et al., 2004). Furthermore, the construct can not bind to APC when APC is 
associated with the mitotic checkpoint complex. The same was also observed with Hsl1-his, 
which is a physiological substrate of the APC (Herzog et al., manuscript in preparation). 
These findings support the notion that its behavior resembles that of a “natural” substrate. 
Xenopus APC isolated from frog egg extracts which have been depleted from coactivators is 
able to bind to N702x-GST (Yamano et al., 2004). This study by Yamano et al. for the first 
time demonstrated the existence of a D box receptor on APC. Substrate binding is, however, 
greatly enforced by the presence of Cdc20 (Yamano et al., 2004). Moreover, it has been 
shown that human APC binds N702x-GST with relaxed specificity and selectivity upon 
Cdc20 depletion (Eytan et al., 2006). Eytan et al. have reported no difference in the affinity of 
APC to wild type and D box mutant substrates in the absence of Cdc20 (Eytan et al., 2006). In 
presence of Cdc20, they have found little binding of the D box mutant to APC. This binding 
was not further reduced after Cdc20 depletion (Eytan et al., 2006). In contrast, Yamano et al.
have observed reduced binding of an N702x-GST D box mutant compared to wild type N702x-
GST after Cdc20 depletion (Yamano et al., 2004). These experiments indicate that Cdc20 
plays an important role in substrate specificity and affinity to APC. It is not clear, however, 
whether APC can bind to N702x-GST specifically in absence of Cdc20. 
We therefore believe that it is important to carry out photocrosslinking experiments with 
APC and N702x-GST in the presence of a coactivator. Adding Cdc20 or Cdh1 to mitotic 
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APC increased the levels of N702x-GST that were bound to APC ((Eytan et al., 2006), 
personal communication from Ivana Primorac). For our crosslinking experiments, we are 
therefore considering to add recombinant Cdc20, purified from insect cells, to stimulate 
substrate binding to APC. Since crosslinks between APC substrates and APC coactivators 
have already been detected in two studies ((Kraft et al., 2005); personal communication from 
Yuu Kimata and Hiro Yamano), it is not unlikely that we might detect a similar interaction as 
well, especially when adding extra Cdc20. The position of the crosslinker might, however, 
determine whether a crosslink product is formed between substrate and Cdc20 or between 
substrate and APC subunit. Both the crosslinker position relative to the D box and, in case 
of our tandem fragment, whether it is in the first or second D box, might be important. By 
employing many N702x-GST versions, each of which carries the photoactivatable amino acid 
at a different position, we are hoping to identify a specific crosslink to a core APC subunit
(Section 2.4). One might also use APC from mitotic HeLa extracts which have been depleted 
of Cdc20 for crosslinking experiments. Because this reduces substrate binding and might 
increase unspecific binding (see above), however, this attempt is not our first choice.
The hypothesis that the photocrosslinker position determines whether the substrate might 
crosslink to Cdc20 or to an APC subunit is based on APC substrate recognition models 
proposing “simultaneous” or “multivalent” interactions between APC, Cdc20 and a 
substrate ((Eytan et al., 2006; Passmore and Barford, 2005; Yu, 2007); Figure 3-3). In a 
simultaneous binding model, both APC and Cdc20 build a composite binding site for 
substrates and the substrate’s destruction motif binds at the interface between APC and 
Cdc20. APC substrates often contain more than one degron. In a multivalency model, APC 
and Cdc20 each have weak binding sites for D or KEN boxes. An APC-Cdc20 complex 
might therefore produce high affinity binding due to the synergistic effect of multiple weak 
interactions. Moreover, substrates might bind sequentially to APC-Cdc20 such that the 
substrate is first bound by Cdc20 and then transferred to an APC subunit. An allostery 
model includes a conformational changes being induced in APC upon coactivator binding. 
These might expose binding sites on core APC which had been masked before. None of the 
models can satisfy all the observations that have been made in the past with respect to APC 
substrate recognition. A valid model would therefore rather contain aspects of several 
models. It would have to account for the finding that both APC core and coactivators have 
substrate binding sites; yet the substrate binding is only highly selective and efficient in the 
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presence of both entities (Burton et al., 2005; Eytan et al., 2006; Kraft et al., 2005; Passmore 
and Barford, 2005). The observation that substrate recognition by APC-Cdc20 is more 
selective than in absence of Cdc20 might support a sequential binding model in which the
degrons on APC substrates would be tested for “correctness” at two binding sites before a 
substrate gets degraded (Eytan et al., 2006). The increased substrate affinity which has been 
reported for reactions containing APC and coactivator (Eytan et al., 2006; Passmore and 
Barford, 2005; Yamano et al., 2004) matches a setting in which Cdc20 binding to APC might 
induce a conformational change within APC. This might be reflected in the observation that 
Cdh1 binding to APC induces a conformational change in APC (Dube et al., 2005). In line 
with this, Hershko and coworkers have reported that increasing amounts of Cdc20 increase 
the catalytic rate of substrate ubiquitination (Eytan et al., 2006). The fact that several APC 
substrates contain multiple degrons and the observation that elimination of a single degron
often does not abolish APC substrate recognition completely (Fang et al., 1998; Zur and 
Brandeis, 2001) might be explained with a multivalency model. Coactivator and one or more 
APC subunit(s) might contain substrate receptor sites and several weaker interactions might 
sum up to a binding of high affinity. Maybe the N702x-GST construct, which contains two D 
boxes, binds mitotic APC so well (Eytan et al., 2006; Yamano et al., 2004) because its two 
degrons can simultaneously interact with two substrate receptors, one of which is Cdc20.
Also Hsl1(667-872), which binds human APC with similar specificity (Herzog et al., manuscript 
in preparation; personal communication from Ivana Primorac), contains a D and a KEN 
box. It is not clear whether in such a setting contacts between certain degrons and certain 
substrate receptors would be “predetermined”, or whether interactions happen at random. 
Likewise, binding of the substrate to its multiple receptors might be highly dynamic. Analysis 
of APC constructs such as N702x-GST or Hsl1, which have been mutated by swapping or
eliminating degradation motifs or by insertion of linkers, in binding assays might tell us why 
these proteins are such good APC binders. This could provide valuable information about 
the mechanism of substrate recognition. Ultimately, however, we will need structural data at 
atomic resolution to understand how substrate recognition by APC works in detail. 
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Figure 3-3: Four models for APC substrate recognition involving an APC coactivator 
and an APC core subunit. Modified from (Buschhorn and Peters, 2006; Yu, 2007). The 
WD40 domains of Cdc20 and Cdh1 functionally interact with a substrate’s destruction box 
(D box). In addition, a core subunit of APC contributes to substrate recognition. Both 
coactivator and APC might interact with the D box simultaneously. In the “sequential” 
setting, the D box might first be recognized by a coactivator and then be transferred to core 
APC. According to an allostery model, binding of a coactivator might induce a 
conformational change in APC which might expose a substrate binding site on core APC. 
With respect to substrate binding, the allosteric model has to be combined with either of the 
three other models. Finally, multiple degrons (such as a D box and a KEN box) within 
substrates might be recognized by substrate binding sites present in both core APC and 
coactivator. Multivalent weak interactions might produce a binding of higher affinity. The 
four models are non-mutually exclusive. In fact, APC substrate recognition is likely to feature 
aspects of several models.
3.5 EM analyses to study APC assembly and function
APC is an essential regulator of cell cycle events and has been intensively studied for the last 
decade. Yet there are many unresolved questions concerning its regulation and its catalytic 
mechanism. Answering these questions requires insights into the overall structure of APC 
and into the 3D topology of its subunits. APC versions from different species contain 
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roughly the same number of subunits (see Table 1-1) and the domains which could be 
identified within these subunits are conserved at the primary amino acid sequence level. 
Thus, one would expect the structures of APC molecules from different species to be 
similar. However, structures published so far for APC purified from human cells (Dube et al., 
2005; Gieffers et al., 2001), frog egg extracts (Dube et al., 2005), fission yeast (Ohi et al., 2007)
and budding yeast (Passmore et al., 2005b) display some striking differences. The budding 
yeast structure (Passmore et al., 2005b) is particularly different from the structures of 
vertebrate APC obtained recently in our lab ((Dube et al., 2005), Herzog et al., manuscript in 
preparation). We therefore decided to generate a 3D model of budding yeast APC under 
sample preparation and imaging conditions that are comparable to the conditions under 
which 3D models of vertebrate APC were obtained (Figure 2-11). At first glance, our 
structure of budding yeast APC shares similarities with the structures of fisson yeast (Ohi et 
al., 2007) and human APC (Figure 2-11C), which is a refined version of the model published 
in ((Dube et al., 2005), Herzog et al., manuscript in preparation). All theses structures are 
characterized by an asymmetric shape and an inner cavity, though the latter is of different 
size in the different models. Human and frog APC ((Dube et al., 2005), Herzog et al., 
manuscript in preparation) have a pronounced “head” domain. In our new structure and in 
the fission yeast structure, no such prominent “head” domains can be found. It is important 
to note that Ohi et al. did not determine the handedness of their structure; in fact, random 
conical tilt analyses have shown that the handedness of budding yeast APC is different from 
the one that was reported by Ohi et al. ((Ohi et al., 2007), Holger Stark, personal 
communication). It is therefore difficult to align and compare our budding yeast structure 
with the structure of fission yeast APC. It is also surprising in view of the wrong handedness 
of the fission yeast model that the authors were able to place the atomic structure of the SCF 
complex into their model (Ohi et al., 2007). All APC 3D models contain prominent ridges at 
the back of the complex (see below). This includes the published budding yeast structure
(Passmore et al., 2005b); although in this model the ridges are less pronounced. However, it 
is possible that these differences are caused by differences in the image analysis procedures 
that were used. When having a closer look at Figure 2-11D similar features between the two 
budding yeast structures become evident. Our structure appears asymmetric, slimmer and 
more defined. It could be that structural details in the published structure are “smeared out” 
and the structure might be broadened as a result of a pseudo-symmetry that was not 
DISCUSSION
85
removed (see also discussion in (Dube et al., 2005)). Maybe, some of the striking differences 
between the available 3D models of APC stem from difficulties with image processing and 
structure determination. Removing these will be essential – yet difficult due to the lack of 
parameters describing structure validity – since only faithful models can contribute to the 
understanding of APC function. 
At the resolutions achieved so far (~20 Å for human APC (Herzog et al., manuscript in 
preparation) 27 Å for fission yeast APC (Ohi et al., 2007) and ~20 Å for budding yeast 
(Passmore et al., 2005b)), the identification of tertiary structure elements and their 
assignment to individual APC subunits is impossible. Getting insight into the molecular 
organization of subunits within APC therefore – until higher resolution EM and 
crystallography approaches are successful – requires approaches such as antibody labeling or 
mutant analysis to determine subunit localizations. These approaches have already led to an 
overall idea of APC subunit assembly. Recently, an almost full set of antibody labeling data 
has been published for fission yeast APC subunits (Ohi et al., 2007). The authors have 
analyzed the binding sites of antibodies on single APC molecules. Because they could only 
localize the antibody binding sites on a 2D image, implications from this subunit map are 
limited (Ohi et al., 2007). Franz Herzog and Holger Stark have generated an impressive 3D 
model of human APC, onto which they have mapped the localization of 8 APC subunits and 
the coactivator Cdh1 ((Dube et al., 2005); Herzog et al., manuscript in preparation}. They 
have analyzed dimers of two APC molecules crosslinked via a single APC subunit-specific 
immunoglobulin by negative staining EM. By computational analysis of the relative 
orientations of the two APC molecules to each other they obtained the subunit localizations
on the surface of an APC 3D model (Dube et al., 2005, Herzog et al., manuscript in 
preparation). Due to the flexibility and relatively big size of the antibodies and the fact that a 
2D image is mapped onto a 3D structure, these analyses rather lead to assignment of a 
region to an APC subunit than to a precise localization. Importantly, the area which is 
assigned to an individual subunit does not represent the entire subunit but marks the
antibody binding site.
We have compared the 3D models of APC and APCdoc1 to localize Doc1 on our budding 
yeast APC model (Section 2.3.2). This has allowed the assignment of a well defined region to 
Doc1 and thereby improves the previous localization of Doc1 which had been obtained by 
antibody labeling (Herzog et al., manuscript in preparation). The overall structure of APC 
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does not change upon removal of Doc1. However, whether or not Doc1 association with 
APC induces small conformational changes – which might be sufficient to affect the 
processivity of APC ubiquitination – can not be determined at this resolution. 
We have started to analyze the 3D APC subunit assembly by fusing big globular tags to 
individual subunits (Section 2.3.3). The success of this method requires a) the yeast strain to 
be viable, b) the tag to not interfere with APC assembly or with the integration of the tagged 
subunit into APC and c) the tag to be exposed to the surface of the molecule so that it is 
visible. While the data acquisition is elaborate since it requires a 3D model to be generated 
for each tagged subunit, the data obtained might allow the most precise subunit localization 
achieved for core APC subunits (except Doc1, see above) to date. We have so far obtained 
data for the TPR subunit Cdc27 and for Apc5 (Section 2.3.3). According to these, Apc5 
localizes to the “basis” or “platform” of APC. A similar localization has been observed for 
Apc5 in human APC, as determined by antibody labeling experiments (Herzog et al., 
manuscript in preparation). The tag on Cdc27 localizes close to the head region and at the 
edge of the prominent back-side ridges. Based on antibody labeling experiments (Herzog et 
al., manuscript in preparation) and computational analysis (Passmore et al., 2005b) multiple 
TPR repeats have been proposed to form these ridges, and our result lends support to this.
Our subunit localizations indicate that Cdc27 and Doc1 are direct neighbors within APC. 
This supports previous findings (Vodermaier et al., 2003; Wendt et al., 2001) and supports
our crosslinking data (Section 2.1, discussed in Section 3.1). Strikingly, we have only 
observed one additional mass in the Cdc27-td2-tagged APC model indicating that there 
might be only one copy of Cdc27 present in budding yeast APC. This would be in 
disagreement with the studies by Passmore et al. and Ohi et al. who have proposed a relative 
Cdc27 copy number of 1.65 and 2, respectively (Ohi et al., 2007; Passmore et al., 2005b). We 
can not exclude the possibility that the tag of a second Cdc27 protein might be buried within 
APC. Our observed single mass is consistent with the stoichiometry reported for human 
APC, where Cdc27 is the only TPR subunit which is present only once per complex (Dube et 
al., 2005). However, higher eukaryotes contain the TPR subunit Apc7 which is closely related 
to Cdc27 (Pal et al., 2007a; Yu et al., 1998) and has been reported to be present twice as well 
(Dube et al., 2005). When having a close look at the human and yeast structures from the 
“back” view (Figure 2-11C), the yeast model appears to contain fewer ridge-like domains. 
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One might therefore speculate that this “compressed” appearance is due to fewer TPR 
repeats being present in budding yeast APC.
With more of these tagged APC versions currently being analyzed (Table 2-3) we are hoping 
to contribute to more precise insights into the 3D topology of APC subunits. In addition, 
the analysis of APC subcomplexes such as the “TPR subcomplex” and the “catalytic 
subcomplex” obtained from APC deletion strains (Thornton et al., 2006) might be 
worthwhile. This might lead to the further identification or confirmation of subunit 
localizations and possibly to a higher resolution. Creating 3D models of APC purified from 
different cell cycle stages might tell us whether phosphorylation of APC changes its 
conformation. Purification of APC from a prometaphase-like stage with the MCC associated 
with APC has already led to new insights into the mechanism of APC inhibition by the APC 
(Herzog et al., manuscript in preparation). Likewise, and with highest importance to the 
focus of this study, localization of an APC substrate might give important hints at the 
mechanism of substrate recognition, which would then have to be supported and explored 
further biochemically. 
3.6 Apc16 is a novel subunit of human APC
We have identified the gene product of c10orf104 as a novel component of human APC, 
which we therefore named Apc16. Apc16 was initially found as a protein that specifically 
associates with human APC in tandem affinity purifications followed by in solution 
digest/mass spectrometry analysis (Martina Sykora, Jim Hutchins, personal communication).
We have confirmed by reciprocal immunoprecipitation that Apc16 and Cdc27 are part of 
one complex. Moreover, antibodies specific for Apc16 precipitated the complete APC (as 
determined by silver staining), which is active in ubiquitination assays upon Cdh1 activation, 
indicating that Apc16 is a component of active APC. The protein is remarkably conserved 
among higher eukaryotes with a sequence homology of 99 % (Section 5.3). Therefore, we 
speculate that Apc16 might also be associated with APC in other species including Xenopus
and mouse, which we will address in the near future.
In earlier APC preparations obtained with a Cdc27 antibody followed by mass spectrometry 
analysis, Apc16 was also present, but due to the large number of other copurifying proteins 
this observation was not followed up (Franz Herzog, personal communication). We have not 
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been able yet to detect Apc16 by silver staining. This explains why Apc16 has not been 
detected earlier despite innumerous SDS-PAGE/silver staining analyses which have been 
carried out in our lab in the past. The identification of Apc16 therefore underscores the 
power of tandem affinity purification protocols followed by in-solution mass spectrometry.
When looking at Apc16’s protein sequence we were initially reminded of ubiquitin and 
ubiquitin-like proteins (UBL), because human Apc16 contains a C-terminal glycine. 
Furthermore, this could explain its high conservation among higher eukaryotes (Section 5.3). 
However, three sequences – all from fish – do not contain this C-terminal glycine, which 
contradicts such function, since this glycine is needed for the formation of both a thioester 
with E1 and E2 enzymes and an isopeptide bond with substrates (Pickart, 2001).
What could then be the function of Apc16? In our preliminary immunofluorescence analysis 
of Apc16-depleted cells we found a decreased mitotic index. Immunoblot analysis revealed 
decreased cyclin B1 levels. Furthermore, when cells were synchronized in S phase and then 
treated with taxol, which activates the SAC, Apc16 depleted cells did not accumulate in 
mitosis. Instead, they appeared to have problems in either progressing through S and G2 
phases or in entering mitosis. Since S and G2 are the phases of the cell cycle where APC is 
not active, this is a surprising finding. One might therefore speculate that instead of being 
necessary for APC activity, Apc16 could be involved in keeping APC inactive. APC lacking 
Apc16 could thus be, at least partially, active and delay the ordered progression through S 
and G2 phases or the timely entry into mitosis by premature degradation of substrates
including cyclin A and cyclin B. Such a role has recently been demonstrated for Emi1 in 
human cells, where it, apart from preventing rereplication, is required for accumulation of 
cyclin A and cyclin B (Di Fiore and Pines, 2007). A very speculative hypothesis is that Apc16 
is required for Emi1 inhibition of APC in interphase. In further experiments we will first 
address where exactly cells are delayed by live cell imaging and immunofluorescence 
microscopy using appropriate S and G2 phase markers such as PCNA and aurora B. We will 
also carry out ubiquitination assays with Apc16-depleted APC to test whether Apc16 is 
required for APC activity. Furthermore, understanding the function of this novel APC 
subunit will also require the thorough parallel analysis of APC after depletion of other APC 
subunits since only few studies exist in which APC subunits were inactivated (Gimenez-
Abian et al., 2005; Wirth et al., 2004).
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4 Material and Methods
4.1 cDNA clones
The following cDNA clones were generated and/or used in this study.
 Doc1 in pME (this study)
 Doc1 in pET28 (this study)
 Doc1 plus 500 bp upstream of the translation start site in pRS316 (CEN/ARS, 
URA3)
 pME-Hsl1 (amino acids 667-882, this study)
 His6-Cdh1 in pET28 (David Barford)
 His6-Ubc4 in pET15b (David Barford)
 GST-Hsl1 (amino acids 667-872) in pGEX4T (Ivana Primorac)
 N702x-GST (wild type and D box mutant) in pET15b (Hiro Yamano)
 UbcH10 and UbcH10-His6C114S in pET28 (Michael Rape)
 His6-Usp2-cc in pET15b (Ron Kopito)
 cyclin B (amino acids 1-87)-myc-His6 in pTrcHis2A (Michael Gmachl)
For untagged constructs in pME vectors, pME34 (Carroll et al., 2005) was used and the 
original STOP codon of the ORF was kept. DOC1 was cloned into pME using the EcoRI 
and BamHI restriction sites and into pET28 using NheI and BamHI. To introduce DOC1
including its endogenous promoter into pRS316, the DOC1 ORF plus 500 bp upstream of 
the translation start were amplified from yeast genomic DNA and cloned into pRS316 via 
EcoRI sites. The obtained clones were then checked for the correct orientation. The HSL1
fragment was cloned into pME via XhoI and HindIII.
Amber (TAG) and ochre (TAA) STOP codons as well as alanine and phenylalanine mutations 
were generated using the Quikchange method (Stratagene). For truncation of Doc1’s C-
terminus (Doc1IR) the ochre STOP codon was introduced at Q235 which resulted in 
deletion of the last 16 amino acids.
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4.2 Peptides and antibodies 
For immunobloting, antibodies were used at 2 µg/ml in 4 % milk-TBS/T unless indicated; 
glycine elutions were typically preferred over magnesium elutions.
Antibodies against yeast APC subunits: Peptides that were used for rabbit immunization and a 
basic characterization of the yeast APC and Hsl1 antibodies generated for this study can be 
found in the Appendix (Section 6). The following antibodies were used: Apc1 (1686), Apc2 
(1688), Cdc27 (1518), Cdc16 (1514), Doc1 (1512 and 1513), Apc11 (1742), Hsl1 (1740).
Unless indicated, the glycine elutions were used; the concentration was usually 2 µg/ml. The 
rabbit antibody against yeast Cdc26 (used 1:500) was a gift from David Morgan.
Antibodies against human APC subunits: Antibodies raised against human Apc6/Ccd16
(Grossberger et al., 1999) as well as Apc2 and Apc3/Cdc27 (Gieffers et al., 1999) have been 
described. The antibody against Apc10/Doc1, raised against recombinant protein, was a gift 
from Franz Herzog (Herzog et al., manuscript in preparation). C10orf104/Apc16 antibodies 
raised against peptides 2184 (CLEADEWRFKPIEQLLGFTPSSG), 2185 
(ASSSSSSAGGVSGSC) and 2186 (DLAPPRKALFTYPKGAGEMLEDGSERFLC) are 
described in the result section (Section 2.5). 
Other non-commercial antibodies: Monoclonal antibodies against myc (9E10) and HA (12CA5) 
were made in house. The rabbit anti-BubR1 antibody was a gift from Gregor Kohlmaier. 
Commercial antibodies: The goat polyclonal GST antibody was purchased from Amersham (27-
4577-01), the mouse monoclonal cyclin B1 antibody from Santa Cruz Biotechnology (GNS1, 
sc-245), the mouse monoclonal ubiquitin antibody (P4D1) from Santa Cruz, the tubulin 
antibody from Sigma (B-512), the mouse Rad21 antibody from Millipore (05-908), and an
antibody to Histone H3 phosphorylated on serine 10 from Upstate Biotechnology (05-499).
Alexa 488- and Alexa 568-labeled secondary antibodies as well as DAPI were from 
Molecular Probes (Invitrogen).
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4.3 Generation of (tmd)phe-tRNA
4.3.1 Production of tRNACUA
The template for the transcription reaction was generated by PCR amplification from 
pTHG73 (Saks and Sampson, 1996) using primers 5’-GCGGTCCTACTGGGATT-3’ and 
5’-AATTCGTAATACGACTCACTATAG-3’. The PCR product was extracted with phenol 
pH 7.9 and chloroform followed by ethanol precipitation. Run off transcription reactions
were performed using a T7-MEGAshortscript kit (Ambion). About 5 µg PCR product 
(dissolved in water) was used for a 100 µl transcription reaction. Transcriptions were 
typically performed in 500 µl reaction volumes (1 kit) and the total volume was split into 4 x 
125 µl aliquots for incubations. Reactions were performed according the manufacturer’s 
protocol. After 2 h incubation (300 rpm, 37°C) 10 µl of the provided DNAse was added per 
tube and incubated for further 15 min. 437 µl nuclease-free water and 63 µl 3 M NaOAc was 
added per tube, samples were transferred to 2 ml Eppendorf tubes for extraction with 
phenol, phenol/chloroform and chloroform. (The phenol used had been adjusted to pH 4.5 
with 250 mM NaOAc, pH 4.5). RNA transcripts were ethanol precipitated (15 to 20 min at 
-80°C), centrifuged (13000 rpm, 15 min, 4°C) and washed twice with 70 % ethanol. The 
pellet was dried and dissolved in 130 µl tRNA loading buffer (50 mM Tris-HCl pH 7.5, 5 
mM MgCl2, 50 mM NaCl) per tube. Dissolved transcripts were combined, filtered and the 
filter washed with 500 µl tRNA loading buffer. Filtrates were combined and loaded onto a 1 
ml Resource Q column (GE Healthcare) equilibrated with tRNA loading buffer (flow rate 1 
ml/ml). The column was washed with 5 volumes each tRNA loading buffer and tRNA 
washing buffer (50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 300 mM NaCl) before elution with 
tRNA elution buffer (50 mM Tris-HCl pH 7.5, 5 mM MgCl2, 1 M NaCl). The collected 
fractions were subjected to ethanol precipitation. After washing with 70 % ethanol, pellets 
were dissolved in 100 µl water and the tRNA content was determined by measuring the A260
with a NanoDrop. tRNA usually eluted in fractions C6 to C10. tRNA containing fractions 
were combined, aliquoted into 5 A260/tubes, lyophilized and stored at -80°C until ligation. 
The average yield varied between 5 and 10 A260.
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4.3.2 Ligation of tRNACUA with (tmd)phe-pdCpA
The ligation buffer (55 mM Hepes-NaOH pH 8, 15 mM MgCl2, 3.3 mM DTT, 0.2 µg/µl 
BSA, 0.8 mM ATP) was prepared freshly before each reaction. In a typical reaction, 10 A260
of tmd(phe)-pdCpA were ligated to 10 A260 of purified tRNA. 300 µl tRNA (dissolved in 
water), 100 µl tmd(phe)-pdCpA (in 10 % v/v acetonitril), 100 µl DMSO, 470 µl ligation 
buffer, 10 µl H2O and 20 µl RNA ligase (5 U/µl, Epicentre) were mixed, aliquoted to 250 µl 
per tube and incubated for 90 min at 37°C and 300 rpm. The reaction as boosted with 20 µl 
enzyme/250 µl reaction after 30 min and 60 min. The ligation product was extracted with 
phenol (adjusted to pH 4.5 with 250 mM NaOAc, pH 4.5), phenol/chloroform and 
chloroform. For ethanol precipitation, the extracted product was mixed with 2.5 volumes 
ice-cold 100 % ethanol and 1/10 volume 3 M NaOAc, incubated for 25 min at -20°C, 
followed by 15 min centrifugation (13000 rpm, 4°C). The pellets containing ~2.5 A260 N-
pentenoyl-(tmd)phe-tRNACUA each were then washed once with ice-cold 70 % ethanol, dried 
and dissolved in 100 µl ddH2O. For deprotection, 50 µl of deprotection solution (25 mM 
iodine in 50 % THF) was added to 100 µl of N-pentenoyl-(tmd)phe-tRNACUA and incubated 
at 25°C for 30 min. 150 µl ddH2O, 30 µl 3 M NaOAc pH 5.2 and 750 µl ice-cold 100 % 
ethanol were added, incubated for 10 min at -20°C and centrifuged (13000 rpm, 15 min, 
4°C). The pellet was washed twice with 1 ml ice-cold 70 % ethanol, dried and resuspended in 
25 µl ddH2O to a concentration of ~0.1 A260/µl. (Tmd)phe was aliquoted, snap-frozen in
liquid nitrogen and stored at -80°C.
4.4 Recombinant protein expression and purification
4.4.1 Protein production by in vitro transcription/translation
Doc1 (wild type and Doc1IR) and N702x-GST (wild type and D box mutant) versions as well 
as Hsl1 (amino acids 667-872) were produced using the TNT T7 coupled reticulocyte lysate
system (L4610, Promega). To translate “long” and “short” versions of Doc1 in this system, 8 
µl of PCR products generated with primers 5’-ATCGATTAATACGACTCACTATA-
GGGCTCGAGGCCGCCACCATGGGGCAAAATAAGCGCCGTCTATAT-3’ (forward 
primer “long”) or 5’-ATCGATTAATACGACTCACTATAGGGCTCGAGGCCGCCAC-
CATGGACCCGATTGGAATAAACAAAGT-3’ (forward primer “short”) and 5’-GTGC-
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TCTCGAGTTACATCATGGATCCTTAACGTAATATAGCATCCTGGAAGAATTGTT
-3’ (reverse primer for both) were used directly, without further purification as templates in
25 µl IVT reactions.
For photocrosslinker incorporation into Doc1 or N702x-GST, the same system was used and 
reactions were supplemented with 1 mM MgOAc and 1.6 µl (tmd)phe-tRNA per 50 µl 
reaction. Alternatively, N702x-GST versions with and without a photocrosslinker were 
produced with the E. coli T7 S30 extract sytem (L1130, Promega). Yeast Cdh1 was obtained 
using the TNT Quick coupled reticulocyte lysate system (L1170, Promega). Except when 
using a PCR generated template as described above, 1 µg of circular plasmid DNA was used 
as template in a 50 µl reaction. Plasmid DNA was purified using either the QIAGEN 
plasmid kit or the QIAquick spin mini prep kit followed by ethanol precipitation. 
4.4.2 Expression using the baculovirus-insect cell system
The yeast His6-Cdh1 baculovirus (kindly provided by Topher Carroll and David Morgan) 
was used for infection of Sf9 cells. One ml virus (4th amplification) was used to infect a 175 
cm2 filter capped tissue culture flask (Nunc) of 80 % confluent monolayer cells. Fourty -48 h
after infection, cells were harvested by tapping the culture flask (no scraping!) and washing 
off remaining cells with a small volume of PBS. Cells were centrifuged in 50 ml Falcon tubes 
(500 g, 4°C) and pellets were neither washed nor frozen but directly resuspended in 500 µl 
lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM KCl, 0.1 % Tween 20 and 10 µg/ml each 
aprotinin, pepstatin, and leupeptin). Cells were lysed on ice by douncing 4 x 5 times with 5 
min breaks in between with a glass homogenizer. The soluble protein fraction was recovered 
by centrifugation (13000 rpm, 15 min, 4°C) in an Eppendorf table top centrifuge. The 
supernatant was incubated with 20-40 µl Ni2+-NTA agarose beads (Qiagen) per harvested 
flask (pre-equilibrated with water and lysis buffer) for 60-90 min at 4°C on an end-over-end 
rotator. Sample were washed 5 times with wash buffer containing 50 mM Tris-HCl pH 7.5, 
300 mM KCl, 0.1 % Tween 20 (5 min incubation on rotator per washing step) and eluted 
using 2 times 1 bead volume 50 mM Tris-HCl pH 7.5, 300 mM KCl, 250 mM imidazole. 
Eluates were dialyzed against 1 liter buffer containing 50 mM Tris-HCl pH 7.5, 100 mM 
KCl, 10 % glycerol and 1 mM DTT for 3 h at room temperature. Cdh1 purifications only 
resulted in small amounts of protein; the average yield was about 15-20 µg from ten 175 cm2
flasks. 
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4.4.3 Expression in E. coli
Purified human cyclin B (amino acids 1-87) was a gift from Claudine Kraft, His6-E1 from
Michael Gmachl, S. cerevisiae Ubc4 from Hartmut Vodermaier, human Ubc4 from Claudine 
Kraft and N702x-GST (wild type and D box mutant) from Ivana Primorac.
4.4.3.1 S. cerevisiae His6-Doc1
One liter LB medium supplemented with 25 µg/ml kanamycin was inoculated with 20 ml of 
a fresh over night culture and grown further until an OD600 of 0.6 was reached. Protein 
expression was induced by addition of 1 mM IPTG and expression was allowed for 
approximately 20 h at 18°C. Cells were harvested and pellets frozen until further use. Cell 
pellets were resuspended in 15 ml lysis buffer (50 mM Tris-HCl pH 8, 150 mM KCl, 1 % 
Triton, 2 mM -mercaptoethanol) supplemented with 100 µg/ml DNAse, ½ tablet 
Complete EDTA-free (Roche) and 15 mg lysozyme. After 15 min incubation on ice, the cell 
suspension was sonicated and cell lysate were cleared by centrifugation (18000 rpm, 4°C, 
SS34 rotor, Sorvall RC 5C PLUS centrifuge, Kendro). The supernatant was added to 500 µl 
Ni2+-NTA agarose beads (Qiagen) that had been prepared by washing with water and lysis 
buffer. Following an 1 h incubation on an end-over-end rotator at 4°C, bead-bound proteins 
were washed twice with wash buffer WB1 (50 mM Tris-HCl pH 7.5, 300 mM KCl, 0.5 % 
Triton, 2 mM -mercaptoethanol, 20 mM imidazole), twice with WB2 (50 mM Tris-HCl pH 
7.5, 150 mM KCl, 0.5 % Triton, 2 mM -mercaptoethanol) and once with WB3 (50 mM 
Tris- HCl pH 7.5, 150 mM KCl, 2 mM -mercaptoethanol). Washing steps were carried out 
for 5 min at 4°C. For each of the 2 elution steps beads mixed with 500 µl WB3 containing 
250 mM imidazol and incubated for 15 min at 4°C. Eluates were dialyzed in slide-a-lyzer 
dialysis cups (Molecular Weight cut off 10 KDa, Pierce) against buffer containing 50 mM 
Tris-HCl pH 7.5, 150 mM KCl, 10 % glycerol and 0.5 mM DTT for 12 h including one 
buffer change after 3 h. Eluates were pooled, filtered using Ultrafree- MC Durapore 
centrifugal filter units (0.22 µm, Millipore) and subjected to gel filtration chromatography as 
a second purification step. The eluate was loaded onto a 24 ml Superdex 75 HR 10/30 
column (GE Healthcare) at a flow rate of 0.5 ml/min. The injection loop was emptied and 
fractions of 500 µl each eluted with buffer containing 50 mM Tris-HCl pH 7.5, 150 mM 
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KCl, 10 % glycerol. Peak fractions were pooled and concentrated using Vivaspin cartridges
(Sartorius). 
4.4.3.2 GST-Hsl1(667-872)
An Hsl1 fragment comprising amino acids 667-872 fused to an N-terminal GST-tag (GST-
Hsl1(667-872)) was expressed and purified from E. coli. One liter E. coli BL21(DE3)RP culture 
inoculated from 20 ml of a fresh overnight culture was grown to an OD600 of 0.8. Protein 
expression was induced by the addition of 0.5 mM IPTG and cells were harvested after 2 h. 
The cell pellet was resuspended in 15 ml lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM KCl, 
0.01 % Triton X-100, 10 % glycerol, 1 mM -mercaptoethanol) containing ½ tablet 
Complete EDTA-free (Roche) and 15 mg lysozyme, followed by sonication. The soluble 
protein fraction was recovered by centrifugation at (18000 rpm, SS34 rotor). The 
supernatant was added to 500 µl glutathione sepharose (GE Healthcare) that had been 
washed with lysis buffer and incubated at 4ºC for 1 h on an end-over-end rotator. The beads 
were washed once with wash buffer 150 (50 mM Tris pH 7.5 150 mM KCl, 0.01 % Tween 
20), 3 times with wash buffer 300 (50 mM Tris pH 7.5 300 mM KCl, 0.05 % Tween 20) and 
once with wash buffer 150 again, each time incubating for 5 minutes on an end-over-end 
rotator at 4°C. The bound protein was then eluted 3 times with 700 µl elution buffer (50 mM 
Tris-HCl pH 8, 150 mM KCl, 0.01 % Tween 20, 0.5 mM -mercaptoethanol, 50 mM 
reduced gluthathione), each time rotating for 15 min at 4ºC. Dialysis was performed against 
2 x 1 liter dialysis buffer (20 mM Tris pH 7.5, 150 mM KCl, 10 % glycerole, 0.5 mM -
mercaptoethanol) for 3 h and over night, and eluates were stored in aliquots at -80ºC. The 
yield was about 2.5 mg full-length GST-Hsl1(667-872) from 1 liter culture. It has to be noted 
that a strong second band was obtained in these preparations which represented GST 
protein only (as determined by immunobloting, not shown). About 30-50 % of GST-Hsl1(667-
872) was repeatedly degraded in these purifications, also when the expression was performed 
for 18 h at 18°C. 
4.4.3.3 His6-UbcH10
C-terminally His6-tagged UbcH10 and UbcH10-His
C114S were expressed using the E. coli
BL21(DE3)RIL strain as recommended in (Rape et al., 2006). One liter of LB-amp medium 
was inoculated from 20 ml of a fresh overnight culture and grown further to an OD600 of 0.8, 
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followed by induction of protein expression by adding 0.4 mM IPTG. Cells were harvested 
after 3 h expression at 37°C and purified essentially as described for UbcH5b in (Kraft et al., 
2006) with few changes. The cell pellet was resuspended in 15 ml lysis buffer (50 ml Tris-
HCl pH 8, 150 mM KCl, 2 mM -mercaptoethanol, and 1 % Triton X-100) containing ½ 
tablet Complete EDTA-free (Roche) and 15 mg lysozyme. Following sonication, lysate were 
cleared by centrifugation (18000 rpm, 4°C, SS34 rotor) and bound to 800 µl Ni2+-NTA 
agarose beads (Qiagen) that had been washed with water and lysis buffer beforehand. After 1 
h incubation on an end-over-end rotator at 4°C, beads were washed 5 times with WB1 
containing 50 ml Tris-HCl pH 8, 500 mM KCl, 2 mM -mercaptoethanol, and 0.5 % Triton 
X-100 followed by two washes with WB2 containing 50 ml Tris-HCl pH 8, 150 mM KCl, 
and 2 mM -mercaptoethanol. Each washing step included 5-10 min incubation at 4°C. To 
elute the bound proteins, beads were incubated with 3 x 700 µl WB 2 containing 250 mM 
imidazol for 15 min each on an end-over-end rotator. About 30 mg protein was obtained 
from a 1 liter culture.  
4.4.3.4 His6-Usp2-cc
Usp2-cc comprises amino acids 2-45 of mouse Usp2 (Catanzariti et al., 2004). N-terminally 
His6-tagged Usp2-cc was purified following protocol slightly modified from the one 
described in (Catanzariti et al., 2004). One liter LB-amp medium was inoculated 1:50 with a 
fresh overnight culture of E. coli strain BL21(DE3). At an OD600 of 0.8, protein expression 
was induced by adding 0.4 mM IPTG, with a further 4 h growth. After harvesting cells, 
pellets were resuspended in 15 ml buffer 2A (50 mM Na2HPO4/NaH2PO4 pH 7.2, 300 mM 
NaCl, 20 mM imidazole, 5 mM -mercaptoethanol, 30 % glycerol) containing 1 mM PMSF, 
½ tablet Complete EDTA-free (Roche) and 15 mg lysozyme. Cells were broken by 
sonication and the lysates cleared by centrifugation (18000 rpm, SS34 rotor, 4°C). 500 µl of 
Ni2+-NTA agarose beads (Qiagen) were prepared by washing with water and buffer 2A and 
then incubated with the cleared lysates for 1 h at 4°C on an end-over-end rotator. Bead-
bound proteins were washed five times using buffer 2A with 10 min incubation time each. 
Elution was performed using 3 x 700 ul elution buffer (buffer 2A containing 250 mM 
imidazole) by incubating samples for 15 min each time at 4°C on the rotator. Eluates were 
dialyzed in 2 x 1 liter dialysis buffer (50 mM Na2HPO4/NaH2PO4 pH 7.2, 150 mM KCl, 10 
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% glycerol, 1 mM DTT) for 3 h and over night, respectively. This procedure yielded about 
16 mg protein. 
4.5 Oxidative iodination of proteins
Protein was labeled using the chloramines T procedure according to Parker, as described in 
(Kraft et al., 2006). In a 21 µl reaction, 3 µl of protein (3 µg/µl) was labeled. After dialysis and 
addition of glycerol, a protein solution of about 60 µl was obtained, 1 µl of which was 
generally used per ubiquitination reaction.  
4.6 Yeast methods
The genotypes of all yeast strains used in this study are provided in Table 4–1. Deletion and 
tagging of genes was performed following the one-step PCR method (Knop et al., 1999; Puig 
et al., 2001; Rigaut et al., 1999; Wach et al., 1994). For tagging of APC subunits with td2, 
pKT146 (pFA6a-link-tdimer2-SpHIS5, (Sheff and Thorn, 2004)) was used. Transformations
with PCR products derived from this construct were performed using the following protocol 
(kindly provided by Irina Häcker, MPI-BPC Göttingen). An overnight starter culture was 
diluted to an OD600 of about 0.2 in 50 ml YEP medium containing 2 % glucose. When the 
OD reached about 0.8 to 1/ml, cells were harvested by centrifugation in 50 ml Falcon tubes 
(20 min, 2500g, 4°C) and washed with 50 ml 10 mM Tris-HCl pH 7.5. The pellet was 
resuspended in 25 ml Li-T (10 mM Tris-HCl pH 7.5, 100 mM lithium acetate) containing 10 
mM DTT. This suspension was incubated at room temperature for 40 min with gentle 
shaking, then centrifuged and resuspended in 750 µl Li-T plus 10 mM DTT. 
Transformation reactions containing 50 µl Li-T, 50 µl salmon sperm DNA, 20 to 50 µg PCR 
fragment, and 100 µl of cell suspension in Eppendorf tubes were incubated at room 
temperature for 10 min with gentle shaking. 300 µl freshly made sterilized PEG solution (2 g 
PEG 4000 in 2 ml Li-T) and 50 µl DMSO were added and the mixture was incubated for 
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Table 4-1: Yeast strains used in this study. All strains used in this study are derivatives of 
K699 (MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1, GALpsi) and K700 
(MATalpha ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1, GALpsi) with the exception of 
the strains used for spotting experiments (Figure 2-9C), which are derivatives of S288C
(hi3D1 leu2D0 met15D0 ura3D0 doc1::KanMX). Kl denotes the TRP1 gene from Klyveromyces 
lactis, Sp the HIS5 gene from Schizosaccharomyces pombe. 
Strain Relevant genotype Creator
J9 MATa APC4-TAP::KlTRP1 H. Vodermaier
J42 MATa APC4-TAP::KlTRP1 APC5-myc9::KlTRP1 H. Vodermaier
J61 MATa CDC27-myc9::TRP1 Marta Galova
J109 MATa APC1-ha3::HIS3 (Zachariae et al., 1996)
J110 MATalpha APC1-myc6::HIS3 (Zachariae et al., 1996)
J118 MATa APC1-myc18::HIS3 W. Zachariae
J180 MATa APC4-TAP::KlTRP1 doc1::KanMX this study
J182 MATa APC4-TAP::KlTRP1 APC1-myc18::HIS3 doc1::KanMX this study
J187 MATa APC4-TAP::KlTRP1 APC5-myc9::KlTRP1 doc1::KanMX this study
J189 MATa APC4-TAP::KlTRP1 APC2-myc9::TRP1 doc1::KanMX this study
J203 K699
J220 MATa doc1::KanMX this study
J235 MATa APC4-TAP::TRP1 CDC16-myc6::URA3 doc1::KanMX this study
J266 MATa APC4-TAP::KlTRP1 CDC27-myc9::TRP1 doc1::KanMX this study
J315 MATalpha CDC16TAP::KlTRP1 pep4::URA3 (Schwickart et al., 2004)
J319 MATalpha APC4-TAP::KlTRP1 pep4::URA3 this study
J320 MATa CDC16TAP::KlTRP1 doc1::KanMX pep4::URA3 this study
J323 MATa APC4-TAP::KlTRP1 doc1::KanMX pep4::URA3 this study
J325 MATa/alpha APC1-ha3::HIS3/APC1-myc6::HIS3 this study
J326 MATa APC1-ha3::HIS3 doc1::KanMX this study
J327 MATalpha APC1-myc6::HIS3 doc1::KanMX this study
J328 MATa/alpha APC1-ha3::HIS3/APC1-myc6::HIS3 doc1::KanMX this study
J329 MATa APC4-TAP::KlTRP1 APC1-tmono::SpHIS5 pep4::URA3 this study
J347 MATalpha CDC16TAP::KlTRP1 pep4::URA3 APC4-tdimer2::SpHIS5 this study
J376 MATalpha CDC16TAP::KlTRP1 CDC27-tdimer2::spHIS5 pep4::URA3 this study
J378 MATa APC4-TAP::KlTRP1 CDC16-tdimer2::spHIS5 pep4::URA3 this study
J380 MATalpha CDC16-TAP::KlTRP1 APC5-tdimer2::SpHIS5 pep4::URA3 this study
J406 MATa CDC16TAP::KlTRP1 pep4::URA3 CDC26-tdimer2::SpHIS5 this study
J407 MATa CDC16TAP::KlTRP1 pep4::URA3 MND2-tdimer2::SpHIS5 this study
J408 MATa CDC16TAP::KlTRP1 pep4::URA3 APC2-tdimer2::SpHIS5 this study
J422 MATa CDC16-TAP::KlTRP1 pep4::URA3 APC11-tdimer2::SpHIS5 this study
J428 MATa CDC16TAP::KlTRP1, pep4::URA3 SWM1-tdimer2:sp:HIS5 this study
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further 10 min with gentle shaking, followed by a 15 min heat shock at 42°C. The cell 
suspension was briefly centrifuged and the pellet was resuspended in 1 ml YEP-glucose 
medium. Cells were incubated for 60 min at 30°C and 300 rpm. For plating on selective 
medium, cells were briefly centrifuged again to remove YEP-glucose, and the cell pellets 
were resuspended in 100 µl of 10 mM Tris-HCl ph 7.5.
4.7 Yeast cultures and extract preparation
Yeast strains were grown in YEP medium containing 2 % glucose. For APC purifications, an 
overnight culture was usually diluted to an OD600 of 0.2 to 0.3, incubated for further 4 to 5 h
until the OD600 reached 1-1.5/ml, and then harvested by centrifugation. The cell suspension 
was aliquoted and cells were stored as 200 µl pellets in Eppendorf tubes or in Falcon tubes. 
“Large-scale” cultures were grown in a self-made “fermenter” (constructed by the IMP 
workshop) that is composed of 2 glass beakers of 10 liters each placed in a water-filled basin 
and a tubing system providing compressed air, which ensured both aeration and agitation
(for a description see PhD thesis of Mark Petronczki, IMP). Two or 4 of these 10 liter 
cultures were harvested using a continuous flow centrifuge (Modell LE, CEPA, 30000 rpm, 
4°C), washed 3 times with cold water, aliquoted and stored as pellets in Falcon tubes. When 
growing cells for electron microscopy purposes, cells were washed twice with water, once in 
EM lysis buffer (20 mM Hepes-KOH pH 8, 200 mM KCl, 10 % glycerol, 1.5 mM MgCl2) 
and then resuspended in one pellet volume of EM lysis buffer supplemented with 0.1 M 
PMSF and 1 tablet Complete EDTA-free (Roche) per 15 ml buffer. The cell suspension was 
then dripped directly into liquid nitrogen using a 5 ml glass pipette. This resulted in small 
yeast beads of about 2 mm diameter, which were stored at -80°C until further use.
Harvesting cells from 40 liters of culture at an OD600 of around 1.5 usually resulted in about 
80 to 100 g of solid wet pellet or six 50 ml Falcons filled with yeast beads. 
Frozen yeast pellets were thawed at room temperature, resuspended in 1-1.5 volumes of the 
appropriate lysis buffer containing protease inhibitors and DNase I (10 µg/ml) and passed 
through a French Press (Constant Systems LTD, version V4-35-9/96; 2 runs at 2 kpsi). The
minimum pellet volume for this procedure was 5 ml. Alternatively, if lysis was to be 
performed at a smaller scale, acid washed glass-beads (425 µm to 600 µm, Sigma) were added 
to the cell suspension and cells were broken by vortexing 4 times or 2-3 minutes with 5 min 
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on ice in between. Lysates were cleared by centrifugation (19000 rpm, 30 min, 4°C, SS34 
rotor or 13000 rpm, 30 min, 4°C, Eppendorf tabletop centrifuge). Yeast beads were ground 
in a mortar grinder (RM100, Retsch) while constantly adding liquid nitrogen for 12 min.
Ground cell powder was thawed in a water bath at 28°C followed by 2 centrifugation steps. 
Cell extracts were pre-cleared by centrifugation in an SS34 rotor (19000 rpm, 30 min, 4°C), 
followed by ultra-centrifugation (37000 rpm, 60 min in T865 or 42000 rpm, 50 min in 
T647.5, both at 4°C).
4.8 Yeast growth assay
For this assay, doc1 yeast strains were used that had been transformed with pRS316 
(URA3) plasmids containing DOC1 versions under the endogenous promoter. As a control, 
a strain transformed with the empty plasmid was used. Two ml yeast cultures were 
inoculated from a single colony and grown until late log phase in synthetic medium lacking 
uracil. Cultures were then diluted to an OD600 of 0.02 and grown for another 20 h. After 
measuring the OD600 of the log phase cultures, they were diluted to similar densities. A 
dilution series was made by diluting cultures 3 times 10-fold. 3.5 µl of each dilution was
plated onto solid drop-out medium and incubated at 25°C and 37°C for 1-2 days. 
4.9 Cell culture, cell synchronization and RNA interference
Adherent HeLa cells were grown in 145 mm tissue culture dishes (Greiner) at 37°C in the 
presence of 5 % CO2 in Dulbecco’s Modified Eagle Medium (DMEM, made in house) 
supplemented with 10 % fetal bovine serum (PAA Laboratories), 0.3 µg/ml L-glutamine 
(Sigma-Aldrich), 100 U/ml penicillin (Sigma-Aldrich) and 100 µg/ml streptomycin (Sigma-
Aldrich). To arrest cells in mitosis by activating the SAC, logarithmically proliferating cells 
(8x106 cells per plate) were treated with 10 µM taxol (Paclitaxel, Sigma-Aldrich) for 16 h
followed by a 40 min-treatment with 10 µM proteasome inhibitor (MG132, Sigma-Aldrich). 
To then inactivate the SAC, 100 nM hesperadin (Boehringer Ingelheim) was added for 60 
min. Cells were harvested by a harsh mitotic shake-off, washed twice with PBS and frozen as 
pellets. Alternatively, cells were arrested in mitosis by the addition of 100 ng/ml nocodazole 
for 18 h. S phase arrest was induced by treating cells for 18 h with 2 mM hydroxyurea or by 
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treating cells for 24 h with 2 mM thymidine. For double thymidine arrest release, HeLa cells 
were arrested at 50 % confluency by the addition of 2 mM thymidine (Sigma-Aldrich). After 
16 h, cells were released by washing once with PBS and addition of fresh medium. Eight h
later, the second arrest was induced by the addition of 2 mM thymidine. Cells were released 
from the second arrest after further 16 h as before and samples were collected at the 
indicated time points. For RNAi experiments, cells were transfected as previously described 
(Hirota et al., 2004) using preannealed siRNA oligos targeting c10orf104 from Ambion. The 
two oligo sequences were 5’-CGCUUAAACAGGUGAAACAtt-3’ (117) and 5’-
GCUUACAUAGCCAUCCAGAtt-3’ (118). 
4.10 Protein purification and fractionation
4.10.1 Yeast APC purification using TAP-method
Table 4-2: Buffers for TAP-purification. The protocol was modified from (Passmore et al., 
2005a; Rigaut et al., 1999).
buffer component
Lysis buffer 50 mM Tris-HCl pH 8.0, 150 mM KCl, 10 % glycerol
TST 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05 % Tween-20
IgG wash buffer 50 mM Tris-HCl pH 8.0, 150 mM KCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % NP-
40
CaM binding buffer 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 % glycerol, 10 mM -mercaptoethanol, 
1 mM MgOAc, 2 mM CaCl2, 0.1 % NP-40
CaM elution buffer 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 10 % glycerol, 0.5 mM EDTA, 10 mM -
mercaptoethanol, 1 mM MgOAc, 3 mM EGTA, 0.1 % NP-40
EM lysis buffer 20 mM HEPES-KOH pH 8.0, 200 mM KCl, 10 % glycerol, 1.5 mM MgCl2
EM IgG wash buffer 50 mM Tris-HCl pH 8.0, 150 mM KCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % NP-
40, 0.03 % octyl- beta-D-glucopyranoside (Sigma)
EM CaM binding buffer 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 % glycerol, 10 mM -mercaptoethanol, 
1 mM MgOAc, 1 mM imidazole, 2 mM CaCl2, 0.03 % octyl--D-glucopyranoside
EM CaM elution buffer 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 5 % glycerol, 10 mM -mercaptoethanol, 
1 mM MgOAc, 1 mM imidazole, 2 mM CaCl2, 3 mM EGTA, 0.03 % octyl--D-
glucopyranoside
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Yeast extracts were supplemented with 0.5 mM EDTA and 0.1 % NP-40. 100 µl IgG 
sepharose 6 Fast Flow (bed volume, Amersham) per 10 g yeast pellet was packed into 0.8 x 4 
cm poly prep columns (Biorad) via gravitiy flow. IgG sepharose was washed with 5 bed 
volumes of TST, followed by 3 volumes each of 0.5 M acetic acid pH 3.4 (adjusted with 
ammonium acetate), TST and acetic acid. Beads were then washed with TST until the pH 
was neutral again, followed by equilibration with 10 ml IgG wash buffer supplemented with 
2 mM EGTA. Yeast extract was added and the sealed column was rotated for 90 min at 4°C.
The column was then washed by gravity flow with 20 ml IgG wash buffer containing 2 mM 
EGTA and ½ tablet Complete EDTA-free (Roche), followed by a wash with 15 ml IgG 
wash buffer containing 1 mM DTT. One ml of the latter buffer and TEV protease (100 units
AcTEV, Invitrogen) was added and the sealed column was rotated for 90 to 120 min at 
room temperature. Eighty µl calmodulin sepharose 4B (Amersham) was packed into a similar 
poly prep column and washed with 10 ml water and 20 ml CaM binding buffer. The column 
was sealed at the bottom, placed underneath the IgG sepharose column and the TEV-eluate 
was dripped directly into the new column. IgG sepharose beads were washed with 3 ml CaM 
binding buffer, again directly into the CaM column, and the final CaCl2 concentration of the 
eluate was adjusted to 5 mM. The sealed column was rotated for 60 min at 4°C, followed by 
extensive washes with 40-70 ml CaM binding buffer. APC was eluted by addition of 80 µl 
CaM elution buffer. Up to 8 fractions were collected, leaving 3-5 min incubation time in 
between 2 fractions. Apart from the TEV cleavage, all steps were carried out in a cold room 
and with chilled buffers.
For electron microscopy purposes, extracts prepared by mortar grinding were used. Buffers 
were slightly modified (see Table 4-2) and the first purification step was carried out in 50 ml 
Falcon tubes. For a typical purification, cells from 20 liters culture were used with 300 µl IgG 
sepharose, 200 µl calmodulin sepharose, 400 units of TEV protease, and 180 µl elution 
buffer per fraction. The first eluted fraction was discarded and fractions 2 to 4 were 
“blindly” combined and loaded onto glycerol-glutaraldehyde gradients. 
4.10.2 APC purification with IgG Sepharose or APC-specific antibodies
Cleared extracts from yeast strains carrying a TAP-tag on Apc4 or Cdc16 were bound to IgG 
sepharose (Amersham) by incubating for 60-90 min at 4°C. After washing with IgG wash 
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buffer (50 mM Tris-HCl pH 8, 150 mM KCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % NP40), 
bead-bound APC was eluted by boiling in SDS sample buffer or by TEV cleavage (10 units 
AcTEV per 10 µl beads). Alternatively, bead-bound APC was directly used in activity or 
crosslinking assays. Immunoprecipitation of APC was carried out with antibodies raised 
against APC subunits or with myc (9E10) antibodies. Antibodies were used either after pre-
incubation with protein A beads (BioRad, in case of APC antibodies) and GammaBind G 
sepharose (GE Healthcare, for 9E10), or they were crosslinked using dimethylpimelimidate
(DMP) as described (Harlow, 1988). About 3 mg yeast cell extract was used per 10 µl 
antibody beads and incubated on an end-over-end rotator at 4°C for up to 90 min, followed 
by washes with TBS/T (TBS containing 0.01 % Tween 20). Elution was carried out using 1-
2 bead volumes of 100 mM glycine pH 2.2 or by boiling beads in SDS sample buffer. 
4.10.3 Co-immunoprecipitation
12CA5 and 9E10 antibodies were bound to protein A sepharose (Biorad) and GammaBind 
G sepharose (GE Healthcare) beads, respectively. Extracts of strains J109, J110 and J325 
were prepared in buffer (50 mM Tris pH 7.5, 50 mM NaCl, 10 % glycerol, 0.2 % Triton X-
100, 1 mM DTT) containing protease inhibitors. 10 µl beads each were incubated with 
cleared lysates containing 2 mg protein for 90 min at 4°C on an end-over-end rotator. Beads 
were washed extensively with buffer, and bound proteins were eluted with 15 µl 100 mM 
glycine pH 2.2. Samples were analyzed by immunobloting using 9E10 and 12CA5 antibodies.
4.10.4 Purification of human APC
HeLa cells were thawed on ice and resuspended in 0.75 to 1 pellet volume lysis buffer 
(20mM Tris pH7.5, 150mM NaCl, 5 % glycerol, 2 mM EDTA, 0.05 % Tween 20) containing 
protease inhibitors (0.1 M PMSF, 20 µg/ml each aprotinin, pepstatin, and leupeptin) and 4 
µg/ml okadaic acid (Alexis). The cell suspension was passed several times through syringe 
needles (0.8 mm and 0.4 mm in diameter) and the extract was cleared by centrifugation 
(13000 rpm, 15 minutes, 4°C). APC was isolated with antibodies against Cdc27 or 
C10orf104/Apc16. Antibodies were coupled to protein A beads (BioRad) and crosslinked (if 
possible) using DMP as described (Harlow, 1988). About 2-3 mg HeLa cell extract was used
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per 10 µl antibody beads and incubated on an end-over-end rotator at 4°C for 60-90 min, 
followed by washes with TBS/T. Elution was carried out using 1-2 bead volumes of 100 
mM glycine pH 2.2 or by boiling beads in SDS sample buffer. Alternatively, bead-bound
APC was directly used in binding or activity assays.
4.10.5 Sucrose density gradient centrifugation
Sucrose density gradients were prepared in disposable ultra-clear centrifuge tubes (19 x 95 
mm, Beckman) by mixing 2 sucrose solutions using a GradientMaster (Biocomp). Cell 
extracts were pre-cleared in an Eppendorf table-top centrifuge (13000 rpm, 15 min, 4°C) and 
then centrifuged at 42000 rpm (TLA45 rotor) for 15 min in an Optima MAX ultracentrifuge 
(Beckman Coulter). Cleared HeLa cell extract (2.5 mg protein) was layered on 10-30 % 
sucrose gradients in TBS/T. Centrifugation was carried out at 34000 rpm for 18 h at 4°C in
a Beckman SW40 rotor in a Beckman Optima MAX ultracentrifuge (Beckman Coulter).
Gradients were fractionated into 400 µl aliquots using an ISCO fractionator at a flow rate of 
1 ml/min.
4.10.6 Glycerol glutaraldehyde gradient centrifugation
Gradients were prepared in Beckman polyalomer centrifuge tubes (11 x 60 mm) by mixing a 
10 % glycerol solution containing 0.05 % glutaraldehyde (25 %, EM grade, Polysciences) and 
a 40 % glycerol solution containing 2 % glutaraldehyde using a GradientMaster. Both 
glycerol solutions were prepared in gradient buffer (20 mM Hepes-KOH pH 7.9, 150 mM 
NaCl, 2 mM MgCl2, 0.05 % octyl--D-glucopyranoside). 500 µl from the top of the gradient 
were replaced by a 10 % glycerol cushion that did not contain glutaraldehyde. 500 µl TAP-
purified APC was carefully layered on the gradient at 4°C and tubes were placed into a 
Beckman SW60Ti rotor. Centrifugation was performed at 37000 rpm for 14 h at 4°C. The 
centrifuge was set to “9” for both acceleration and deceleration. Gradients were fractionated
in 130 µl aliquots (5 drops) using a home-made apparatus with a peristaltic pump. APC was 
detected by online measurement of the absorbance at 280 nm. 
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4.11 APC assays
4.11.1 Doc1 binding assay
TAP-tagged APC (from strain J187, J220 served as a control) was purified by rotating 20 µl 
IgG sepharose beads (Amersham) with yeast lysates containing 5 mg protein for 90 min at 
4°C on an end-over-end rotator. After washing with IgG wash buffer (50 mM Tris-HCl pH 
8, 150 mM KCl, 10 % glycerol, 0.5 mM EDTA, 0.1 % NP40) supplemented with 1 mM 
DTT, 30 µl Doc1 IVT was added and incubated for the indicated times at room 
temperature. Beads were washed extensively with the same wash buffer and APC was eluted 
from beads by TEV cleavage (20 units AcTEV (Invitrogen), 90 min, room temperature). 
Eluates (½ of the sample) as well as Doc1 input were analyzed by SDS-PAGE followed by 
phosphorimaging, and by immunobloting using myc and Doc1 antibodies. 
4.11.2 N702x-GST binding assay
The assay was modified from a protocol described in (Eytan et al., 2006). APC was isolated 
from extracts of mitotically arrested HeLa cells (“SAC off”) using a Cdc27 antibody bound 
to protein A beads (Biorad). Bead-bound APC was washed with TBS/TG (TBS containing 
0.01 % Tween 20 and 2 % glycerol) and 15 µl beads were incubated for 60 min at room 
temperature with 45 µl of buffer A (50 mM Tris pH 7.5, 10 % glycerol, 1 mM DTT) 
containing 4 mg/ml BSA and 70 nM purified N702x-GST- versions, or with 45 µl or 60 µl in 
vitro translated N702x-GST-versions diluted 1:5 in buffer A. Samples were washed 3 times 
with buffer B (50 mM Tris pH 7.5, 150 mM NaCl, 5 mM EDTA, 0.5 % Tween 20) and 
bound proteins were eluted with 20 µl 100 mM glycine pH 2.2. Samples were analyzed by 
immunobloting using Apc2 and GST antibodies and by phorphorimaging.
4.11.3 Ubiquitination assay using yeast APC
Ubiquitination assays were performed in 10-14 µl reaction volumes with 40 mM Tris pH 7.5, 
10 mM MgCl2, 2.7 mM ATP, 7.5 µg of ubiquitin (Sigma or Affiniti), 0.2 µg of ubiquitin 
aldehyde, 4 mM N-acetyl-Leu-Leu-Norleu-aldehyde (LLnL, Sigma), 0.5 µg of His6-E1, 1 µg 
of His6-Ubc4, 2 µl of Cdh1 (recombinant at ~0.1 µg/µl, or in vitro translated), 1-3 µl of 
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radiolabeled substrate, and 4 µl of purified APC (about 15 ng). Samples were incubated in a 
thermomixer for up to 90 min at 25°C and 800 rpm. Reactions were stopped with SDS 
sample buffer, and mixtures were analyzed by SDS-PAGE and autoradiography. 
Alternatively, when a purified unlabeled protein was used as a substrate, samples were 
analyzed by immunobloting. 
4.11.4 Ubiquitination assay using human APC
Three -5 µl APC bound to antibody beads were incubated in 7-10 µl XB buffer (20 mM Tris-
HCl pH 7.5, 150 mM NaCl, 0.02 % Tween 20) containing 10 µg ubiquitin, ATP regenerating 
system (7.5 mM creatine phosphate, 1 mM ATP, 1 mM MgCl2, 0.1 mM EGTA, 30 U/ml 
rabbit creatine phosphokinase typeI (Sigma)), 0.25 µg His6-E1, 1 µg of E2 (His6-UbcH10 or 
a mixture of His6-UbcH10 and His6-Ubc4), and 0.2 µg purified Cdh1. An iodinated fragment 
of human cyclin B (amino acids 1-84, 3 µg) was used as a substrate. Reactions were 
incubated in a thermomixer (1400 rpm, 37°C) for the times indicated and the reaction was 
stopped by the addition of SDS sample buffer. Samples were analyzed by SDS-PAGE and 
phosphorimaging. 
4.11.5 Photocrosslinking assays
Photocrosslinking experiments were usually carried out with yeast cell extracts prepared 
freshly by bead beating in lysis buffer (50 mM Tris-HCl pH 8, 150 mM Cl, 10 % glycerol, 0.1 
% NP40) containing 1 tablet Complete EDTA-free (Roche) per 15 ml buffer. Samples 
containing photocrosslinkers were always protected from light in all steps prior to addition 
of SDS-loading buffer. APC was bound to IgG Sepharose beads (Amersham) by incubating 
extract and sepharose (1-2 mg protein per 5 µl beads) for 60 to 90 minutes at 4°C on an end-
over-end rotator. Beads were washed extensively before addition of reticulocyte lysate
containing in vitro translated Doc1 versions carrying a photocrosslinker. Samples were 
rotated at room temperature for 20 minutes followed by 3-4 brief washes with lysis buffer. 
Lysis buffer containing 1 mM DTT was used for all washing steps apart from the last one 
before crosslinking and addition of ubiquitination mix, respectively, for which DTT was 
usually omitted. When crosslinking experiments were carried out in presence of 
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ubiquitination mix, 28 µl of ubiquitination buffer containing ubiquitination mix components 
at concentrations described in Section 4.11.3 were added and the samples were incubated for 
5-15 min at 25°C with vigorous shaking. For photocrosslinking samples were incubated with 
open lids on a shaker (1300 rpm, 9°C) while irradiating them with a black ray long UV-lamp 
(B-100AP, 100W, UVP) with a wave length of 360 nm at a distance of 10 cm for 5-8 min. In 
a typical experiment, 15-20 µl bead-bound APC, 35 µl reticulocyte lysate containing Doc1 
and 28 µl ubiquitination mix were used. 
4.12 Immunofluorescence microscopy
Cells were grown on 18 mm coverslips in 12 well plates and fixed with 4 % PFA. Antibodies 
were used at a concentration of 2 mg/ml in 3 % BSA, DNA was counterstained with 
Hoechst 33342 and slides were mounted using Vectashield Mounting Medium (H1000, 
Vector Laboratories). Image acquisition was performed as described (Waizenegger et al., 
2000).
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5 Appendix
5.1 Generation of antibodies recognizing yeast APC subunits 
For each APC subunit, two peptides from the yeast protein sequences were chosen for 
rabbit immunization (Table 5–1). The choice of sequence was based on the surface 
prediction of the respective yeast APC subunits using the software Protean. One peptide per 
subunit was usually located close to the N- and one peptide close to the C-terminus of the 
proteins (Table 5–1). All peptides were synthesized by the IMP Protein Chemistry Facility 
and sent to Gramsch Laboratories in Schwabhausen/Germany for immunization. Antisera 
obtained from the immunizations were tested for their ability to recognize the antigen on 
immunoblots. Alternatively, they were immediately purified and the obtained pure antibodies 
were analyzed for antigen specificity in immunobloting experiments.
Table 5-1: Peptides derived from APC subunit protein sequences which were used for 
rabbit immunization.
protein antigenic peptide sequence
Doc1 1512 HNKPSVLVLDDRIVDAATKDLC
Doc1 1513 CSNEPHQDTHEWAQTLPETNNV
Cdc16 1514 CALRKGGHDSKTGSNNADDDFDAD
Cdc16 1515 THYYKSSKATSNLKSSNRVLC
Cdc23 1517 SLADESPLRNKQGVPKQMFC
Cdc27 1518 CKELTVAMNLDPKGNQVIIDELQK
Cdc27 1519 CIVGRKKDAIKELTVAMNLDPKG
Apc1 1685 KPSTRNDYLPRETHNGEYTGDSPEC
Apc1 1686 CDDERSSNGSDISDPTAYLEDKKDIDDHYG
Apc2 1687 SPNDAKSNHQLRPPSLRIC
Apc2 1688 CTLHDSDINQDTNITKRDKNKKS
Hsl1 1740 FEKENTLSSSYLEEQKPKRAALSDITC
Apc11 1742 CVDFDEPIRQNTDNPIGRQQV
Affinity purification of antisera was carried out by performing High Performance Liquid 
Chromatography over a matrix coupled to the immunogenic peptide. Antibodies were eluted 
from the matrix in two steps: a “magnesium elution” (M) with 1.5 M MgCl2, 100 mM Na-
APPENDIX
109
acetate, pH 5.2, was followed by a “glycine elution” (G) using 100 mM glycine pH 2.45. Both 
elutions were usually collected separately and dialyzed in tubings with a Molecular Weight 
cut off (MWCO) of 3.5KDa against 2 l buffer containing 20 mM Hepes-KOH pH 7.9, 150 
mM NaCl and 10 % glycerol for about 8-12 h. The dialysis buffer was changed after 2-4 h. 
All yeast strains used for the basic characterization of the antibodies are listed in Table 5–2.
Table 5-2: Yeast strains used in antibody tests. All S.cerivisiae strains used are derivatives 
of K699 (MATa ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1, GALpsi) and K700 
(MATalpha ade2-1 trp1-1 can1-100 leu2-3,112 his3-11,15 ura3-1, GALpsi).
Yeast strain Genotype Creator
J9 MATa APC4-TAP::TRP1 H. Vodermaier
J33 MATa APC4-TAP::KlTRP1 cdc27::KanMX4 myc9-CDH1::LEU2 
multiple integration of SIC1::HIS3 at SIC1 locus
H. Vodermaier
J42 MATa APC4-TAP::KlTRP1 APC5-myc9::TRP1 H. Vodermaier
J61 (K6197) MATa CDC27-myc9::TRP1 Marta Galova
J118 (K6329) MATa APC1-myc18::HIS3 W. Zachariae
J134 (K7898) MATa APC2-myc9::TRP1 W. Zachariae
J224 MATalpha CDC23-myc9::LEU2 this study
J203 K699
J224 MATalpha CDC23-myc9::LEU2 this study
J269 MATa APC4-TAP::TRP1 APC11-HA3::TRP1 doc1::kanMX4 this study
5.1.1 Apc1 and Apc2 antibodies
Antisera taken four weeks after immunization were directly tested in immunobloting for 
their ability to recognize Apc1 or Apc2 in immunopurified APC preparations and on yeast 
cell extracts (Figure 5–1A). APC was isolated from yeast strains carrying a myc-tag on Apc1 
(J118), Apc2 (J61) or Cdc27 (J134) by immunoprecipitation using an antibody against the 
myc-epitope (9E10, made in house). As a control, an untagged yeast strain (J203) was used. 
Purified 9E10 antibody (12.5 µg ) and 10 µl GammaBind G separose (GE Healthcare) per 
sample were incubated for 15 min prior to 1.5 h incubation with yeast cell lysate containing 2 
mg of total protein. Antibody beads were washed 3 times briefly and 3 times with a 10 min 
incubation with IP buffer containing 50 mM Tris pH 8, 150 mM KCl, 10 % glycerol and 0.1 
% NP-40. All incubation and washing steps were carried out at 4°C on an end-over-end
rotator. Elution was carried out by boiling beads in SDS-PAGE sample buffer. 10 µl 
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immunopurified APC sample and 75 µg yeast extract per lane were separated by SDS-PAGE 
and transferred to a PVDF membrane. The membranes were incubated with a 1:250 dilution 
of the respective antisera in TBS-T containing 4 % milk powder. In order to easily identify 
an antigen-specific signal, I analyzed APC purifications which contained a tagged version of 
the antigen next to those containing the untagged antigen. Antigen specific signals were then 
indicated by a band which appeared at a size corresponding to the size of antigen in 
immunoprecipitations from strains in which the antigen was untagged and which shifted to a 
higher molecular weight in preparations from tagged strains. Both Apc1 antisera (1685 and 
1686) specifically recognized tagged and untagged Apc1 after immunoprecipitation via the 
myc-epitope on Apc1 (“APC1-myc18”, lanes 3 and 8) and Cdc27 (“APC1”, lanes 4, 5, 9, 10), 
respectively. Similarly, the Apc2 antisera 1688 and 1688 recognized Apc2 versions in APC 
immunoprecipitates of Apc2-myc9 (“APC2-myc9”, lanes 2 and 5) and Cdc27-myc9 (“APC2”, 
lanes 3, 4, 5 and 6). At the conditions tested here, all 4 antisera did not recognize their 
antigens on yeast cell lysates (Figure 5– 1A, lanes 1 and 6 and data not shown). Purified 1686 
antibody, however, stains Apc1 also on extracts (Figure 5– 2, lane 1).
5.1.2 Cdc27 antibodies
To test purified antibodies raised against Cdc27 peptides, I took advantage of a Cdc27 
deleted yeast strain (“cdc27”, J33) and a corresponding wild type strain (“CDC27”, J42). 
Both strains in addition carried a TAP-tag on Apc4. APC was pulled down for 1 h from 
these strains using IgG Sepharose beads (Amersham, 2 mg total yeast protein per 10 µl 
beads) and washed extensively with IgG Wash buffer buffer (50 mM Tris pH 8, 150 mM 
KCl, 10 % glycerol, 0.1 % NP-40 and 0.5 mM EDTA). Bound proteins were eluted using 
one bead volume SDS-PAGE sample buffer. Sample from 10 µl beads, about 75 ng TAP-
purified APC containing Cdc27 (purified from J42) as well as yeast lysates (75 µg total 
protein) from CDC27 and cdc27 strains were separated by SDS-PAGE gels followed by 
Western bloting. Membranes were developed with the glycine elutions of both antibodies at 
a dilution of 2 µg/ml. Both 1518 and 1519 antibodies specifically recognized a band 
corresponding to the size of Cdc27 in purified APC samples. Importantly, this band was not 
present in APC pull downs from the cdc27 strain (Figure 5–1C, lanes 3, 4, 7, 8). When using 
these antibodies on yeast cell extracts, however, several bands were recognized (Figure 5–1C,
lanes 1, 2, 5, 6). None of these bands was lost in Cdc27-deleted samples. In addition, none of 
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the recognized bands had the same size as the band which was recognized in the purified 
samples, indicating that both Cdc27 antibodies do not recognize their antigen on cell 
extracts.
5.1.3 Cdc23 antibodies
The immunization program for an N-terminal peptide of Cdc23 (peptide 1516, 
CYKRSIKASQTVDQNTS) was stopped early because the antiserum did not give a specific 
signal in immunobloting experiments. Both 1517 antibody fractions were tested by Western 
bloting for their ability to recognize tagged and untagged Cdc23 in APC 
immunoprecipitations, similarly as described in 5.1.1. APC was purified from CDC23-myc9 
strains (J224) with the 9E10 antibody (“CDC23-myc9”) using IP buffer and from an Apc4-
TAP (J9) strain containing wild type Cdc23 allele (“CDC23”) using IgG sepharose beads and 
IgG wash buffer as in 5.1.1 and 5.1.2. Sample eluted from 10 µl beads per lane were analyzed 
by SDS-PAGE and Western bloting. The fact that rabbit secondary antibody also stains the 
Protein A-tag (which is part of the TAP-tag) on Apc4 complicates the interpretation of the 
result after developing membranes with the 1517 antibody fractions (Figure 5–1D, lanes 1 
and 6). Nevertheless, both antibody fractions clearly recognize Cdc23 on purified APC 
preparations containing either wild type or myc9-tagged Cdc23 (Figure 5–1D, lanes 1-6).
5.1.4 Doc1 antibodies
All 4 Doc1 antibody fractions were tested in immunobloting experiments. Two µl Doc1 in 
vitro translation product, 60 ng APC purified from DOC1 wild type  and doc1 yeast strains via 
the TAP-method and cell extracts from DOC1 and doc1 yeast strains (75 µg/lane) were 
separated by SDS-PAGE and transferred to PVDF membranes. These were incubated with 
the antibody fractions at a dilution of 2 µg/ml in milk/TBS-T. Both antibodies recognize the 
in vitro translated protein with high specificity. Moreover, the antibodies stain a band 
corresponding to Doc1’s size (33 kDa) on samples of purified APC, which is not present in 
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Figure 5-1: Initial specificity tests of peptide antibodies raised against APC subunits.
A – F) Yeast cell lysates or purified samples were separated by SDS-PAGE and analyzed by 
immunobloting using the indicated antibodies at 2 µg/ml. Details are described in the text. 
IgG pull-down (IgG p.d.), TAP-purified APC (TAP-purif.), extract (xt), in vitro translation 
(IVT).
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preparations of APC lacking Doc1 (Figure 5–1E). When using these antibodies on yeast cell 
extracts, only a very faint band (Figure 5–1E, lanes 3 and 15) was recognized or several 
bands were stained in addition (Figure 5–1E, lane 21). Importantly, however, the 33 kDa 
band is lost in all samples containing doc1 extracts, indicating that both 1512 and 1513 
antibodies recognize Doc1 on yeast cell extracts. 
5.1.5 Apc11 antibodies
The suitability of the 1742 antibody for Western bloting is shown in Figure 5–1F. APC 
isolated from an APC11-HA3 (J269) strain was loaded next to a preparation from APC 
containing untagged Apc11. For both preparations, IgG sepharaose pull downs were 
performed as described in Section 5.1.2 (the yeast strains also contained a TAP-tag on 
Apc4). After SDS-PAGE, Western bloting and incubation of the membrane with the glycine 
elution of 1742 (1742G), only one band per lane is stained. This band corresponds to the 
size of Apc11 in the APC11 sample (Figure 5–1F, lane 2) and shifts in the APC11-HA3 
sample (Figure 5–1F, lane 1), indicating that the antibody specifically recognizes Apc11 on 
purified APC. 
5.1.6 Yeast APC antibodies in immunoprecipitation experiments
I tested whether the newly generated antibodies are also suitable for purification of the APC 
under native conditions. Affiprep Protein A beads (Biorad) were washed twice with at least 
10 volumes of TBS-T, then resuspended in 10 volumes TBST and 1.5-2 µg purified antibody 
was added per µl bead volume. Beads and antibodies were incubated for 20 min at room 
temperature on an end-over-end rotator and were then washed twice with TBST and once 
with IP buffer containing 50 mM Tris pH 8, 150 mM KCl, 10 % glycerol and 0.1 % NP-40. 
Yeast extracts containing 2 mg of total protein were added per 10 µl antibody beads. The 
samples were incubated for 60-90 min at 4°C on an end-over-end rotator and then washed 
extensively with IP buffer. Elution was carried out by resuspending beads in 1.5 volumes 0.1 
M glycine pH 2.2. SDS sample buffer was added to the glycine eluates and the samples were 
neutralized with 1.5 M Tris pH 9.2 and boiled.
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Figure 5-2: Immunoprecipitation of APC with APC-specific antibodies. Details are 
given in the text. 
After SDS-PAGE and transfer to PVDF membranes, the membranes were incubated with 
antibodies specific for three different APC subunits (Apc1, Apc2-myc9 or Apc5-myc and 
Doc1) to analyze APC composition. One antibody each generated against Apc1 (1685G), 
Apc2 (1688G), Cdc27 (1518G), Cdc16 (1514G), Cdc23 (1517G) and Apc11 (1742G) was 
able to pull down all 3 subunits that were stained for, which implies that they might isolate 
the complete complex (Figure 5–2, lanes 4, 6, 7, 8, 11, 12). The Doc1 1513 antibody does 
bring down all three proteins tested for, but a large amount of immunoprecipitated Doc1 is 
probably not bound to APC (Figure 5–2, lane 3). The 1512, 1515 and 1686 antibodies 
contain very little or nothing of one or more subunits that were stained for under the 
conditions tested here. They do immunoprecipitate their respective antigens (Figure 5–2, 
lanes 2, 5, 9), but they are probably not suitable for purification of the entire APC. Further 
characterization of these antibodies might be necessary before using them for 
immunopurifying APC, such as silver staining or bloting for more APC subunits. In 
summary, I generated peptide antibodies against 7 yeast APC subunits, which specifically 
recognize their respective antigens in immunobloting experiments. Some of them also 
precipitate the entire APC together with the antigen which might make them useful tools for 
further yeast APC studies.
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5.2 Generation of an antibody against Hsl1(667-872)
A peptide antibody generated against an sequence within the Hsl1 fragment (which 
comprises amino acids 667 to 872) was produced as described in Section 5.1. Since I wanted 
to use the antibody to analyze ubiquitination assays in which Hsl1(667-872) had been used as a 
substrate, I tested the antibody on purified protein and on a protein mix containing Hsl1(667-
872 and the components of a ubiquitination mix (E1 and E2 enzymes, Cdh1, ubiquitin, ATP). 
No crossreactivities were observed, indicating that this antibody could be suitable as an 
alternative to the use of radiolabeled substrates Figure (5–3A and B).
Figure 5-3: Initial specificity test of Hsl1 peptide antibody. A) The indicated amounts 
(in µg) of purified (purif.) His6-Hsl1 and 1 µg of Ubc1-His6 (control, ctrl) as well as lysates 
(WCE) from uninduced (u.i.) and induced (i.) bacteria that were expressing His6-Hsl1 were 
separated by SDS-PAGE and analyzed by immunobloting using the glycine elution of the 
Hsl1 antibody (1740G). As a control, a parallel analysis with an anti- His6 (Penta, Qiagen)
antibody was carried out. Both antibodies were used at 2 µg/ml. B) To test the suitability for 
the 1740G antibody in analysis of ubiquitination assays, 1 µg of purified His6-Hsl1 or GST-
Hsl1 was separated next to a ubiquitination mix (ubi-mix) containing 1 µg of the respective 
Hsl1 versions as well as E1 and E2 enzymes, TAP-purified APC, purified Cdh1, ubiquitin 
and ATP. Samples were analyzed by immunobloting using 1740G at 2 µg/ml. 
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5.3 Sequence alignment of C10orf104/Apc16 protein sequences
Figure 5-4: Multiple sequence alignment of full-length 
C10orf104 orthologs from a range of bony vertebrate 
species. Jalview was used for alignment visualization with 
ClustalX shading and Lupas coiled-coil prediction (PMID: 
14960472). Sequences are derived from NCBI/Entrez and 
Ensembl databases and are listed in the following order: 1) 
Primates 1.1) Homo sapiens- NP_775744 1.2) Otolemur 
garnettii- ENSOGAP00000007350 2) Rodents 2.1) 
Spermophilus tridecemlineatus ENSSTOP00000000619 
2.1) Mus musculus- NP_079790 3) Laurasiatheria 3.1) Bos 
taurus- NP_001014960 3.2) Sorex araneus-
ENSSARP00000001443 4) Marsupials; Monodelphis 
domestica XP_001362179 5) Monotremes; 
Ornithorhynchus anatinus XP_001508726 6) Aves 6.1) 
Gallus gallus- XP_421587 6.2) Meleagris gallopavo-
EH290378 7) Amphibia 7.1) Xenopus laevis 
NP_001085523 7.2) Xenopus tropicalis NP_001004873 8) 
Teleostei 8.1) Danio rerio- NP_001017878 8.2) Oryzias 
latipes- ENSORLP00000011498 8.3) Tetraodon 
nigroviridis- CAG13305. Provided by Maria Novatchkova.
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6 Abbreviations
A alanine
Å Angström
ab antibody
Ama1 activator of meiotic APC protein-1
amp ampicillin
APC anaphase-promoting complex/cyclosome
ATP adenosine triphosphate
a.u. arbitrary unit
A260, A280 absorption at 260/280 nm
bp base pairs
BSA bovine serum albumin
cDNA complementary DNA
cdc cell devision cycle
Cdk cyclin dependent kinase
2 D/3 D two-dimensional/three-dimensional
DAPI 4’,6’-diamino-2-phenylindol
DM D box mutant (R-X-X-L  A-X-X-A)
DMP dimethylpimelimidate
DNA deoxyribonucleic acid
DMSO dimethylsulfoxyde
Doc1 degradation of cyclin B protein-1
DTT dithiothreithol
DUB deubiquitinating enzyme
E glutamic acid
E1 ubiquitin-activating enzyme
E2 ubiquitin conjugating enzyme
E3 ubiquitin ligase
E. coli Escherichia coli
EDTA ethylenediamine tetraacetic acid
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EGTA ethylene glycol tetraacetic acid
EM electron microscopy
F phenylalanine
G glycine elution (of purified antibody)
GST glutathione-S-transferase
H histidine
h hour
ha epitope on influenza virus hemagglutinin (sequence: 
YPYDVPDYA)
His6 His-tag comprising 6 histidines
HECT homology to E6-AP C-terminus 
Hepes N-2-hydroxyethylpiperazin-N’-2-ethane sulphonic acid
HU hydroxyurea
ILR isoleucine-leucine-arginine
IR isoleucine-arginine
IgG immunoglobulin G
IPTG isopropyl β-D-1-thiogalactopyranoside
IVT in vitro translation
kDa kilo Dalton
LAP localization and affinity purification
K lysine
L leucine
LB Luria-Bertani
log logarithmic
N asparagine
M magnesium elution (of purified antibody)
MCC mitotic checkpoint complex
MDa mega Dalton
Mnd2 meiotic nuclear division protein-2
MgOAc magnesium acetate
min minute
MR methionine-arginine
ABBREVIATIONS
119
myc human c-myc epitope (sequence: EQKLISEEDL)
NaOAc sodium acetate
NEM N-ethylmaleimide
Ni-NTA nickel-nitrilotriacetic acid
noc nocodazole
OD600 optical density at 600 nm
ORF open reading frame
PAGE polyacrylamide gel electrophoresis
PBS phosphate buffered saline
PCR polymerase chain reaction
Pds1 precocious dissociation of sister chromatids
PEG polyethylenglycole
PFA paraformaldehyde
PMSF phenylmethylsulphonyl fluoride
PVDF polyvinylidene fluoride transfer membrane
Q glutamine
R arginine
RING really interesting new gene
RFP red fluorescent protein
RNA ribonucleic acid
Rpn regulatory particle non-ATPase
rpm rounds per minute
S Svedberg
S serine
SAC spindle assembly checkpoint
S. cerevisiae/S. c. Saccharomyces cerevisiae
SCF Skp1/Cul1/F box
SDS sodium dodecyl sulphate
SGD Saccharomyces genome database
S. pombe/S. p. Schizosaccharomyces pombe
Swm1 spore wall maturation protein-1 
TAP tandem affinity purification
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TBS tris buffered saline
td2 tdimer2 (tandem dimer of a dimeric DsRed variant)
tmono “half a tdimer2”; monomeric DsRed
TEV tobacco etch virus
THF tetrahydrofuran
(tmd)phe L-4’-(3-[trifluoromethyl]-3H-diazirine-3yl) phenylalanine
TPR tetratrico peptide repeat
Tris tris-(Hydroxymethyl)aminomethane, 2-amino, 2-
(hydroxymethyl),1-3-propandiol
tRNA transfer RNA
UBL ubiquitin-like
UV ultraviolet
Usp44 ubiquitin-specific protease-44
v/v volume per volume
WB Western blot
WD tryptophane aspartate
wt wild type
YPD yeast extract peptone dextrose
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